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Thesis outline 
The main topic covered in this thesis is the development and evaluation of albumin based 
lyophilisomes as a drug delivery system for cancer treatment. More specifically, the 
potential of lyophilisomes to treat ovarian cancer through tumoral ECM drug delivery is 
investigated. 
In Chapter 1, the strategy of drug delivery systems targeting the tumor extracellular 
matrix is described. Up to now, most studies on targeted drug delivery for cancer focus on 
active targeting of specific tumor cells. A limited number of studies describe targeting to 
the ECM of tumors. This chapter provides an overview of extracellular matrix targets and 
the potential therapeutic benefits of this approach. 
Chapter 2 describes the results of a systematic review and meta-analysis of drug delivery 
systems used for ovarian cancer treatment in animal models. An overview of all animal 
studies that used capsules to deliver chemotherapeutics for ovarian cancer treatment is 
presented. 
In Chapter 3, lyophilisomes, albumin based nano/microparticles, are deployed and 
evaluated as a drug delivery system for chemotherapeutics (doxorubicin and curcumin). 
A method to prepare lyophilisomes and to load chemotherapeutics is presented. 
Lyophilisomes loaded with chemotherapeutics in their lumen are able to eliminate ovarian 
cancer cells in vitro. 
In Chapters 4, we show that modified lyophilisomes can actively target ovarian cancer 
stroma by exploiting the overexpression of chondroitin sulfate type-E. Once loaded with 
doxorubicin, these lyophilisomes are able to efficiently eradicate ovarian cancer cells in a 
CS-E rich environment in vitro. 
The final chapters describe the results of in vivo studies with non-targeting and CS-E 
targeting lyophilisomes. Chapter 5 evaluated the biodistribution of non-modified 
lyophilisomes after intravenous administration. Results indicate the liver and spleen being 
the prime organs of lyophilisomal accumulation.  
In Chapter 6, we administered CS-E targeting lyophilisomes loaded with doxorubicin 
intraperitoneally to mice with ovarian tumors to increase tumor targeting to intraperitoneal 
tumors. Results indicate that lyophilisomes are largely restricted to the intraperitoneal 
cavity, and that doxorubicin distributes to the nucleus of tumor cells. However, penetration 
of lyophilisomes into the tumor is poor.
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Abstract
Systemic chemotherapy is a primary strategy in the treatment of cancer, but comes with 
a number of limitations such as toxicity and unfavorable biodistribution. To overcome 
these issues, numerous targeting systems for specific delivery of chemotherapeutics to 
tumor cells have been designed and evaluated. Such strategies generally address subsets 
of tumor cells, still allowing the progressive growth of tumor cells not expressing the 
target. Moreover, tumor stem cells and tumor supportive cells, such as cancer associated 
fibroblasts and cancer associated macrophages, are left unaffected by this approach. In 
this review, we discuss an alternative targeting strategy aimed at delivery of anti-tumor 
drugs to the tumoral extracellular matrix with the potential to eliminate all cell types. 
The extracellular matrix of tumors is vastly different from that of healthy tissue and offers 
hooks for targeted drug delivery. It is concluded that matrix targeting is promising, but 
that clinical studies are required to evaluate translation. 
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Introduction
Targeted drug delivery of chemotherapeutics is an increasingly important area in the field 
of cancer treatment research. Although conventional chemotherapy remains one of the 
most important treatment modalities, significant side effects may be induced that can 
result in preliminary cease of chemotherapy [1-3]. Moreover, chemotherapeutics have an 
unfavorable biodistribution and are generally rapidly removed from the body. Advanced 
drug delivery systems may overcome these hurdles. By entrapping chemotherapeutics in 
a drug delivery system, exposure to healthy cells may be decreased, which, together with 
an increased concentration of chemotherapeutics specifically at the tumor site, can result 
in enhanced treatment efficacy with reduced side effects [4]. However, to achieve this, 
drug delivery systems should be designed to deliver chemotherapeutics to tumors only 
and not to surrounding healthy tissue. Several approaches, including passive targeting 
and ligand mediated targeting, are currently being evaluated to achieve local delivery to 
tumor cells. While the majority of the field is focusing on targeting the tumor cells itself, 
we here discuss an alternative approach i.e. targeting the tumor’s extracellular matrix 
(ECM). This strategy may result in a higher treatment efficacy by affecting not only tumor 
cells, but also tumor supportive cells. Tumor supportive cells are considered to have major 
roles in supporting tumor growth. The cancer associated fibroblast (CAF), for instance, 
is a tumor-distinctive cell type responsible for excretion of proliferating, pro-angiogenic, 
and anti-immunogenic factors, creating an ideal environment for tumor growth and 
subsequent metastasis [5]. Further, the cancer associated macrophage shares many of 
the tumor supportive characteristics of CAFs. Once derived from monocytes to its specific 
subtype and located in the ECM of tumors the cancer associated macrophage is thought 
to produce and secrete tumor enhancing factors [6, 7]. Endothelial cells are another cell 
type considered as key players in tumor growth. By facilitating the supply of nutrients 
(e.g. oxygen, glucose, etc.) through the generation and support of novel blood vessels, 
tumors continue to proliferate [8]. Finally, the tumor stem cell is a major player in tumor 
progression. Tumor stem cells are considered responsible for self-renewal of tumor 
cells thereby driving tumor growth [9, 10]. A strategy that simultaneously affects tumor 
cells and tumor supportive cells may be beneficial in improving treatment efficacies. 
We will present an overview of the possibilities and limitations of strategies to deliver 
chemotherapeutics to and release them in the tumor extracellular matrix.
Conventional tumor targeting strategies
Passive targeting is one of the main strategies to guide drug delivery systems to cancer 
cells making use of the enhanced permeability and retention effect (EPR) [11]. This 
phenomenon is based on newly formed leaky vessels in tumor areas (permeability) 
with decreased lymphatic drainage resulting in an increased retention [12]. As a result, 
accumulation of drug delivery systems at the tumor site may occur. Despite extensive 
evaluation over the last 30 years and initial promising preclinical results of passively 
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targeted chemotherapeutic drug delivery through the EPR effect, serious questions have 
been raised about the existence and clinical application of the EPR effect in humans [13, 
14]. 
The opposite of passive targeting, active targeting, is therefore under growing attention. 
Active targeting is based on the concept that drug delivery systems can actively bind and 
subsequently internalize into tumor cells using tumor cell specific antibodies or ligands 
[11, 15]. The ideal target is highly overexpressed on tumor cells, and absent or expressed 
to a limited extent on healthy cells. Examples are membrane bound receptors such as the 
human epidermal growth factor receptor 2 (HER2), epidermal growth factor receptor-1 
(EGFR), transferrin receptor and folate receptor-α. However, there are several limitations 
associated with targeted delivery to tumors that need to be resolved in order to further 
improve the treatment outcome.
Limitations of current active targeting strategies
Conventional drug delivery systems that target tumor cells through binding membrane 
bound molecules have several pitfalls. First, tumors show a high intratumoral heterogeneity 
resulting in heterogeneous expression of targets for drug delivery [16]. This may implicate 
that in practice targeted therapy may result in removal of only the subset of tumor cells 
expressing the target, while tumor cells lacking the target are left unaffected. As a result, 
these cells may proceed proliferating and finally result in a tumor lacking expression of the 
initial target (Figure 1).
Figure 1. Limitations of the conventional tumor targeting strategy. By addressing a specific tumor 
marker, tumor cells lacking the marker may survive and continue to grow progressively.
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A second aspect of the current tumor targeting is the disregard of tumor supportive 
cells being present in the tumoral extracellular matrix (ECM). Tumor supportive cells are 
responsible for important cues for tumor proliferation and involved in the maintenance 
of a tumor supportive environment. Drug delivery strategies aimed at a specific tumor 
cell can leave other tumor cells and, perhaps even more importantly, tumor stem cells, 
tumor supportive cells and their supportive environment intact and may therefore not be 
sufficient to eradicate the whole tumor and prevent relapse. 
Thirdly, delivery of entrapped drugs to their location of action by a targeted drug delivery 
system has proven more complex than initially anticipated. The majority of the current 
targeting drug delivery systems are designed to deliver their payload to their site of 
action (e.g. the nucleus). For most chemotherapeutics, this implicates that once a drug 
delivery system is bound to its target (e.g. membrane receptor) rapid internalization 
should occur. Thereafter, the drug should be released and subsequently move to its 
site of action, and not diffuse back into circulation. Although targeting the tumor cell 
membrane with subsequent internalization can be accomplished using antibodies or 
ligands, the steps to deliver chemotherapeutics to its site of action are more complicated. 
Once internalized into lysosomal compartments in the cytoplasm, the drug should be 
released from its carrier. A wide range of drug delivery systems struggle to release their 
payload after internalization because of failure to escape from lysosomal compartments 
in which they end up after internalization [17, 18]. For example, the majority of injected 
PEGylated liposomal doxorubicin, a clinically approved passive targeting drug delivery 
system for doxorubicin, is found to be entrapped in lysosomes after internalization. In vivo 
experiments have shown that as a consequence of this lysosomal entrapment, less than 
1% of the administered doxorubicin from liposomes reaches the nucleus, its actual target 
[19]. Lysosomal sequestering of drug delivery systems following internalization can thus 
prevent chemotherapeutics from reaching their site of action. 
Overall, the majority of the tumor targeting drug delivery strategies for chemotherapeutic 
delivery focus on targeting tumor cells and may result in eradication of only a specific 
subset of tumor cells. Importantly, tumor supportive cells and tumor stem cells are left 
unaffected. Impaired release of chemotherapeutics and lysosomal entrapment may 
further limit the treatment efficacy. Therefore, an alternative targeting strategy that 
tackles these issues is desired.
Alternative active targeting strategy
Targeting chemotherapeutics to the extracellular matrix (ECM) of tumors may be a 
promising alternative strategy that can offer advantages over conventional targeting. The 
strategy is not aimed to target membrane bound receptors on specific tumor cells, but 
is aimed to target the unique tumoral ECM. Upon binding, depots of chemotherapeutic 
carriers in the tumor ECM are formed. Finally, when chemotherapeutics are released 
in the ECM they are able to diffuse to and affect all surrounding tumor cells including 
the heterogeneous tumor cell subsets, tumor supportive cells and tumor stem cells 
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(Figure 2). Here we will discuss this emerging field and define a number of conditions 
necessary to use drug delivery systems or antibody-drug conjugates as local extracellular 
chemotherapeutic depots.
Figure 2. A schematic overview of targeting to the extracellular matrix. Drug delivery systems 
bind to a molecule abundantly present in the extracellular matrix of tumors. Upon binding, the 
chemotherapeutic compound is released and diffuses into all tumor cell subsets, but also into other 
cells (e.g. cancer associated fibroblasts, cancer associated macrophages, tumor stem cells). Adapted 
from Van der Steen et al. [20] under the Creative Commons Attribution License (CC BY 4.0).
The unique tumoral extracellular matrix 
The normal ECM has many important functions including support and strength for tissues. 
It consists of various components such as (glyco)proteins (e.g. tenascin, collagen, elastin, 
laminin, fibronectin, and proteoglycans) and glycosaminoglycans (e.g. heparan sulfate 
and chondroitin sulfate) [21, 22]. The tumoral ECM is considered distinct from normal 
tissue ECM in various aspects. For instance, several types of collagen are abundantly 
deposited during tumor formation and chondroitin sulfate and heparan sulfate are also 
more abundantly present in the ECM of tumors, both having the capacity to bind tumor 
promoting growth factors. Moreover, ECM remodeling enzymes are overexpressed in 
tumors [23]. It is believed that these factors contribute to tumor progression and invasion. 
Consequently, the deregulated tumoral ECM may also provide targeting possibilities as 
the tumor ECM may be enriched in certain molecules that are almost absent in normal 
ECM.
14
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Targets in the tumoral extracellular matrix
As mentioned, the tumoral ECM is distinct from the normal ECM and may offer targeting 
possibilities. To ensure specific tumor delivery, the target should be expressed specifically 
in the ECM of tumors. Several ECM targets that may be used for drug delivery have been 
described as suitable. An overview of tumor ECM targeting strategies is presented in Table 
1, and some examples will be discussed here. 
Tenascin-C is a large glycoprotein of about 300 kDa which is highly expressed in the ECM 
of several tumors including breast, colon, lung, and ovarian tumors. It supports several 
aspects of tumor growth, such as tumor proliferation, angiogenesis and metastasis [24]. 
Moreover, its expression in normal ECM is almost absent [24], making it suitable for ECM 
targeting. Dal Corso et al. used a non-internalizing antibody directed against tenascinC 
to deliver a chemotherapeutic compound (the anthracycline PNU159682) to the ECM of 
tumors [25]. Upon intravenous injection, the antibody-drug conjugate bound to tenascin-C 
(Figure 3) and the drug was released through cleavage of the protease-sensitive linker 
between the drug and antibody. Significant tumor growth inhibition was observed in 
epidermoid carcinoma mouse xenografts. Chen et al. developed a strategy targeting 
tenascin-C using liposomes functionalized with a tenascin-C binding peptide and loaded 
with navitoclax, a small molecule inducing apoptosis primarily in CAFs. These liposomes 
modulated the ECM of tumors through efficient removal of CAFs, making the ECM more 
accessible for subsequently administered doxorubicin loaded nanoparticles [26, 27]. 
Because only CAFs were affected by the initial ECM targeting strategy, they still had to 
apply a subsequent tumor cell specific targeting method. Using nanoparticles containing 
doxorubicin and targeting the human transferrin receptor, significant tumor growth 
inhibition was observed in liver tumorbearing mice. Kang et al. targeted both, tumor 
cells using neuropilin-1 and tumor ECM tenascin-C with nanoparticles for glioma therapy. 
When loaded with paclitaxel, they tripled the median survival of intracranial glioma tumor 
bearing mice [28]. Lin et al. evaluated another tenascin-C targeting strategy. Doxorubicin 
loaded liposomes functionalized with sulfatide, a tenascin-C binding glycosphingolipid, 
were evaluated in mice bearing subcutaneous colorectal tumors and subcutaneous glioma 
tumors [29-32]. Although prolonged survival and decreased side effects were observed, 
the strategy was still dependent on endocytic cellular uptake of liposomes by glioma cells, 
which may limit the full potential of this strategy due to lysosomal entrapment of the 
liposomes. Another tenascin-C targeting approach was evaluated by Li et al. in a breast 
cancer mouse model. Mice were treated with paclitaxel loaded sulfatide-containing lipid 
nanoparticles. Again, despite increased efficacy over non-targeted delivery and free drug, 
the nanoparticles had to internalize into tumor cells in order to function [33]. It should be 
noted, however, that sulfatide, while suitable for incorporation in lipid based drug delivery 
particles (e.g. liposomes) and favoring binding to tenascin-C, has been reported to bind 
other matrix molecules [32], which could result in potential off-target effects. Therefore, 
the use of a tenascin-C binding peptide or a selected aptamer [34, 35] may be preferred. 
Overall, tenascin-C appears to be a promising target because of its almost exclusive 
15
Introduction and thesis outline  
 1
Chemotherapeutic drug delivery by tumoral extracellular matrix targeting
expression in the ECM of tumors. However, most tenascin-C targeting strategies could 
be improved by introducing drug release in the ECM to overcome potential lysosomal 
sequestration of the internalized drug delivery particles.
Figure 3. An example of an in vivo tumoral extracellular matrix targeting strategy. (A) Mice bearing 
A431 human epidermoid carcinoma xenografts showed strong tenascin-C expression (green), 
especially around tumor vessels (red). (B) In tumors of mice treated with an antibody-drug 
conjugate directed against tenascin-C (green), the antibody was found to localize to tenascin-C in 
the direct area of tumor vessels (red). (C) Tumors of mice injected with a control antibody (directed 
against hen egg lysozyme) did not show presence of the antibody. (D) Results of an efficacy study 
in mice with A431 human epidermoid carcinomas that were treated with tenascin-C targeting 
antibody-drug conjugate (closed circles) indicate a statistically significant tumor growth inhibition 
compared to control antibody-drug conjugate (against hen egg lysozyme; open circles) or vehicle 
only (PBS; triangles). Data points represent mean tumor volume ± SEM, n = 5 per group. Blue: nuclei. 
Scale bars: 100 µm. Reprinted with permission [25].
Another molecule to target in the ECM of tumors is fibronectin, a glycoprotein consisting 
of two 250 kDa subunits. Two alternatively spliced isoforms (i.e. extra domain-A and 
-B) of fibronectin are abundantly present in the tumor ECM of various types of cancer 
and almost absent in the normal ECM, making them prospective targets for ECM drug 
delivery (as extensively reviewed in [36] and [37]). A few studies evaluated fibronectin 
as a target for ECM targeted cancer treatment. For instance, Perrino et al. showed that a 
straightforward strategy, targeting the fibronectin extra domain-A with an antibody-drug 
(maytansinoid derivative MD1) conjugate, was able to induce complete remission in a 
subcutaneous teratocarcinoma mouse model [38]. Interestingly, this approach was 
based on non-internalizing antibodies that released the drug extracellularly due to the 
release of reducing agents (e.g. cysteine or glutathione) from dying cells which then 
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released the drug by reduction of the disulfide bonds. These results suggest that release 
of a chemotherapeutic drug in the ECM of tumors can indeed affect the whole tumor. 
Additionally, it was shown by Park et al. that nanoparticles functionalized with peptides 
with a high affinity towards fibronectin extra domain B accumulated specifically in tumors 
of a Lewis lung carcinoma model [39]. Alternatively, other groups used a combination 
of liposomes with single chain variable fragment (scFv) antibodies against fibronectin 
extra domain B for ECM targeting. However, therapeutic in vivo studies in mice bearing 
subcutaneous teratocarcinomas treated with fibronectin extra domain B targeting 
liposomes loaded with the cytotoxic compound 5-FdU-NOAC showed no significant 
differences in comparison to non-targeting liposomes [40]. This lack of therapeutic 
advantage may be due to the absence of an extracellular release mechanism resulting in 
the required internalization of liposomes for therapeutic activity. Carnemolla et al. were 
able to successfully target the fibronectin extra domain B using a biologically active fusion 
protein of interleukin-2 and a scFv antibody (clone L19) to induce an anti-tumor immune 
response [41]. Subcutaneous F9-mouse teratocarcinoma tumors were significantly smaller 
when treated with the interleukin-2-scFv conjugate, indicating that the L19 scFv may be a 
suitable candidate to use for tumoral ECM drug delivery.
Others have targeted fibronectin in the tumor ECM through its interaction with plasma 
proteins. Plasma proteins extravasating through vessels can form complexes with 
fibronectin such as fibrin-fibronectin [42]. This tumor specific complex, also called clotted 
plasma proteins, may be used as a target to deliver chemotherapeutics to the tumor ECM. 
In a glioblastoma mouse model, nanoparticles functionalized with CLT-1 (CGLIIQKNEC), 
a fibrinfibronectin binding peptide, loaded with paclitaxel, were able to significantly 
prolong survival. However, a possible by-stander effect by eliminating surrounding tumor 
(supportive) cells may have been limited because the strategy was dependent on integrin 
mediated cellular internalization into tumor cells and not on extracellular drug release [43]. 
Fibrin-fibronectin targeting with the CLT-1 peptide was also used by Tan et al. to visualize 
prostate tumors by MRI indicating the suitability of CLT-1 for tumor ECM targeting [44, 
45]. Next, Kruse and coworkers used CREKA, a peptide that also binds fibrin-fibronectin 
complexes [46]. Although the iron oxide nanoparticles were able to specifically target 
fibrin-fibronectin in vitro, no in vivo tumor targeting or therapeutic studies were reported. 
CREKA was also used for tumoral ECM targeting by others. Wang et al. prepared doxorubicin 
loaded CREKA-functionalized liposomes with thermosensitive release characteristics. 
Mice bearing subcutaneous multi-drug resistance adenocarcinomas showed significant 
inhibition in tumor growth when treated with doxorubicin loaded CREKA liposomes [47]. 
Moreover, when tumors were heated to induce doxorubicin release, tumor growth was 
even more inhibited, indicating that upon binding in the ECM of tumors, the released 
doxorubicin was able to reach its site-of-action and affected tumor growth. In a slightly 
different approach, Yasunage et al. targeted fibrin clots in the tumoral ECM using an 
antibody that was conjugated with the cytotoxic compound SN-38, the active metabolite 
of irinotecan, that was modified to be only cytotoxic upon release from the antibody due 
to an alkaline labile ester bond [48]. An in vivo therapeutic study in a chemically induced 
skin carcinoma mouse model showed a significant tumor growth inhibition in mice 
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treated with the antibody-drug conjugate. Further analyses showed a significantly higher 
concentration of the drug in tumors of mice treated with the antibody drug conjugate, 
indicating that fibrin-fibronectin targeting in the tumor ECM may be useful for targeted 
chemotherapeutic drug delivery.
Although targeted less frequently, collagen may also be a potential target in the ECM of 
tumors. Collagen is a structural protein abundantly present in the ECM of most tissues. 
Despite the presence of collagen throughout the body and risk of off-targeting with 
toxicity as a result, several attempts have been made to target collagen in the tumoral 
ECM for the delivery of chemotherapeutics. Yasunaga et al. developed an antibody drug 
conjugate against type IV collagen that released the antineoplastic drug SN-38 through 
the labile ester bond linker in the tumor ECM [49]. Evaluation in mice with two types of 
subcutaneous pancreatic tumors (stroma poor and stroma rich tumors) showed almost 
complete tumor growth inhibition of stroma rich tumors treated with the anticollagen 
drug conjugate. Interestingly, growth of stroma poor tumors was less affected by the 
antibody-drug conjugate suggesting specific targeting of stroma rich tumors. In spite of 
the abundant expression of collagen in the body, body weight was not affected and no 
toxicity in the liver, kidney and bone-marrow was observed, suggesting that distribution 
to other organs may be limited. Liang et al. also targeted  collagen in the ECM of tumors. 
They designed an antibody drug conjugate by combining a collagen (collagen type not 
specified) binding domain peptide with the Fab fragment of a clinically approved antibody 
(cetuximab) directed against the epidermal growth factor receptor (EGFR) which has 
antitumor activity itself [50]. In a therapeutic in vivo study with mice bearing subcutaneous 
EGFR positive tumors, tumor growth was significantly inhibited in mice treated with the 
collagen binding domain-anti EGFR conjugate compared to cetuximab only. In general, the 
full potential of tumoral ECM targeting was not utilized because the therapeutic molecule 
required binding of a specific receptor (EGFR) on a tumor cell subset.
Next to collagen, galectin-1 has been used for targeting to the tumoral ECM. Galectin-1 
is a carbohydrate binding protein that plays a role in cellular interactions. Underlining 
the limitations of cellular targeted therapies due to the tumor heterogeneity of triple 
negative breast cancer (i.e. breast tumors not overexpressing the estrogen receptor, 
progesterone receptor and epidermal growth factor receptor-2), Upreti and colleagues 
developed a tumor ECM targeting strategy directed at galectin-1 [51, 52]. Cisplatin and 
arsenic trioxide loaded liposomes functionalized with anginex, a small galectin-1 binding 
peptide, were evaluated for their therapeutic efficacy in an orthotopic triple negative 
breast cancer mouse model. They showed significant tumor growth reduction compared 
to treatment with non-targeting drug loaded liposomes. Although initial results were 
promising, an increased efficacy may be reached by applying extracellular release of the 
cytotoxic agents instead of using liposomes requiring receptor mediated endocytosis and 
release inside cells to be therapeutically active.
As proteoglycans are abundantly present in the ECM, they may be used for targeting 
chemotherapeutics to the tumor ECM as well. For instance, aggrecan, a proteoglycan 
expressed in the ECM of cartilage but also abundantly present in the ECM of 
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chondrosacromas was targeted by Peyrode et al. [53-55]. Using a conjugate of quaternary 
ammonium with the chemotherapeutic compound melphalan, aggrecan was targeted in 
an orthotopic Swarm rat chondrosarcoma model. Results showed a reduction of tumor 
volume for the drug conjugate. The reduction, however, was not significantly different 
from non-targeted melphalan, although more toxicity was observed for this group 
indicating an improved toxicity profile for the aggrecan targeting drug conjugate. Despite 
promising results, care should be taken with possible off-targeting to aggrecan rich tissues 
such as cartilage, a tissue that was not included in the toxicity evaluations, even though 
toxicity may be limited due to the limited blood supply to cartilage. Another proteoglycan 
targeted in the ECM of tumors is heparan sulfate, which is found highly upregulated in 
ECM of tumors making it an attractive target for tumoral ECM chemotherapeutic drug 
delivery [56]. Hu et al. used a CGKRK peptide with high affinity to heparan sulfate and 
conjugated it with an endothelial cell binding peptide to paclitaxel loaded nanoparticles 
[57]. This strategy was evaluated in mice bearing intracranial glioblastoma tumors and 
showed that mice treated with paclitaxel loaded nanoparticles targeted against heparan 
sulfate and endothelial cells significantly improved survival. It is not clear whether the 
effect is through extracellular release with potential removal of tumor supportive cells 
or by internalization in tumor cells only. Finally, chondroitin sulfate can be a target in 
the tumoral ECM because of its high expression in the ECM of various tumor types [58]. 
Lee et al. used cisplatin loaded liposomes modified with the chondroitin sulfate binding 
molecule TRX20 (3,5-dipentadecycloxybenzamidine hydrochloride) which showed tumor 
growth inhibition in a subcutaneous mouse tumor model [59]. While the strategy was 
designed to target chondroitin sulfate at tumor cell membranes, it may also be applied as 
ECM targeting to tumors with chondroitin sulfate in the ECM. Our group developed a drug 
delivery system that targets chondroitin sulfate subtype-E (CS-E), which was found to be 
highly upregulated in the ECM of ovarian cancer [60]. Although currently only evaluated 
in vitro, doxorubicin loaded albumin particles functionalized with a scFv antibody against 
CS-E were indeed able to target CS-E and efficiently eliminate ovarian cancer cells by 
extracellular drug release [20]. Overall, proteoglycans and glycosaminoglycans in the 
tumoral ECM may offer several opportunities, but care should be taken with off target 
effects to healthy tissue due to expression of these molecules throughout the body.
Extracellular drug release
Next to the presence of promising targets in the ECM, a tumor ECM drug delivery strategy 
is also highly dependent on the type of drug carrier. Many chemotherapeutic drug 
delivery systems have been developed over the last decades. Each system has unique 
characteristics that can be important for tumoral ECM drug delivery, such as size, drug 
content, charge, base material, modifications, etc. An important characteristic of drug 
delivery systems for tumoral ECM drug delivery is the drug release mechanism. Upon 
release, most drug molecules will retain in the tumor area because of the enhanced 
retention effect and will pass cell membranes due to the hydrophobic properties of the 
majority of chemotherapeutics. However, if not rapidly taken up by tumor or tumor 
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supportive cells, there is a risk of diffusion back into the circulation, which may result in 
off-target effects. Unfortunately, preclinical studies generally do not assess reuptake of 
released drugs into the circulation, but such analyses should be included in future studies. 
Without sufficient release of chemotherapeutics once a drug delivery system is bound 
to its target, no therapeutic effect will be induced. Therefore, extracellular release once 
bound to the ECM of tumors is required. Next to simple diffusion, with possible unwanted 
preliminary drug release, several innovative release mechanisms have been developed. 
Examples are triggered release by enzymes, pH, magnetism, heat, light, and ultrasound. 
For example, by exploiting the lower pH in the tumor extracellular matrix (6.2 – 6.9) 
caused by accumulation of lactic acid produced by highly proliferating tumor cells [61], 
Chiang et al. designed tumor ECM targeting doxorubicin-loaded liposomes in which the 
imidazole ring of histidine was protonated in an acetic environment resulting in increased 
uptake of the doxorubicin liposomes [62]. Dong et al. synthesized a pH and enzyme 
responsive doxorubicin delivery system [63]. The acetic tumor environment exposed 
the gelatin-DNA-doxorubicin complex to subsequently release doxorubicin by enzymatic 
degradation of gelatin due to matrix metalloproteinases upregulated in the tumoral ECM. 
In antibody-drug conjugates, triggered release is applied as well. For example, Rossin et al. 
developed a non-internalizing antibodydrug conjugate with a click-to-release mechanism 
[64]. Upon binding to the tumor specific membrane bound target, the non-internalizing 
antibody-drug conjugate released its payload after reaction of an administered activator 
compound. This strategy enables release of the drug specifically at the tumor site as 
non-bound antibody-drug complexes are allowed to be excreted from the body before 
administration of the activator compound. Next to these examples, a manifold of other 
release mechanisms have been developed. As thorough discussion of these external/
internal stimuli driven response is beyond the scope of this review, we refer to excellent 
reviews on this topic [61, 65, 66]. The combination of stimuli triggered release and binding 
to a tumor ECM target seems a promising idea, but more studies should be performed to 
indicate its full potential.
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Future outlook
The therapeutic effect of conventional tumor targeting chemotherapeutic delivery 
systems that addresses molecules on cancer cells may be limited by intratumoral 
heterogeneity and inadequate drug release due to lysosomal entrapment. Combining the 
knowledge of tumor heterogeneity and the importance of the tumor extracellular matrix 
with its tumor supportive cells, delivery of chemotherapeutics to the tumoral ECM may 
be a promising alternative. Various studies have identified unique tumoral ECM targets. 
In vivo studies indicate that targeting these unique tumoral ECM targets combined with 
extracellular release of chemotherapeutics can improve treatment outcome. Tumoral 
ECM targets should be critically selected. Potential expression in healthy tissue may cause 
off-targeting with possibilities of inducing toxicity and side effects. Moreover, care should 
be taken when selecting a drug delivery system. The effect caused by extracellular drug 
release and diffusion of the drug to tumor supportive cells in the tumor area may be 
limited when the drug as such is not released extracellularly, but instead is contained in a 
carrier that is taken up into the cell through endocytosis. To overcome these limitations, 
stimuli driven extracellular drug release may offer promising opportunities. By external 
or internal triggered drug release, chemotherapeutic agents will only be released in 
the tumor area and will be able to diffuse into tumor cell and tumor supportive cells. 
Moreover, it may prevent early drug release that results in exposure to healthy tissue. Next 
to chemotherapeutic delivery, the emerging field of immunotherapy may greatly benefit 
from tumor ECM drug delivery. In a study from Zegers et al. [67], the chemokine IL2 was 
targeted to the tumoral ECM fibronectin extra domain B. Upon radiation, the cytotoxic 
effect of infiltrating CD8 cytotoxic T lymphocytes was enhanced by the extracellular 
presence of IL2, illustrating the possibilities to include tumor ECM targeted drug delivery 
in immunotherapy. 
Despite a number of promising in vivo results, no clinical studies using tumor ECM targeted 
chemotherapeutic delivery were identified. Therefore, to understand the full potential of 
this strategy, the step to clinical studies should be taken once the most potential tumoral 
ECM targeting strategy has been identified.
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Table 1 
Overview of drug delivery strategies targeting the extracellular matrix in tumors.
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Abstract
Current ovarian cancer treatment involves chemotherapy that has serious limitations, 
such as rapid clearance, unfavorable biodistribution and severe side effects. To overcome 
these limitations, drug delivery systems (DDS) have been developed to encapsulate 
chemotherapeutics for delivery to tumor cells. However, no systematic assessment of the 
efficacy of chemotherapy by DDS compared to free chemotherapy (not in a DDS) has been 
performed for animal studies. Here, we assess the efficacy of chemotherapy in DDS on 
survival and tumor growth inhibition in animal studies.
We searched PubMed and EMBASE (via OvidSP) to systematically identify studies 
evaluating chemotherapeutics encapsulated in DDS for ovarian cancer treatment in 
animal studies. Studies were assessed for quality and risk of bias. Study characteristics 
were collected and outcome data (survival/hazard ratio or tumor growth inhibition) were 
extracted and used for meta-analyses. Meta-analysis was performed to identify and 
explore which characteristics of DDS influenced treatment efficacy. 
A total of 44 studies were included after thorough literature screening (2735 studies found 
after initial search). The risk of bias was difficult to assess, mainly because of incomplete 
reporting. A total of 17 studies (377 animals) and 16 studies (259 animals) could be 
included in the meta-analysis for survival and tumor growth inhibition, respectively. In 
the majority of the included studies chemotherapeutics entrapped in a DDS significantly 
improved efficacy over free chemotherapeutics regarding both survival and tumor growth 
inhibition. Subgroup analyses, however, revealed that cisplatin entrapped in a DDS did 
not result in additional tumor growth inhibition compared to free cisplatin, although 
it did result in improved survival. Micelles did not show a significant tumor growth 
inhibition compared to free chemotherapeutics, which indicates that micelles may not be 
a suitable DDS for ovarian cancer treatment. Other subgroup analyses, such as targeted 
versus non-targeted DDS or IV versus IP administration route, did not identify specific 
characteristics of DDS that affected treatment efficacy. 
This systematic review shows the potential, but also the limitations of chemotherapy 
by drug delivery systems for ovarian cancer treatment. For future animal research, we 
emphasize that data need to be reported with ample attention to detailed reporting.
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Introduction
Ovarian cancer is the most lethal of all gynecological cancers. It is estimated that 
approximately 65,500 women were diagnosed with ovarian cancer and that about 42,700 
women deceased due to ovarian cancer in Europe in 2012 [1]. Conventional therapy includes 
neoadjuvant chemotherapy with subsequent surgical interval debulking and subsequent 
chemotherapy or primary surgical debulking with adjuvant chemotherapy [2, 3]. Although 
systemic intravenous administration of chemotherapeutics results in elimination of cancer 
cells, it is associated with serious shortcomings. Chemotherapeutics have a short half-life, 
are toxic to healthy cells and show an unfavorable biodistribution resulting in undesired 
side effects such as bone-marrow suppression, neuropathy, cardiotoxicity, hair loss and 
nausea [4-9]. Moreover, next to systemic intravenous (IV) administered chemotherapy, 
local intraperitoneal (IP) in combination with IV administration is applied as well and 
was found to increase survival time in ovarian cancer patients [10-12], but these 
patients had more side effects. Drug delivery systems (DDS) may overcome the current 
disadvantages of chemotherapeutics. By encapsulating toxic chemotherapeutics, DDS are 
designed to increase concentrations of chemotherapeutics at the tumor site, which could 
eventually result in higher treatment efficacy, while simultaneously reducing exposure of 
chemotherapeutics to healthy cells, resulting in a therapy with reduced side effects. 
To date, abundant research has been performed on DDS, which has resulted in many 
kinds of DDS, such as liposomes, micelles or ‘nanoparticles’ [13, 14], with different 
characteristics for treatment of various types of cancer, including ovarian cancer. Several 
factors may affect the efficacy of DDS. For instance, size can be of importance as for long 
blood-circulation times and optimal tumor penetration an optimal size range of DDS 
is estimated to be in the sub-100 nm, but not smaller than 6 nm to prevent unwanted 
removal [15]. Another parameter that is often varied among DDS is PEGylation, which 
is intended to prevent unwanted uptake by the liver and spleen by coating the surface 
of DDS with poly(ethylene)glycol (PEG) resulting in increased blood-circulation times 
[15, 16]. With increasing circulation time, increased accumulation of DDS can be found 
at the tumor site. By the enhanced permeability and retention (EPR) effect of the 
tumor cell aggregates, due to leaky blood vessels, DDS accumulate in the tumor area 
and release their content, so-called passive targeting [17]. On the other hand, a more 
active way of targeting can be achieved by conjugating anti-tumor antibodies or specific 
receptor ligands to the wall of capsules to target tumor cells specifically [18]. The 
passive and active targeting strategies mainly apply to intravenously (IV) administered 
DDS. However, as IP administered chemotherapy in combination with IV administered 
chemotherapy is being clinically applied, DDS are also being administered IP instead 
of IV in ovarian cancer [19-21], introducing another variable in DDS that can affect the 
efficacy of DDS therapies. Furthermore, the DDS preparation material can be varied from 
metals to polymers to proteins, which influences properties such as biodegradability, 
immunogenicity and toxicity, but also drug release characteristics or cellular uptake of 
DDS. Various chemotherapeutics are entrapped in DDS for ovarian cancer treatment, such 
as cisplatin, paclitaxel or doxorubicin, affecting the outcome of DDS treatment as well. 
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All in all, preclinical studies showed that many parameters can be varied in DDS. It is still 
unclear, however, which variant is most effective. 
The majority of DDS are evaluated in vitro before being tested in animal models using 
different cancer cell lines. In vivo evaluation has shown a wide range of therapeutic 
efficacies, with different treatment regimes and several time periods. Several reviews 
describe possible improved efficacies that chemotherapy by DDS may have in animal 
models for cancers such as breast cancer [22], lung cancer [23], melanoma [24], brain 
cancer [25], colorectal cancer [26] and ovarian cancer [14]. A recent literature overview 
by Tomasina et al. showed a number of DDS that have been studied for ovarian cancer 
treatment [14]. However, no systematic assessment of the efficacy of DDS in experimental 
ovarian cancer, or other cancer types, and the effects of the different characteristics of 
these DDS on treatment outcome has been reported. Therefore, we have conducted a 
systematic review of animal studies in order to gain insight into the effectiveness of the 
many types of DDS tested for ovarian cancer treatment. 
In clinical studies, systematic reviews are common practice and they are also gaining 
popularity in preclinical (animal) studies. Compared to narrative reviews, systematic 
reviews are more structured and more thorough, resulting in a more comprehensive 
and transparent overview. Systematic reviews are therefore an ideal method for gaining 
a better understanding of the role DDS play in ovarian cancer therapy. Furthermore, 
such review may give new insights into the most effective capsule characteristics, how 
to improve the use and design of animal models, and eventually clinical trials. Moreover, 
meta-analysis can be used as an additional tool in systematic reviews of animal studies. 
While in meta-analyses of clinical data the primary goal is mostly to obtain a precise 
estimate of the overall effect of a certain intervention, in meta-analyses of animal studies 
the exact overall effect size may not be that informative (because of the often large 
heterogeneity between animal studies) and therefore the goal is of explorative nature to 
identify factors that affect the main outcome [27]. 
In this article, we report the results of the first systematic review of DDS evaluated in 
ovarian cancer animal models. In a comprehensive literature screening, we included all 
animal studies that used chemotherapeutics encapsulated in a DDS and evaluated their 
therapeutic efficiency in an orthotopic ovarian cancer animal model. A complete overview 
of the available literature including an assessment of the risk of bias of the individual 
studies is included. Where possible, meta-analyses were performed to study the extent to 
the efficacy of DDS depend on the different subgroup characteristics (type of drug delivery 
system, targeted vs. non-targeted DDS, IP vs. IV administration, type of xenografted cell 
line and type of chemotherapeutic in DDS).
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Methods
Search strategy, inclusion and exclusion criteria
To include as many animal studies as possible on drug delivery systems for ovarian cancer 
treatment, a comprehensive search strategy for PubMed and EMBASE (via OvidSP) was 
developed. The search strategy consisted of three specific search components addressing: 
1) drug delivery systems; 2) ovarian cancer; and 3) animal studies. The search strategy 
included thesaurus terms and keywords on the subject of drug delivery systems and 
ovarian cancer (see supplemental methods for complete search strings). To include all 
animal studies, previously developed PubMed and EMBASE search filters were used [28, 
29]. No language restrictions were applied.
After the search strategy had been executed in PubMed and EMBASE (search up until 
September 1th 2014), duplicates were manually removed and the resulting studies were 
screened by title and abstract and classified as included, more information required 
or excluded, according to predefined exclusion criteria to exclude studies that did not 
comply with our research question (see supplemental methods for criteria). Included and 
more information required classified studies were subjected to a full text screening using 
additional exclusion criteria described in the supplemental methods. Screenings were 
performed independently by two reviewers (RR and WD) using Early Systematic Review 
Software 2.0 (EROS, Institute of Clinical Effectiveness and Health Policy, Buenos Aires, 
Argentina). Differences in classification between reviewers were discussed until consensus 
was reached. Studies in a language other than English (e.g. Japanese and Chinese) were 
screened by title and abstract by native speakers for that specific language. If a non-English 
study was included in the systematic review, it was professionally translated by “Radboud 
in ‘to Languages” (Radboud University, the Netherlands). 
Study characteristics
Journal and author information from all included studies was registered. Drug delivery 
characteristics (e.g. material, size, etc.), animal model information (e.g. species, cell lines, 
etc.) and treatment and outcome characteristics (e.g. dose, regime, tumor size evaluation, 
etc.) were extracted. Conference abstracts and studies without data comparing free drug 
vs. encapsulated drug were not included in the meta-analyses. One study [30] was not 
included in the meta-analysis as we were not able to identify the specific inoculation area 
(subcutaneous or intraperitoneal). 
Risk of bias analysis
To gain insight into the methodological quality of the included studies, we performed a 
risk of bias assessment according to an adapted version of the risk of bias tool developed 
by Hooijmans et al. 2014 [31]. Questions regarding reporting of randomization, blinding 
and sample size calculation were added to the items from the risk of bias tool (see 
supplemental methods for complete list). The complete list included 12 questions 
about the study quality such as “Was the allocation adequately concealed?’ and “Were 
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incomplete outcome data adequately addressed?”. Since we were only interested in the 
in vivo experiments, we focused on these experiments for this assessment. Risk of bias 
assessment was performed by two reviewers independently (RR and WD). Differences in 
assessment between the reviewers were discussed until consensus was reached. 
Data extraction and statistical analyses
For statistical analysis, two outcome measures that were presented frequently among the 
included studies were selected; survival (time-to-event data) and tumor growth inhibition.
Studies presenting survival data included experiments that show differences in 
survival of animals during the course of the study between the treatment conditions; 
chemotherapeutics administered in a DDS and chemotherapeutics administered without 
a DDS (free drug control). Tumor inhibition data were expressed in the studies as decrease 
in tumor size measured by, for instance, tumor weight or bioluminescence signal from the 
inoculated ovarian cancer cells. 
To compare each study’s result, data was extracted from the included studies. From 
experiments with survival data, individual time-to-event data was extracted and from 
experiments with tumor growth inhibition data we extracted the raw data such as tumor 
weight or bioluminescence signal. If these data were only depicted graphically, authors 
were contacted by e-mail to provide the numerical data. If the requested data could not be 
provided, we extracted individual time-to-event survival data or tumor growth inhibition 
means with SD and the number of animals using ImageJ (1.46r, National Institutes of 
Health, USA). 
Since raw time-to-event survival data by themselves cannot be used for meta-analysis, 
hazard ratios were calculated. Hazard ratios represent the risk of dying over the course 
of the experiment. A hazard ratio >1 indicates that animals have a higher chance of dying 
due to their experimental condition, while a hazard ratio <1 indicates that animals have 
less chance of dying over the course of the experiment due to their treatment condition. 
If numerical hazard ratios were presented in included studies, they were used directly 
without further processing for meta-analysis. All graphically extracted survival data were 
first analyzed using SPSS Statistics 20.0.01 software (IBM, Amsterdam, the Netherlands). 
Log-hazard ratios and standard errors were determined using a Cox regression analysis 
with treatment conditions set as categorical covariates. Free drug control conditions 
(chemotherapeutic not in a DDS) were set as reference category. To compare results 
between studies with tumor growth outcome measures, data were translated into 
standardized mean differences (SMD; experimental group mean minus control group 
mean divided by the pooled standard deviations of the two groups). A negative SMD 
indicates a larger inhibition of tumor growth due to treatment with DDS compared to free 
drugs (not in a DDS), while a positive SMD value indicates that treatment with free drugs 
is more effective. Means, standard deviations (SDs) and the number of animals were 
extracted from the experiments and used to calculate SMDs.
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Meta-analyses were performed using Review Manager Version 5.1 (Copenhagen, The 
Nordic Cochrane Centre, The Cochrane Collaboration, 2011). Two separate meta-analyses 
were performed for the outcome measures survival and tumor growth inhibition. For 
time-to-event data (survival), a (generic) inverse variance model with random effects 
and hazard ratio as effect measure was applied. In this model, the extracted log-hazard 
ratios with standard errors from the studies were entered in Review Manager and used 
to calculate hazard ratios with 95% confidence intervals for the meta-analysis. For tumor 
growth inhibition data, a (continuous) inverse variance model with random effects and 
standardized mean difference as effect measure was used. If the same study included 
more than two experimental conditions, the separate experiments were included in the 
meta-analysis. If in these cases there was only one control condition, the n for the control 
condition was adjusted by dividing it by the number of included conditions, to prevent 
that animals were included more than once in the meta-analysis. I2 was used as a measure 
of heterogeneity. In order to explore potential causes of heterogeneity, subgroup analyses 
were planned for 1) drug delivery system, 2) chemotherapeutic used, 3) xenografted cell 
line in animal model, 4) targeted vs. non-targeted and 5) IP vs. IV administered DDS. 
Because of a lack of power, subgroups containing less than three experiments were not 
used for subgroup analysis. To further investigate the effect of individual experiments on 
the overall effect or on subgroup effects, sensitivity analyses were performed by checking 
whether the direction of the overall or subgroup effect and their confidence intervals 
altered substantially when individual experiments were removed from the meta-analyses.
Furthermore, to identify possible publication bias (an underrepresentation of small studies 
with neutral or negative effects), a funnel scatter plot with the studies’ intervention effect 
on the horizontal axis and the studies’ standard error on the vertical axis was created and 
evaluated.
Results
Study inclusion and characteristics
Search strategies designed to include animal studies about ovarian cancer and treatment 
using drug delivery systems resulted in a total of 2735 studies, whereof 1682 and 1053 
from EMBASE and PubMed, respectively (Figure 1). After removal of duplicates, 1947 
studies were screened by title and abstract, which resulted in removal of 1682 studies. 
Subsequently, 265 studies were screened by full text. Of the studies screened by full text, 
221 studies were excluded and 44 were included in this systematic review. The major 
reason for excluding studies was the use of a clinically irrelevant animal model (“ovarian 
cancer cells used in other area than peritoneal cavity or ovaries”). 
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Figure 1. Flow chart of study inclusion. PubMed and EMBASE via OvidSP were searched using 
developed search strings to identify studies that used chemotherapeutics in a DDS in ovarian cancer 
animal models. All studies were first screened by title and abstract according to predefined inclusion 
and exclusion criteria. Subsequently studies were more specifically assessed by full text. Screenings 
were performed by two reviewers (RR and WD). Full text studies excluded for “others” were: (1) 
no full text was available or only an abstract that did not include sufficient information (n = 12); (2) 
conference abstract of a previously assessed full-text study (n = 5); (3) the study included only a 
biodistribution experiment (n = 4).
The characteristics of the included studies are summarized in supplementary table 1. 
Many different DDS were designed and used to treat ovarian cancer in vivo. Most studies 
(36%) used liposomes to encapsulate a chemotherapeutic drug. Approximately 16% of 
the studies used micelles while others used capsules labeled as nano- or microparticles 
(9% and 27%, respectively). Furthermore, studies that used nanogels, nanosuspensions, 
microbullets, virus cages and nanobins were included as well. Preparation material varied 
among the different designed DDS as shown in supplementary table 1. Active targeting to 
ovarian cancer cells using antibodies and receptor ligands such as HER-2 [32], OV-TL3 [33, 
34], folate [35-38] or luteinizing hormone-releasing hormone analogs [39] conjugated to 
the DDS were used in 30% of the included studies. 
Several studies applied specific modifications to create a triggered drug-release. Gilmore 
et al. prepared nanoparticles from an acrylate monomer to create particles that are stable 
at neutral pH and expand after endocytosis at low pH to release their payload [40, 41]. 
Xu et al. prepared cisplatin nanoparticles from poly[2-(N,N-diethylamino)ethyl methacry-
late]-block-poly(ethylene glycol) that also released its payload at low pH [42]. Moreover, 
using a poly-isobutylene-maleic-glucosamine cisplatin combination, an acid-triggered 
drug delivery system was developed and probed to treat ovarian cancer by Paraskar et al. 
and Sengupta et al. [43, 44].
Other modifications were applied to ensure specific delivery and release of anti-tumor 
drug to ovarian cancer cells and thus to increase the efficiency of the DDS in vivo. Lu et al. 
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designed two types of tumor penetrating microparticles from poly(DL-lactide-coglycolide) 
that could either prime tumors with a rapid release, or sustain a specific drug level using 
a slow release microparticle [45]. Others applied a post-ultrasound strategy to release 
the chemotherapeutic drug from micelles or to facilitate intracellular drug uptake from 
microbubbles upon injection [39, 46, 47]. 
Frequently used clinically approved chemotherapeutic agents for ovarian cancer 
treatment doxorubicin, cisplatin and paclitaxel were used in 27%, 16% and 36% of the 
studies, respectively. The remainder used other chemotherapeutic agents as described in 
supplementary table 1. One study applied co-delivery of doxorubicin and irinotecan using 
liposomes [48].
Other smaller parameters were applied to the DDS as well. About 32% of the included 
studies applied PEGylation to prolong circulation time. The route of application was 
varied among the included studies. DDS were either administered intraperitoneally (68%), 
intravenously (18%), or a combination of both (14%). 
About 7% of the studies used a rat (Fisher F344, female) model in combination with 
the NuTu19 rat ovarian cancer cell line, while the remaining (93%) used a mouse model 
that was either (73%), male (2%), a combination of male and female male (2%) or not 
described (23%). Within the mice studies, the strains and genotypes varied a lot of which 
an athymic or nude (Foxn1nu) mice lacking T-cells was most frequently used (64%). Among 
the xenografted mice models, most were inoculated with well-established ovarian cancer 
cell lines OVCAR-3 (25%) or SKOV-3 (23%). Different cell numbers were inoculated in the 
mice, but a number of 5·106 cells was most frequently used. Most studies used animals 
that were approximately 4-8 weeks old (52%), although 41% of the studies did not describe 
the age of their animal model.
Risk of bias assessment
Figure 2 provides an overview of the risk of bias assessment of the 44 included studies 
(for scores per individual study see supplemental material). A general observation in our 
risk of bias assessment was that the majority of the included studies did not provide 
sufficient information to assess the risk of bias. The studies did not adequately describe 
details regarding allocation of animals to the experimental groups, adjustments for 
baseline differences, concealment of allocation, randomization, blinding and addressing 
incomplete outcome data. 
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Figure 2. Risk of bias analysis. The risk of bias for all included studies was analyzed using several 
signaling questions. Depicted results are the answers for all studies per question.
Meta-analyses
Two types of outcome measures were frequently described in the included studies: 
survival and tumor growth inhibition. In order to obtain a general idea of the direction of 
the outcome of the different studies, meta-analyses were performed for these outcome 
measures separately. 
Survival
Forest plots
18 studies described results with survival data. These data were used to calculate 
hazard ratios. A total of 30 experiments were suitable for performing a meta-analysis, 
which represented 377 animals. From these 30 experiments, 12 experiments showed a 
significantly decrease in hazard ratio, while one experiment showed a significant increase 
in hazard ratio (Figure 3A). This may indicate that treatment of animal models for ovarian 
cancer with chemotherapeutics in a DDS is more effective in preventing death than 
treatment with free chemotherapeutics. For four studies (due to small group numbers) no 
models could be fitted, which resulted in a hazard ratio of 0 with a very wide confidence 
interval.
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Figure 3. Effects of survival outcome measure of chemotherapeutics in a DDS compared to free 
chemotherapeutics (not in a DDS. A) The forest plot depicts hazard ratios with 95% confidence 
interval (CI) and the weight of the study. A hazard ratio below 1 indicates a smaller chance for the 
animals to die over the course of the experiment due to treatment with chemotherapeutics in a 
DDS. A hazard ratio higher than 1 suggests that animals have a smaller chance of dying when treated 
with the free chemotherapeutic control condition. Statistical significance was reached when hazard 
ratios with their 95% confidence interval did not include the value of 1. Numbers in brackets behind 
study names refer to details of the specific experiments; see supplementary material for details. B) 
Subgroup analysis for type of DDS, type of chemotherapeutic, targeted vs. non-targeted, IP vs. IV 
route of administration and inoculated cell type were performed. n is the number of experiments in 
the subgroups. I2 was used as a measure of heterogeneity.
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Type of DDS
As shown in Figure 3b, a subgroup analysis was performed to evaluate the overall 
effect of experiments that used liposomes (12 experiments) or micro/nanocapsules (15 
experiments). No difference in effect on hazard ratio was found between experiments 
that used liposomes or micro/nanocapsules; all resulted in a significant decrease of the 
hazard ratio. 
Type of chemotherapeutic
To investigate whether different tumor drugs encapsulated in DDS affect the hazard 
ratio, subgroup analysis by chemotherapeutic cisplatin (7 experiments), doxorubicin 
(4 experiments) and paclitaxel (16 experiments) was performed (Figure 3B). Cisplatin, 
doxorubicin and paclitaxel all resulted in a significant decrease in hazard ratio. No 
significant differences were observed among the three drug subgroups.
Targeting vs. non-targeting
Drug delivery systems targeted specifically (12 experiments) to ovarian cancer cells 
did not result in a lower hazard ratio compared to non-targeted DDS (18 experiments). 
Both treatment strategies resulted in a lower subtotal hazard ratio, suggesting that both 
targeted and non-targeted DDS treatment result in improved survival rates (Figure 3B). 
Route of administration
A subgroup analysis of the different routes of administration was performed to explore 
whether this would affect the treatment outcome. Both IP (17 experiments) and IV (7 
experiments) administration significantly lowered the risk of dying over time (Figure 
3B). Moreover, experiments that used a combination strategy of IP and IV treatment (6 
experiments) also resulted in a lower hazard ratio. No statistical differences between IV, IP 
or a combination of IV and IP administration were observed. 
Applied xenografted cell line
Ovarian cancer cell lines SKOV-3 (9 experiments), OVCAR-3 (5 experiments), A2780 (7 
experiments), ID-8 (3 experiments) and IGROV-1 (3 experiments) subgroups could be 
included in the subgroup analysis as these had ≥3 studies in the several subgroups. This 
meta-analysis showed that mice xenografted with SKOV-3, OVCAR-3 and ID-8 followed by 
treatment with chemotherapeutics had a significant decrease in hazard ratio (Figure 3B). 
Mice xenografted with IGROV-1 or A2780 that were treated with DDS did not significantly 
benefit from DDS treatment compared to free drug controls. 
Tumor growth inhibition
Forest plot
A total of 16 studies presented data regarding tumor growth inhibition using a drug delivery 
system compared to a free drug control. From these studies, 21 experiments could be used 
for meta-analysis representing a total of 259 animals. Nine of the experiments showed a 
statistically significant result to the effect that chemotherapeutics in DDS inhibit tumor 
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growth better than free drugs (Figure 4A). The study of Konishi et al. reported a significant 
tumor growth inhibition. However, this could not be included in the meta-analysis due 
to the absence of a standard deviation in the experimental group. No studies reported 
significantly more tumor growth inhibition by free drug treatment compared to the DDS 
treatment. These results suggest that chemotherapeutics in a DDS in general have a higher 
efficacy regarding tumor growth inhibition than free chemotherapeutics.
Figure 4. Effects on tumor growth inhibition outcome measure of chemotherapeutics in a DDS 
compared to free chemotherapeutics (not in a DDS). A) The forest plot depicts SMDs with 95% 
confidence interval (CI) and the weight of the study. A statistically significant difference between 
interventional conditions (chemotherapeutic in DDS) and control conditions (chemotherapeutics 
not in a DDS) was reached when the SMD with its 95% confidence interval was greater or smaller 
than zero. If below zero, the interventional condition is more efficient in reducing the tumor size, 
while if greater than zero, the control condition is more efficient in reducing the tumor size. Numbers 
in brackets behind study names refer to details of the specific experiments; see supplementary 
material for details. B) Subgroup analysis for type of DDS, type of chemotherapeutic, targeted vs. 
non-targeted and IP vs. IV route of administration were performed. n is the number of experiments 
in the subgroups. I2 was used as a measure of heterogeneity.
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Type of DDS
To gain insight in the effectiveness of different types of DDS, a subgroup analysis by DDS 
type was performed (Fig 4b). A statistically significant difference between the subgroups 
micro/nano-particles (13 experiments) and micelles (3 experiments) was observed; 
treatment with micro/nano-particles seemed to perform better than treatment with 
micelles. On the other hand, no significant difference between the results of liposomes (3 
experiments) and micro/nanoparticles was found. 
Type of chemotherapeutic
Subgroup analysis of tumor growth inhibition data by anti-tumor drug was possible for 
the chemotherapeutics cisplatin (7 experiments) and paclitaxel (9 experiments) with 7 
and 9 experiments, respectively (Figure 4B). Surprisingly, cisplatin encapsulated in DDS did 
not result in enhanced tumor growth inhibition compared to free drug control, whereas 
encapsulated paclitaxel was much more effective than free paclitaxel. Moreover, the 
difference between subgroups paclitaxel and cisplatin was statistically significant. 
Targeted vs. non-targeted
Non-targeted DDS reach tumor cells passively by exploiting the leaky vessels of the tumor 
vasculature. On the other hand, DDS can be decorated with tumor-specific antibodies 
or receptor-ligands to actively target tumor cells. A subgroup analysis for targeted (4 
experiments) vs. non-targeted (17 experiments) DDS showed that both targeted and 
non-targeted DDS could significantly inhibit tumor growth more compared to their free 
drug controls (Figure 4B). However, no significant difference was observed between the 
targeted and non-targeted subgroups.
Route of administration
A total of 16 experiments administered their treatment IP, while 4 experiments used an 
IV strategy. Both routes seem to be effective, but no statistical difference in effectiveness 
between the two routes was found, suggesting that IP administration of DDS has no 
advantage over IV in animals. 
Sensitivity analysis
To assess the robustness of the meta-analyses’ results, a sensitivity analysis was 
performed. This analysis assessed the influence of individual studies with their specific 
experimental set-up (e.g. number and type of inoculated ovarian cancer cells, treatment 
dose and regime, or genotype differences) on the overall outcome effect.
Survival data
It was investigated whether studies that had dose differences between the DDS and 
free drug groups (marked with an asterisk in Figure 3 and 4) affected the overall effect. 
Exclusion of these studies, however, did not affect the direction of the overall effect. 
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For experiments from Chaudhury et al. (one experiment), Cirstoiu-Hapca et al. (two 
experiments), and Yang et al. (one experiment), it was not possible to accurately estimate 
a hazard ratio from the log-hazard ratios. In these experiments, there was not enough 
information (e.g. only one event over the course of the experiment) to converge and fit a 
model. This resulted in a hazard ratio of 0 with a very wide confidence interval. Excluding 
these experiments from the analysis hardly had any effect on the overall outcome. 
Tumor growth inhibition data
For tumor growth inhibition data, experiments from Javid et al. 2014 [48] and Lu et al. 
2007 [49] showed extremely high tumor growth inhibition for their DDS groups. Therefore, 
we wondered whether the overall positive effect was caused by these experiments. 
However, these studies did only affect overall tumor growth inhibition to a small extent; 
a meta-analysis without these studies still resulted in a significant inhibition of tumor 
growth due to treatment with chemotherapeutics entrapped in a DDS. 
Li and Howell, and Patankar et al. used different doses of chemotherapeutics in the 
treatment group and control group. Therefore, it was tested whether these studies were 
responsible for the positive overall outcome. However, excluding these studies did not 
affect the overall meta-analysis effect size.
Moreover, it was investigated whether two studies that used a rat model instead of 
a mouse model influenced the overall outcome (Ye et al. 2013 and Lu et al. 2007). A 
meta-analysis without these rat studies still resulted in an overall significant inhibition of 
tumor growth for animals treated with chemotherapeutics in a DDS compared to animals 
treated with free chemotherapeutics.
Publication bias assessment
Publication bias was assessed for the time-to-event outcome measure, since this outcome 
measure included the largest number of studies. To investigate publication bias, a funnel 
plot was created (Figure 5). The experiments with almost infinite confidence intervals 
(Chaudhury et al., Cirstoiu-Hapca et al. and Yang et al.,) were not included in the funnel 
plot as these would introduce a very large y-axis interval making the graph unclear. The 
funnel plot indicated missing studies at the right bottom side of the overall effect where 
small studies with a high hazard ratio (less survival in DDS group) would be expected, 
suggesting publication bias.
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Figure 5. Funnel scatter plot of time-to-event studies. Hazard ratios with a 95% confidence interval 
were extracted and used to create a funnel scatter plot using Review Manager. Bullets represent 
individual experiments from included studies. The x-axis shows the hazard ratio and the y-axis 
represents the standard error of the log(hazard ratio). The funnel plot is missing studies in the 
bottom right area in which studies with a negative outcome are expected. Since there are no studies 
in this area, publication bias is suggested.
Discussion
This systematic review was performed to investigate the effect of chemotherapeutic-DDS 
and their specific characteristics on ovarian cancer treatment in animal models. We 
looked at two outcome measures; survival and tumor growth inhibition, which resulted 
in meta-analyses of 17 and 16 studies that included 377 and 259 animals, respectively. 
Overall, the majority of the studies showed that treatment with chemotherapeutics 
entrapped in DDS used for in vivo treatment of experimental ovarian cancer had better 
efficacies on both survival and tumor growth inhibition compared to chemotherapeutics 
not entrapped in a DDS. This result is to some extent similar to what is found in clinical 
studies, which observed increased efficacy of doxorubicin in a DDS (PEGylated liposomes) 
either in different staged ovarian cancer patient groups or compared to different treatment 
regimes with other chemotherapeutics. Although these studies did not compare free 
doxorubicin and doxorubicin by a DDS, most consider PEGylated liposomal doxorubicin as 
a safe and effective treatment [50-53].
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However, a few observations in the field of drug delivery and ovarian cancer treatment 
were not supported by our results. Our results in animal studies do not show that one 
administration route (either IV, IP or a combination of both) had an advantage over 
another route looking at tumor growth inhibition and survival. This seems to be in contrast 
with clinical data where several lines of evidence suggest that treatment of ovarian cancer 
patients with a combination of IP and IV treatment with free chemotherapeutics may be 
more effective than IV treatment only [12]. It should be taken into account that these 
clinical studies were not performed with DDS and always included an additional systemic 
chemotherapy over the IP therapy. This may explain the lack of improved efficacy by IP 
treatment over IV treatment in our meta-analysis. 
An interesting observation is that our results suggest that cisplatin, a first choice 
chemotherapeutic for ovarian cancer treatment, may not be a suitable candidate for 
treatment of ovarian cancer using DDS, since cisplatin in DDS did not lead to more 
tumor growth inhibition than free cisplatin. However, this was not the case for survival, a 
clinically more important outcome measure, where all chemotherapeutics in DDS resulted 
in a significant improvement of survival compared to free chemotherapeutics. It should 
be noted that results from tumor growth inhibition and survival outcome measures 
were mostly not based on data from the same studies. Interestingly is that in a phase II 
clinical study evaluating liposomal cisplatin a lack of clinical response was observed [54]. 
Moreover, in 1998, Sugiyama et al. evaluated microspheres containing cisplatin compared 
to an aqueous solution of cisplatin and found in a small ovarian cancer patient group 
similar toxicity profiles, but no data on efficacy was shown [55]. No subsequent phase I/II 
clinical trials of this DDS regarding ovarian cancer treatment could be identified in current 
literature, which may suggest a possible lack of clinical outcome. These two cisplatin DDS 
examples may confirm our results that cisplatin may not be the most suitable drug to be 
used in a DDS for ovarian cancer treatment.
Our results show that animal studies do not indicate higher treatment efficacies by active 
targeting, as both active and passive targeting resulted in almost similar inhibition of 
tumor growth and improved survival in animal studies. This seems to be in contrast with 
the current direction of the drug delivery research field where an important goal in the 
development of DDS is to improve treatment efficacy and simultaneously decrease side 
effects of chemotherapeutics. By active targeting of tumor cells with antibodies or tumor 
receptor ligands attached to DDS, it is hypothesized that these DDS only bind to tumor 
cells and not to healthy cells, thereby improving treatment efficacy and simultaneously 
decreasing side effects [56]. All 7 included studies in our systematic review that evaluated 
chemotherapy by both targeted and non-targeted DDS did not show significant differences 
in survival or tumor reduction meta-analyses. However, if targeted therapy would show 
an advantage over non-targeted therapy, such as fewer side effects, chemotherapy by 
targeted DDS would be preferable over chemotherapy by non-targeted DDS. Nevertheless, 
none of the included studies showed data on reduction of side effects by targeted DDS. 
As our results showed no advantage of targeted DDS, although with limited power, we 
therefore carefully hypothesize that chemotherapy by targeted DDS may have no or only 
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little advantage over chemotherapy by non-targeted DDS when only looking at tumor 
growth inhibition and survival. Future animal studies investigating differences between 
chemotherapy by targeted and non-targeted DDS should be performed to show the 
advantages of targeted DDS.
Looking at tumor growth inhibition, our analysis suggested that micro/nanoparticle DDS 
are most efficient and significantly better than micelles. Micelles do not result in significant 
tumor growth inhibition, which suggests that micelles may not be the most suitable DDS 
for chemotherapeutic ovarian cancer treatment. This could not be confirmed with survival 
data, as the micelles subgroup contained too little experiments. The two experiments 
evaluating micelles and showing survival data both did not show a significant improved 
hazard ratio. Future research should therefore show whether chemotherapy using 
micelles would improve survival outcome. Moreover, we would like to emphasize that the 
micro/nanoparticle group was very heterogeneous. However, making subgroups of the 
micro/nanoparticle group was not feasible due to the lack of experiments performed with 
each specific DDS. Therefore, more experiments containing direct comparisons would be 
needed to demonstrate that a specific type or class of DDS has the best efficacy.
We tried to investigate the role of the ovarian cancer animal model. During the screening 
of studies for inclusion in this systematic review, we came across many animal studies 
that used a less physiologically relevant subcutaneous animal model [57]. As these animal 
models do not reflect the disease progression of ovarian cancer, we decided to focus 
only on studies that used a clinically important orthotopic intraperitoneal ovarian cancer 
animal model. This decision may explain why our results are less positive than the current 
direction in literature (e.g. no advantage of targeted DDS).
It is interesting that there is no consensus about the specific cell line used for the 
assessment of DDS efficacy. Domcke et al. evaluated the genetic differences between cell 
lines and original tumor tissue [58]. Most frequently used ovarian cancer cells lines such 
as SKOV3, A2780 and IGROV-1 may not be suitable models for ovarian carcinoma cell lines 
and results from experiments with these cell lines should therefore be interpreted with 
caution, especially when translating these results to the clinic. 
Our results showed no significant improved survival in animal models with A2780 or 
IGROV-1 cell lines. They may be considered to be poor models for ovarian cancer, but 
there are no explanations that these cell lines would be less sensitive for chemotherapy 
by DDS. Despite to their lack of clinical representativity, we have no reasons to prefer a 
certain cell type for experiments regarding chemotherapy by DDS based on results from 
this systematic review and meta-analysis.
We want to mention a number of limitations of this review. Both the overall analysis and 
the subgroup analyses displayed relatively high levels of heterogeneity, even though the 
levels within the subgroups were somewhat lower than in the overall analysis. Because 
of this (expected) heterogeneity, the meta-analyses were used to explore potential 
characteristics of DDS that affect final outcome in a hypothesis-forming rather than 
hypothesis-confirming manner.
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Another limitation is the lack of response from authors from included studies when asked 
to share their raw data. As only a few authors were willing to share their raw data, we had 
to extract raw data from most included studies manually. Although performed carefully, 
this may have introduced small errors in the data used for meta-analyses.
The possibility of bias in the included studies in this systematic review may have 
introduced an overestimation of the meta-analyses’ results. The reliability of the results of 
a systematic review greatly depends on the quality of the included studies. Unfortunately, 
most studies lacked reporting of important details in their experimental set-up. Therefore, 
it was difficult to assess whether studies actually had a low or high risk of bias. To 
compare efficacies of chemotherapeutics in DDS compared to free chemotherapeutics, 
the experimental set-up is of major importance. For instance, blinding and randomization 
contribute to the overall validity of the experimental set-up [59]. Most studies used 
humane endpoints for the sake of the animals’ welfare. However, if not blinded, one can 
imagine that control animals may be considered to meet humane endpoint criteria earlier 
[60], which may introduce a bias in the outcomes of the study, particularly if survival is an 
outcome measure. Moreover, almost all studies used a xenografted animal model that was 
first inoculated with cells before treatment initiation. Without any kind of randomization, 
differences in tumor baseline may be introduced that could alter the final study outcome. 
In most of the included studies it was not mentioned that blinding or randomization was 
performed, which may have introduced bias [61]. Moreover, to ensure enough power of 
an experimental design, power calculations are an essential tool. None of the included 
studies described any kind of power calculation that may suggest lack of power in the 
included studies. These possible overestimations by studies included with bias may 
implicate that our observed effects may be less reliable. However, it may also be true 
that studies were correctly performed, but that experiments were only poorly reported, 
which is known from previous systematic reviews on animal studies that most studies 
poorly describe their in vivo experiments [62]. Therefore, we would like to encourage to 
improve reporting of animal studies by using for instance the golden standard publication 
checklist [63] or the ARRIVE guidelines [64]. Finally, a funnel scatter plot analysis suggests 
publication bias, which could have introduced an overestimation of our results as well.
A major remark regarding our results is that we did not look at side effects as outcome 
measure. This aspect may change the impact of our results. For instance, IP treatment 
in patients results in increased survival, but these patients experience more severe 
side effects (e.g. pain, fatigue and gastrointestinal effects [10-12]). If the application of 
chemotherapeutics in DDS would decrease side effects in IP treatment, this may be a 
major improvement in patient quality of life. Moreover, results suggest that there is not 
a specific characteristic of DDS that outperforms in tumor growth inhibition or survival. 
Again, if a specific characteristic of DDS would show considerably less side effects, this class 
would be clinically very attractive although it does not outperform other DDS regarding 
tumor size or survival in animal studies. The same is valid for the choice of cytostatic drug. 
Our results do not suggest a specific higher efficacy for cisplatin, doxorubicin or paclitaxel 
if entrapped in a DDS regarding survival in animal studies. However, if entrapment of 
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one of these drugs results in significant less side effects, this may be again of clinical 
importance and a major argument to entrap this specific chemotherapeutic in a DDS, 
despite similar efficacies compared to the other drugs as found in this systematic review. 
Although not in ovarian cancer, O’Brien showed that free doxorubicin and PEGylated 
doxorubicin in treatment of metastatic breast cancer showed comparable overall survival 
with significantly less cardiotoxicity in the PEGylated liposomal doxorubicin group [65]. As 
only a few studies included in this systematic review addressed side-effects, an additional 
new systematic review on animal studies with meta-analysis should be performed to 
assess the specific research question; the effect of entrapment of chemotherapeutics in 
DDS on side effects.
In conclusion, delivery of chemotherapeutics with a DDS seems to be effective with regard 
to both tumor size and survival in animal models. Results of this study support the claim 
that delivery of chemotherapeutics is more effective compared to treatment with free 
chemotherapeutics, and that this efficacy is not dependent on specific characteristics of 
DDS. Future well-designed in vivo studies evaluating the efficacy of different characteristics 
of DDS on tumor size inhibition, survival and side effects should be performed to identify 
important characteristics of DDS for clinical translation.
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Supplemental material
Search strategy
PubMed
Search component 1: 
Drug delivery systems
Search component 1a:
(“Drug delivery systems”[MESH] OR “Liposomes”[MESH] OR “Micelles”[MESH] OR “Nanoparticles”[MESH] OR 
“Virosomes”[MESH] OR “Delayed-action preparations”[MESH] OR”Pharmaceutical Vehicles”[MESH] 
OR
Doxil[tiab] OR Caelyx[tiab] OR Nanotax[tiab] OR Genexol-PM[tiab] OR Myocet[tiab] OR Xyotax[tiab] OR 
Paclical[tiab] OR Abraxane[tiab] OR Biocapsul*[tiab] OR Controlled-Release Prepar*[tiab] OR Delayed-action 
prepar*[tiab] OR Delivery system[tiab] OR Delivery systems[tiab] OR Dendrimer*[tiab] OR Dendrite[tiab] OR 
Dendritic Compound*[tiab] OR Dendritic Polymer*[tiab] OR Dendron*[tiab] OR Drug carrier*[tiab] OR Drug 
targeting*[tiab] OR Drugcarrier*[tiab] OR Hollow particle[tiab] OR Hollow particles[tiab] OR Liposom*[tiab] OR 
Micell*[tiab] OR Micro capsul*[tiab] OR Microcapsul*[tiab] OR Micro partic*[tiab] OR Micropartic*[tiab] OR 
Micro spher*[tiab] OR Microspher*[tiab] OR Nano capsul*[tiab] OR Nanocapsul*[tiab] OR Nano partic*[tiab] OR 
Nanopartic*[tiab] OR Niosom*[tiab] OR Pharmaceutical Vehicle*[tiab] OR Polymersom*[tiab] OR Prolonged-Action 
Prepar*[tiab] OR Sustained-Release Prepar*[tiab] OR Timed-Release Prepar*[tiab] OR Transferosom*[tiab] OR 
Virosom*[tiab] ] OR biocapsul*[tiab] OR nano biocapsule*[tiab] OR nanobiocapsul*[tiab] OR nano carrier[tiab] 
OR nano carriers[tiab] OR nanocarrier[tiab] OR nanocarriers[tiab] OR nano sphere*[tiab] OR nanosphere*[tiab] 
OR nano spheric*[tiab] OR nanospheric*[tiab] OR nano particl*[tiab] OR nanoparticl*[tiab] OR nano 
particulat*[tiab] OR nanoparticulat*[tiab] OR nano Vehicle[tiab] OR nano Vehicles[tiab] OR nanoVehicle[tiab] 
OR nanoVehicles[tiab] OR Nano Vesicle[tiab] OR Nano Vesicles[tiab] OR nanoVesicle[tiab] OR nanoVesicles[tiab] 
OR nano vesicular*[tiab] OR nanovesicular*[tiab] OR micro biocapsule*[tiab] OR microbiocapsul*[tiab] OR micro 
carrier[tiab] OR micro carriers[tiab] OR microcarrier[tiab] OR microcarriers[tiab] OR micro sphere*[tiab] OR 
microsphere*[tiab] OR micro spheric*[tiab] OR microspheric*[tiab] OR micro particl*[tiab] OR microparticl*[tiab] 
OR micro particulat*[tiab] OR microparticulat*[tiab] OR micro vesicular*[tiab] OR microvesicular*[tiab] OR 
micro Vehicle[tiab] OR micro Vehicles[tiab] OR microVehicle[tiab] OR microVehicles[tiab] OR Micro Vesicle[tiab] 
OR Micro Vesicles[tiab] OR microVesicle[tiab] OR microVesicles[tiab])
OR
Search component 1b:
(antineoplastic agents[MESH] OR Antineoplastic Agents[Pharmacological Action] OR Pharmaceutical 
Preparations[MESH] OR Cytostatic agents[MESH] OR chemotherap*[tiab] OR Cytostat*[tiab] OR Drug[tiab] OR 
Drugs[tiab] OR Medicin*[tiab] OR Pharmaceutical Preparat*[tiab] OR pharmaceutical agent[tiab])
AND
( capsul*[tiab] OR carrier[tiab] OR carriers[tiab] OR encapsul*[tiab] OR particl*[tiab] OR particulat*[tiab] 
OR sphere*[tiab] OR spheric*[tiab] OR Vehicle[tiab] OR Vehicles[tiab] OR Vesicle[tiab] OR Vesicles[tiab] OR 
Vesicular*[tiab] )
Search component 2:
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Ovarian cancer
Ovarian Neoplasms [MESH] OR Meigs syndrome[tiab]OR Brenner tumor [tiab] OR Luteoma [tiab] 
OR (Cancer[tiab] OR Cancers[tiab] OR Carcinoma*[tiab] OR Adenocarcinoma*[tiab] OR Adeno-carcin*[tiab] 
OR Cystadenocarcin*[tiab] OR Neoplas*[tiab] OR Dysplas*[tiab] OR Hyperplas*[tiab] OR Tumor[tiab] OR 
Tumors[tiab] OR Tumour*[tiab] OR Malignan* [tiab]) AND (Ovar*[tiab] OR Brenner [tiab] OR Adnex[tiab] OR 
Adnexa*[tiab] OR Fallopian tube*[tiab]) NOT ovariectomy[MESH]
EMBASE
Search component 1: 
Drug delivery systems
Search component 1a:
Exp drug delivery system/ OR Exp nanoparticle/ OR Exp controlled release formulation/ OR
(Doxil or Caelyx or Nanotax or Genexol-PM or Myocet or Xyotax or Paclical or Abraxane or Biocapsul* or 
Controlled-Release Prepar* or Delayed-action prepar* or Delivery system or Delivery systems or Dendrimer* 
or Dendrite or Dendritic Compound* or Dendritic Polymer* or Dendron* or Drug carrier* or Drug targeting* 
or Drugcarrier* or Hollow particle or Hollow particles or Liposom* or Micell* or Micro capsul* or Microcapsul* 
or Micro partic* or Micropartic* or Micro spher* or Microspher* or Nano capsul* or Nanocapsul* or Nano 
partic* or Nanopartic* or Niosom* or Pharmaceutical Vehicle* or Polymersom* or Prolonged-Action Prepar* 
or Sustained-Release Prepar* or Timed-Release Prepar* or Transferosom* or Virosom* or biocapsul* or nano 
biocapsule* or nanobiocapsul* or nano carrier or nano carriers or nanocarrier or nanocarriers or nano sphere* 
or nanosphere* or nano spheric* or nanospheric* or nano particl* or nanoparticl* or nano particulat* or 
nanoparticulat* or nano Vehicle or nano Vehicles or nanoVehicle or nanoVehicles or Nano Vesicle or Nano Vesicles 
or nanoVesicle or nanoVesicles or nano vesicular* or nanovesicular* or micro biocapsule* or microbiocapsul* 
or micro carrier or micro carriers or microcarrier or microcarriers or micro sphere* or microsphere* or micro 
spheric* or microspheric* or micro particl* or microparticl* or micro particulat* or microparticulat* or micro 
vesicular* or microvesicular* or micro Vehicle or micro Vehicles or microVehicle or microVehicles or Micro 
Vesicle or Micro Vesicles or microVesicle or microVesicles).ti,ab,kw.
OR
Search component 1b:
Exp pharmaceutics/ OR Exp antineoplastic agent/ OR ((chemotherap* or Cytostat* or Drug or Drugs or Medicin* 
or Pharmaceutical Preparat* or pharmaceutical agent).ti,ab,kw.)
AND
((capsul* or carrier or carriers or encapsul* or particl* or particulat* or sphere* or spheric* or Vehicle or Vehicles 
or Vesicle or Vesicles or Vesicular*).ti,ab,kw.)
Search component 2: 
Ovarian cancer
exp ovary tumor/ OR (Meigs syndrome or Brenner tumor or Luteoma).ti,ab,kw. OR ((Cancer or Cancers or 
Carcinoma* or Adenocarcinoma* or Adeno-carcin* or Cystadenocarcin* or Neoplas* or Dysplas* or Hyperplas* 
or Tumor or Tumors or Tumour* or Malignan*).ti,ab,kw. )
49
Drug delivery systems for ovarian cancer treatment:
 2
a systematic review and meta-analysis of animal studies
AND 
(Ovar* or Brenner or Adnex or Adnexa* or Fallopian tube*).ti,ab,kw.
Exclusion criteria
Title and abstract screening:
1. not ovarian cancer; 
2. no drug delivery system; 
3. no primary study (i.e. only research articles, no reviews);
4. not an animal study.
Full text screening:
1. not ovarian cancer (other type of cancer cell line/primary culture); 
2. ovarian cancer in other area than peritoneal cavity or ovaries (e.g. subcutaneous); 
3. drug is not encapsulated in a particle (e.g. drug-particle conjugate);
4. drug antibody conjugate; 
5. no drug delivery system (e.g. free drugs); 
6. no chemotherapeutic drug; 
7. gene therapy (including siRNAs, immune therapy, hormone therapy or anti-angiogenesis therapy); 
8. not a primary study (i.e. only research articles, no reviews);
9. not an animal study (e.g. human or in vitro study).
Risk of bias analysis
List of items:
1. (Reporting) is it mentioned that the experiment was randomized?
2. (Bias)Was the allocation sequence adequately generated and applied?
3. Were the groups similar at baseline or was adjusted for confounders in the analysis?
4. (Reporting) Is it mentioned that the experiment was blinded (level unknown)?
5. (Bias)Was the allocation adequately concealed?
6. (Bias) Are the animals randomly housed during the experiment?
7. (Bias) Were the caregivers/ and or investigators during the course of the experiment blinded from 
knowledge of which intervention each animal received?
8. (Bias) Were animals selected at random for the outcome assessment?
9. (Bias) Was the outcome assessor blinded?
10. (Bias) Were incomplete outcome data adequately addressed?
11. (Bias) Was the study apparently free of other problems that could pose a high risk of bias?
12. (Reporting) Is a power/sample size calculation shown?
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Risk of bias scores individual studies.
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Remarks to Risk of bias scores individual studies table.
1) Potential conflict of interest
2) Not blinded while using a humane endpoint
3) Differences at baseline
4) No clear materials and methods
5) Incorrect randomization method
Supplemental material to Figure 3. Experimental details on specific experiments in meta-analysis survival 
data:
1) Chaudhury et al. 2012: carboplatin loaded non targeted liposomes vs. free carboplatin (15 mg/kg; IP)
2) Yang et al.2014: paclitaxel-microspheres vs. free paclitaxel (20 mg/kg; IP)
3) Cirstoiu-Hapca et al. 2010: Treatment initiated on day 3: Nanoparticles-paclitaxel-rituximab 
(anti-CD20) vs. free paclitaxel (initial: 20 mg/kg; subsequent 10 mg/kg; IV/IP)
4) Cirstoiu-Hapca et al. 2010: Treatment initiated on day 3: Nanoparticles-paclitaxel-trastuzumab 
(anti-HER2) vs. free paclitaxel (initial: 20 mg/kg; subsequent 10 mg/kg; IV/IP)
5) Konishi et al. 2012: irinotecan liposomes vs. free irinotecan hydrochloride (45 mg/kg; IV)
6) Pu et al. 2014: Targeted paclitaxel loaded microbubbles+ultrasound vs. free paclitaxel +ultrasound 
(20 mg/kg; IP)
7) Winer et al.2010*: F3-peptide-cisplatin-nanoparticles vs. blank+free cisplatin (75 μg/kg; IP)
8) Cirstoiu-Hapca et al. 2010: Treatment initiated on day 5: Nanoparticles-paclitaxel- rituximab 
(anti-CD20) vs. free paclitaxel (initial: 20 mg/kg; subsequent 10 mg/kg; IV/IP)
9) Shaikh et al. 2013: Encapsulated doxorubicin and irinotecan vs. free doxorubicin and free irinotecan 
(10 µmol/kg; IV)
10) Pastorino et al. 2008: TVT-doxorubicin vs. free doxorubicin (5 mg/kg; IV)
11) Pastorino et al. 2008: Caelyx vs. free doxorubicin (5 mg/kg; IV)
12) Patankar et al. 2013: Topophore C vs. free topotecan (5 mg/kg; IV)
13) Pu et al. 2014: Targeted paclitaxel loaded microbubbles vs. free paclitaxel (20 mg/kg; IP)
14) Winer et al.2010*: F3-peptide-cisplatin-nanoparticles vs. blank+free cisplatin (150 μg/kg; IP/IV)
15) Tong et al.2014: Folate-paclitaxel-liposomes vs. free paclitaxel (20 mg/kg; IP)
16) Cirstoiu-Hapca et al. 2010: Treatment initiated on day 5: Nanoparticles-paclitaxel- trastuzumab 
(anti-HER2) vs. free paclitaxel (initial: 20 mg/kg; subsequent 10 mg/kg; IV/IP)
17) Tang et al.2012: cisplatin-microparticles vs. free cisplatin (2 mg/kg; IP)
18) Winer et al.2010*: F3-peptide-cisplatin-nanoparticles vs. blank+free cisplatin (75 μg/kg IV)
19) Lee et al. 2013*: Paclitaxel-NS (25 mg/kg; IP) vs. free paclitaxel (15 mg/kg; IV)
20) Xiao et al.2009: paclitaxel nanoparticles vs. free paclitaxel (20 mg/kg; IP)
21) Li and Howell 2010*: Hyplat (CD44-targeted nanoparticles; 5 mg/kg; IP) vs. free cisplatin (10 mg/kg; 
IP)
22) Tong et al.2014: paclitaxel-liposomes vs. free paclitaxel (20 mg/kg; IP)
23) Rapoport et al. 2004: P-105 doxorubicin vs. free doxorubicin (3 mg/kg; IP)
24) Lu et al. 2008: Single dose priming tumor penetrating microparticles paclitaxel vs. single dose free 
paclitaxel (40 mg/kg; IP)
25) Tong et al.2014: Folate-paclitaxel-liposomes vs. free paclitaxel (20 mg/kg; IV)
26) Javid et al. 2014: doxorubicin-magnenite nanoparticles vs. free doxorubicin (10 mg/kg; IP)
27) Javid et al. 2014: paclitaxel-magnenite nanoparticles vs. free paclitaxel (10 mg/kg; IP)
28) Chaudhury et al. 2012: carboplatin loaded folate-liposomes vs. free carboplatin (15 mg/kg; IP)
29) Pu et al. 2014: Nontargeted paclitaxel loaded microbubbles+ultrasound vs. free paclitaxel+ultrasound 
(20 mg/kg; IP)
30) Pu et al. 2014: Nontargeted paclitaxel loaded microbubbles vs. free paclitaxel (20 mg/kg; IP)
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Supplemental material to Figure 4. Experimental details on specific experiments in meta-analysis:
1) Javid et al. 2014: Doxorubicin-magnenite nanoparticles vs. free doxorubicin (10 mg/kg; IP); tumor 
volume (mm3)
2) Javid et al. 2014: Paclitaxel-magnenite nanoparticles vs. free paclitaxel (10 mg/kg; IP); tumor volume 
(mm3)
3) Lu et al. 2007: paclitaxel-nanoparticles vs. free paclitaxel (5 mg/kg; IP); tumor weight (g)
4) Ateh et al. 2011: Paclitaxel-microparticles CD95ligand targeted vs. free paclitaxel (20 mg/kg; IP); 
relative radiance
5) Ateh et al. 2011: Paclitaxel-microparticles non-targeted vs. free paclitaxel (20 mg/kg; IP); relative 
radiance
6) Patankar et al. 2013-1*: Topophore C (2.5 mg/kg; IV) vs. free topotecan (15 mg/kg; IV); % increase in 
bioluminescence at day 42
7) Zhang et al. 2013: Nanobins(As) vs. free AsO3 (4 mg/kg; IP); tumor weight (g)
8) Yang et al. 2014: Paclitaxel-microspheres vs. free paclitaxel (20 mg/kg; IP); bioluminescence
9) Cirstoiu-Hapca et al. 2010: Nanoparticles-paclitaxel-rituximab (anti-CD20) vs. free paclitaxel (20 mg/
kg; IV/IP); % bioluminescence at day 70
10) Zhang et al. 2013: Nanobins(As) urokinase plasminogen activator targeted vs. free AsO3 (4 mg/kg; 
IP); tumor weight (g)
11) Sengupta et al. 2012: cisplatin-nanoparticles vs. free cisplatin (3 mg/kg; IV); fold change 
bioluminescence
12) Xu et al. 2006: Cisplatin pH responsive nanoparticles vs. free cisplatin (10 mg/kg; IP); tumor nodule 
number
13) Paraskar et al. 2010: cisplatin-nanoparticles vs. free cisplatin (3 mg/kg; IV); bioluminescence fold 
change
14) Ye et al. 2013: Liposu (paclitaxel-liposomes) vs. free paclitaxel (5 mg/kg; IP); tumor weight
15) Li and Howell 2010*: Hyplat (CD44-targeted nanoparticles; 5 mg/kg; IP) vs. free cisplatin (10 mg/kg; 
IP); bioluminescence
16) Gilmore et al. 2012: Paclitaxel-expansile nanoparticles vs. free paclitaxel (10 mg/kg; IP); tumor mass 
(g)
17) Xiao et al. 2009: paclitaxel-nanoparticles vs. free paclitaxel (20 mg/kg; IP); bioluminescence AU
18) Jin et al. 2007: Cisplatin-poly(ethylene glycol)-2k-50% nanogels vs. cisplatin (10 mg/kg; IP); tumor/cm
19) Konishi et al. 2012: irinotecan-liposomes vs. free irinotecan hydrochloride (45 mg/kg; IV); ascites 
volume at day 31
20) Xu et al. 2006: Cisplatin pH nonresponsive nanoparticles vs. free cisplatin (10 mg/kg; IP); tumor 
nodule number
21) Jin et al. 2007: Cisplatin-poly(ethylene glycol)-2k-25% nanogels vs. cisplatin (10 mg/kg; IP); tumor/cm
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Abbreviations: AHM = 3-(acryloyloxy)-2-hydroxypropylmethacryamide, APMA = 3-(aminopropyl)
methacrylamide, APTES = (3-aminopropyl)Triethoxysilane, AT = Arsenic Trioxide, AOT = dioctylsulfosuccinate, 
Br-16-PTX = Bromohexadecanoyl-PTX, Brij = PEG-dodecyl ether, CHOL = Cholesterol, CIS = Cisplatin, CPT = 
carboplatin, CYP = Cyclopamine, DiR = (1,19-dioctadecyltetramethyl indotricarbocyanine iodide), DMPS = 
Dimyristoylphosphatidylcholine, DOC = Docetaxel, DOTAP = 1,2-Dioleoyl-3-Trimethylammonium-propane, DOX 
= Doxorubicin, DP = Dicetyl phosphate, DPPC = Dipalmitoylphosphatidylcholine, DPPE-GA = 1,2-Dihexadeca-
noyl-sn-glycero-3-phosphoethanolamine-N-(glutaryl), DSPC =1,2-Distearoyl-sn-glycero-3-phosphocholine, DSPE 
= 1,2-distearoyl-sn-glycero-3-phosphatidyl-ethanolamine, EPG = Phosphatidylglycerol, F = Female, FA = Folate, 
FRa = Folate Receptor a, GSP = Gossypol, HSPC = Hydrogenated soy phosphatidylcholine, ITC = Irinotecan, LHRHa/r 
= Luteinizing hormone-releasing hormone analogue/receptor, M = Male, MPB = N-[4-(p-maleimidophenyl)
butyryl], Na = Not applicable, ND = not described, DCM = dichloromethane NGR = aspargine-glycine-ar-
ginine, PAE = Poly(β-aminoester), PBS = phosphate buffered saline, PC = Phosphatidylcholine, PCL = 
Poly(e-caprolactone), PDEA = Poly[2-(N,N-diethylamino)ethyl methacrylate], PDLA = Poly-D-lactic acid, PDMA 
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= poly[2-(N,N-dimethylamino)ethyl methacrylate], PE = Posphatidylethanolamine, PEG = Poly-ethyleneglycol, 
PEO-PPO-PEO = Poly(ethylene oxide)-co-poly(propylene oxide)-co-(polyethylene oxide) triblock copolymer 
(Pluronic P-105 block polymer), PIMA-GA = Poly-isobutylene-maleic acid – glucosamine, PLA = Polylactic acid, 
PLGA = Poly(lactic-co-glycolic acid), PS = Phosphatidylserine, PSA = Poly(sebacic acid), PTX = Paclitaxel SPIO = 
Superparamagnetic iron oxide, TOP = Tropophore C, uPA = urokinase Plasminogen activator. 
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Abstract
Nanoparticulate drug delivery systems are currently explored to overcome critical 
challenges associated with classical administration forms. In this study, we present a 
drug delivery system based on a novel class of proteinaceous biodegradable nano/
micro capsules, lyophilisomes. Lyophilisomes can be prepared from biomolecules 
without the need for amphiphilicity. Albumin-based lyophilisomes were prepared by 
freezing, annealing and lyophilizing, resulting in capsules ranging from 100 to 3000 
nm. Lyophilisomes were loaded with the anti-tumor drugs doxorubicin and curcumin 
using different concentrations and time/temperature regimes. Incubation in 0.1 mg/
ml doxorubicin or 1.0 mg/ml curcumin resulted in an entrapment efficiency of 95±1% 
and 4±1%, respectively. This corresponds to a drug loading of 0.24 mg doxorubicin per 
milligram albumin and 0.10 mg curcumin per milligram albumin. Drug release profiles 
from doxorubicin and curcumin-loaded lyophilisomes were studied in culture medium 
and showed slow release for doxorubicin (2.7% after 72 h), and rapid release for curcumin 
(55% after 72 h). When applied to cells, non-loaded lyophilisomes did not influence cell 
viability, even at high concentrations (1 mg/ml). Lyophilisomes were internalized by 
cells. When loaded with doxorubicin and curcumin, lyophilisomes strongly reduced cell 
proliferation and viability of SKOV-3 and HeLa cells, respectively, to a level similar or better 
compared to an equal amount of free drugs. In conclusion, albumin lyophilisomes show 
potential as (nano)carriers of drugs for tumor cell elimination. 
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Introduction
The potency of a cancer therapeutic is determined by its ability to eliminate cancerous 
tissue without damaging surrounding healthy tissue. Anti-tumor drugs are usually 
distributed non-specifically throughout the body, thereby affecting healthy tissues 
as well. To generate a successful therapeutic device, it is essential to develop systems 
which increase drug concentrations in a site-specific manner [1]. Nano/micro carrier drug 
delivery systems including polymeric particles and liposomes protect the drug from the 
environment, and may prolong drug retention time, reduce clearance and minimize side 
effects [2–4]. For biomedical applications, it would be advantageous if capsules could be 
prepared from a wide repertoire of natural (proteinaceous) macromolecules, to address 
the variety of medical demands, such as site-specific delivery, receptor-mediated cellular 
uptake and physicochemical parameters such as plasma and serum interaction.
Previously, our group described a new type of nano/micro biocapsule called “lyophilisome”, 
which can be prepared from a diversity of water-soluble macromolecules, including 
proteins, without the need for amphiphilicity [5]. The use of proteins for fabrication of 
drug delivery systems is well described in literature, which has resulted in a growing 
interest in protein delivery carriers as they are generally regarded as safe [6]. Using 
this methodology, the composition of the capsule wall can be modified and additional 
components can be incorporated into the wall (e.g. enzymes) with preserved biological 
activity, enabling an adaption to various applications [5]. In tumor targeting, albumin is 
an interesting material for carrier-mediated drug delivery, because of its biodegradability, 
biocompatibility, its lack of toxicity and of immunogenicity [7]. Lyophilisomes made of 
albumin may therefore show potential as a carrier system to be used as a delivery system 
for anti-tumor drugs such as doxorubicin and curcumin.
Doxorubicin is widely used in cancer chemotherapy and has a broad range of reactivity, 
showing anti-neoplastic activity against a number of human cancers [8,9]. The drug acts 
as an DNA intercalating agent that inhibits the enzyme topoisomerase II essential for DNA 
replication, resulting in cell death [10]. However, its clinical use is seriously hampered due 
to severe side effects [11–13]. 
Curcumin is used for its anti-tumor, anti-oxidant, and anti-inflammatory properties 
[14–18]. It affects cell proliferation, differentiation and apoptosis and the anti-carcinogenic 
properties are most likely due to effects on multiple molecular targets [19,20]. However, 
the water solubility of free curcumin is poor (maximally 11 ng/ml) [21]. It is therefore not 
possible to administer curcumin systemically.
In this study, we formulate a new protein-based drug delivery system consisting of 
lyophilisomes prepared from albumin using a freezing, annealing and lyophilization 
regime, followed by drug-loading. The loading and release characteristics of doxorubicin 
and curcumin are studied, and cytotoxicity and cellular uptake are evaluated. Finally, the 
tumor cell eliminating potential of drug-loaded lyophilisomes is described.
76
Chapter 3
Materials and methods
Materials
Bovine serum albumin (BSA) was purchased from PAA Laboratories (Linz, Austria). 
Doxorubicin, curcumin, and fluorescein isothiocyanate (FITC) conjugated bovine albumin 
were purchased from Sigma Aldrich (Steinheim, Germany). DyLight633 (amine reactive) 
was purchased from Pierce (Rockford, IL, USA). CellMask orange was purchased from 
Invitrogen (Breda, Netherlands). Glutaraldehyde and formaldehyde were obtained from 
Merck (Darmstadt, Germany). 
Methods
Preparation of lyophilisomes
A solution of 0.25% (w/v) BSA in 0.01 M acetic acid (20 µl droplets) was frozen in liquid 
nitrogen (–196°C). Generally, we use 40 ml corresponding to 100 mg albumin (2.5 mg/ml). 
In order to visualize the lyophilisomes, FITC-conjugated albumin was added to non-labeled 
albumin (1:10) in the starting solution prior to the preparation of lyophilisomes. The 
frozen albumin preparation was incubated at –10 to –20°C for 3 h (annealing step), 
and subsequently lyophilized [5]. This procedure results in hollow nano/micro spheres 
(“lyophilisomes”). The exact conditions of the freeze drying program are presented in more 
detail in Table S1 (Supplementary data). To stabilize the lyophilisomes, vapor crosslinking 
was performed using a 1:1 mixture of 25% glutaraldehyde and 37% formaldehyde for 2 h. 
To quench free aldehydes, 3.5 mg lyophilisomes were incubated in 1 ml 1% (w/v) glycine 
(Scharlau, Barcelona, Spain) in phosphate buffered saline (PBS, pH 7.4). Using gentle 
sonication (Branson Sonifier 250, 10 s, output 20) lyophilisomes were separated, washed 
three times in combination with three to four low-speed centrifugation steps (60 x g; 
Thermo, Heraeus Fresco 17; Newport Pagnell, Great Britain) to remove large lyophilisomes 
and sheet-like structures, until no pellet was observed. After this procedure, about 30% of 
the original weight of lyophilisomes remained. One fifth of this preparation (200 µg) was 
used for loading experiments and taken up in 500 µl of drug solution (see section ‘Loading 
and visualization of doxorubicin and curcumin lyophilisomes’).
In order to produce red fluorescent lyophilisomes, DyLight633 was activated by a 
N-hydroxysuccinimide ester and conjugated to the free amine groups in albumin (according 
to the manufacturer’s protocol), and subsequently dialyzed in 0.01 M acetic acid and 
mixed with non-labeled albumin in a 1:4 ratio, followed by lyophilisome preparation as 
earlier described.
Scanning electron microscopy
Lyophilisomes were deposited on poly-D-lysine coated cover slips or mounted on carbon 
tape, sputtered with gold, and analyzed using a JEOL JSM-6310 scanning electron 
microscope (Tokyo, Japan) at an accelerating voltage of 15 kV. 
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Transmission electron microscopy
Lyophilisomes were embedded in 1.5% (w/v) agarose, fixed in 2% (v/v) glutaraldehyde in 
0.1 M phosphate buffer (pH 7.4), post-fixed with 1% (w/v) osmium tetroxide, dehydrated 
in an ascending series of ethanol, and embedded in Epon 812. Ultrathin sections (60 nm) 
were cut and picked up on Formvar-coated grids, post-stained with lead citrate and uranyl 
acetate, and examined in a JEOL 1010 transmission electron microscope (Tokyo, Japan).
Dynamic light scattering
Dynamic light scattering (DLS, Zetasizer Nano-S, Malvern Instruments Ltd., Malvern, 
UK) was used to measure particle size of lyophilisomes. Stabilized lyophilisomes were 
dispersed in 0.1% (v/v) Tween-20 (Sigma Aldrich, Steinheim, Germany) in PBS (PBS-T, pH 
7.4) and analyzed by DLS.
Particle size measurements by qNano
The qNano was used to measure particle size of lyophilisomes [22]. Fluid cells were 
washed with de-izonized water and dried with a tissue. In the center of the lower fluid cell 
80 µl standard electrolyte buffer, provided by manufacturer (Izon, Science Ltd., Burnside, 
New Zealand), was placed avoiding air bubbles. The membrane was mounted on the 
instrument. The upper fluid cell was placed into position and 50 µl of standard electrolyte 
buffer was added. Pore width was controlled by adjusting the arm of the tunable nanopore 
onto the holding stage, and voltage was controlled by the connected computer. To ensure 
a continuous flow of particles, a pore size of approximately 700 to 1600 nm was used. At 
constant voltage (0.2 V), the pore was open when a direct correlation could be observed 
between ionic current and adjustment of the tunable arms of the nanopore. Finally, 
particles were added on the upper fluid cell for measurements. Data was analyzed with 
Izon Control Suite 2.1 software. 
Loading and visualization of doxorubicin and curcumin lyophilisomes
Lyophilisomes (200 µg) were incubated overnight in 500 µl 0.1 and 1.0 mg/ml doxorubicin 
in 10 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) buffer (pH 7.4; 
Promega, Madison, WI, USA), and 0.1 and 1.0 mg/ml curcumin in 100% (v/v) ethanol 
at either 4°C, room temperature or 37°C. Subsequently, they were centrifuged (17,000 
x g), washed three times in 1.0 ml 0.1% PBS-T and stored at 4°C. Loaded capsules were 
deposited on poly-D-lysine coated cover slips and the location of doxorubicin and 
curcumin in lyophilisomes was studied using confocal laser scanning microscopy (Olympus 
FV1000, Olympus GmbH, Hamburg, Germany) and analyzed with FV 10-ASW 1.6 Viewer 
software. FITC-lyophilisomes and curcumin were visualized with an argon laser at 488 
nm, DyLight633 lyophilisomes and doxorubicin with a diode laser at 559 and 635 nm, 
respectively.
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Entrapment efficiency
The entrapment efficiency of doxorubicin and curcumin in lyophilisomes was determined 
as follows: lyophilisomes were separated from the free drug using centrifugation (17,000 
x g) and washed three times in 1.0 ml PBS-T. The supernatant with free drug was collected 
and absorbance was measured spectrophotometrically using a Synergy 2 plate reader 
at 490 nm for doxorubicin and 420 nm for curcumin (Biotek, Winooski, VT) assuming 
that drug not present in the supernatant was entrapped in lyophilisomes [23,24]. The 
concentration was calculated using a calibration curve of doxorubicin and curcumin in 
HEPES buffer and ethanol respectively and all measurements were performed in triplicate. 
Entrapment efficiency was calculated as follows: 
Drug release from doxorubicin and curcumin loaded lyophilisomes 
Drug release from loaded lyophilisomes was examined at three temperatures (4°C, room 
temperature, and 37°C), at three time points (24, 48, and 72 h) and both in PBS and culture 
medium. Lyophilisomes (200 µg) were loaded with 500 µl of 0.1 mg/ml doxorubicin and 
1.0 mg/ml curcumin at room temperature as described above. Subsequently, samples 
were centrifuged (17,000 x g, 5 min, 4°C) and washed three times in 1.0 ml PBS. Pellets 
were resuspended in 500 μl PBS or culture medium (RPMI 1640 + L-glutamine without 
phenol red, Gibco Karlsruhe, Germany). Culture medium was supplemented with 10% 
(v/v) heat-inactivated fetal calf serum (FCS; PAA Laboratories, Pasching, Austria). In this 
study, curcumin was dissolved in ethanol prior to loading. Released curcumin precipitated 
in the medium and was dissolved in ethanol and measured spectrophotometrically. 
Release was determined spectrophotometrically at 490 nm for doxorubicin and 420 nm 
for curcumin, and calculated as follows:
Cell culture
All culture media were purchased from Gibco (Karlsruhe, Germany) unless indicated 
otherwise. The human ovarian cancer cell line SKOV-3 was cultured in McCoy 5A GlutaMAX 
medium supplemented with 10% (w/v) FCS. HeLa cells were cultured in RPMI 1640 
GlutaMAX supplemented with 10% (w/v) FCS. The cells were cultured in a humidified 
atmosphere with 5% CO2 at 37°C. Subconfluent cells were dissociated with 0.05% (w/v) 
trypsin and 0.02% (w/v) ethylenediaminetetraacetic acid (EDTA) in Dulbecco’s-PBS (PAA 
Laboratories, Pasching, Austria) and were maintained as proliferating cultures.
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Cytotoxicity studies
To investigate the cell viability of cancer cells exposed to lyophilisomes with and without 
doxorubicin or curcumin, the 4-[3-(4-iodophenyl)-2-(4-nitrophenyl)-2H-5-tetrazolio]-1,3-
benzene disulfonate (WST-1, Roche Diagnostics, Mannheim, Germany) cell proliferation 
assay was performed. SKOV-3 cells were chosen to analyze the cell eliminating potential 
of doxorubicin loaded lyophilisomes because this drug is frequently used to treat 
ovarian cancer [25,26]. HeLa cells were used to examine the effect of curcumin-loaded 
lyophilisomes, since this tumor cell line is susceptible to the cytotoxic effect of curcumin 
[23,27]. To access the efficiency of doxorubicin or curcumin on SKOV-3 and HeLa cells, free 
doxorubicin or curcumin was added to cells in an ascending concentration (0, 1, 5, 10, 20 
and 50 µM). To efficiently eliminate SKOV-3 and HeLa cells, 20 µM of free doxorubicin or 
curcumin was required. For curcumin, a stock solution (2 mM) was prepared in ethanol. 
This was further diluted in medium before adding to the cell culture. As a control, ethanol 
only was added in equal concentration to cells and this did not affect cell viability (results 
not shown). Cells were seeded into 96-well plates at a concentration of 2000 cells per well. 
On the next day, equivalent amounts of free and lyophilisome-incorporated doxorubicin/
curcumin were added corresponding to 20 µM of the drug. As a control, a similar 
concentration of empty lyophilisomes was added. After 24, 48, and 72 h, medium was 
replaced, WST-1 reagent was added and incubated for 2 – 4 h at 37°C. Absorbance was 
analyzed using a Synergy 2 plate reader at 410 nm. Untreated cells served as a control. All 
experiments were performed in triplicate.
Intracellular uptake study
To study internalization of lyophilisomes, confocal microscopy was performed on living 
cells. Cells were cultured up to 80% confluency and incubated with 50 µl of lyophilisome 
suspension (lyophilisome content 125 µg/ml) for 24 h in RPMI medium containing 10% 
FCS. After incubation, cells were washed once, incubated for 5 min with CellMask orange 
(5 µg/ml) to visualize the cell membranes and then washed again, all with the same 
medium. Cells were kept at 37°C on a temperature controlled microscope stage and living 
cells were imaged immediately with a Leica SP5 confocal microscope (Leica Microsystems, 
Mannheim, Germany). FITC was excited at 488 nm and emission was collected between 
500 and 550 nm. CellMask orange was excited at 561 nm and emission was collected 
between 570 and 650 nm. Images were recorded sequentially using Leica Application 
Suite Software (Advanced Fluorescence Lite, 2.3.0. build 5131). 
Statistical analysis
Data are presented as mean with standard deviation. Drug entrapment experimental 
data were analyzed using two-tailed Student’s t-tests. Cell eliminating potential assays 
were analyzed using two-way Anova Bonferroni post tests. All statistical analyses were 
performed in Graphpad Prism 5.0 (Graphpad, San Diego, CA, USA).
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Results
Characterization of lyophilisomes
Lyophilisomes were prepared by a freezing, annealing and lyophilization regime, and 
analyzed by dynamic light scattering (DLS), qNano, scanning and transmission electron 
microscopy (SEM, TEM). 
Table 1
Figure 1. Scanning electron microscopical image (a) and transmission electron microscopical image 
(b) of lyophilisomes, showing spherical capsules ranging from 100 up to 3000 nm. Bar represents 10 
µm in (a) and 1 µm in (b).
The size distribution of lyophilisomes is summarized in table 1. Using DLS, the mean 
particle diameter of lyophilisomes was measured 1695 ± 55 nm with a polydispersity 
index of 0.726 ± 0.035. This indicates a rather heterogeneous particle size distribution. For 
DLS it is known that larger particles will dominate smaller particles during measurement, 
resulting in a larger mean particle size. When measuring the lyophilisomes using qNano, 
a mean particle size of 1214 ± 79 nm was found. Using this instrument, particles smaller 
than 700 nm were not detected with the specific pore used for our experiments (700 
– 1600 nm), since they were eliminated against background levels. To investigate the 
lyophilisome preparation further, SEM was used and revealed globular structures ranging 
from 100 nm up to 3000 nm (Figure 1A) and TEM verified that capsules indeed contained 
a lumen (Figure 1B). Besides capsules, sheet-like structures were formed. In order to use 
81
Lyophilisomes as a new generation of drug delivery capsules
 3
lyophilisomes as a drug delivery system they were stabilized by crosslinking in the vapor of 
a mixture of glutaraldehyde and formaldehyde. Particles thus prepared did not coagulate 
and no aggregation was observed in buffer or culture medium.
Loading and visualization of doxorubicin and curcumin in lyophilisomes
To visualize entrapment of doxorubicin and curcumin within lyophilisomes and to 
demonstrate the drug distribution within the lyophilisomes, FITC- and DyLight633 labeled 
lyophilisomes were used, respectively. For doxorubicin loaded FITC-lyophilisomes confocal 
microscopy showed red auto-fluorescence of doxorubicin within green-fluorescent 
lyophilisomes (Figure 2A). Curcumin loaded DyLight633 lyophilisomes (Figure 2B) 
showed green auto-fluorescence of curcumin within the red-fluorescent DyLight633 
lyophilisomes. Both doxorubicin and curcumin showed a homogeneous distribution 
throughout the capsule lumen, but they were also visible in the capsule wall (Figure 2A 
and B). The merged image (Figure 2A3 and B3) is an overlay of doxorubicin and curcumin 
in lyophilisomes (Figure 2A2 and B2) and the corresponding lyophilisome image (Figure 
2A1 and B1). 
For the loading of doxorubicin and curcumin in lyophilisomes, two concentrations were 
used at room temperature, i.e. 0.1 and 1.0 mg/ml. For doxorubicin, 0.1 mg/ml resulted 
in an entrapment efficiency of 95±1%. With 1.0 mg/ml, an entrapment efficiency of 
48±2% was obtained (Figure 2C). Despite this lower entrapment efficiency, the absolute 
amount of doxorubicin was 5 x higher when incubated at the higher concentration. This 
corresponds to a drug loading of 0.24 and 1.2 mg doxorubicin per milligram albumin 
(Table 2). For curcumin, an entrapment efficiency of 5±2% was achieved using 0.1 mg/ml 
curcumin. Using 1.0 mg/ml, entrapment was 4±1% resulting in an 8 x higher loading of 
curcumin (Figure 2D). This corresponds to a drug loading of 0.01 and 0.10 mg curcumin 
per milligram albumin (Table 2). As an alternative to establish the amount of doxorubicin 
in lyophilisomes, they were digested using papain resulting in the liberation of the 
encapsulated doxorubicin that was measured spectrophotometrically. Using this method, 
a loading efficiency of 95% was calculated. To verify that the anti-tumor drugs were 
entrapped in lyophilisomes, bare lyophilisomes and doxorubicin and curcumin loaded 
lyophilisomes were centrifuged. Results show clear supernatants and colored pellets for 
doxorubicin and curcumin, indicating the absence of free anti-tumor drug (Figure 2E). Use 
of other temperatures (4°C, 37°C) did not influence entrapment efficiency, which was 92 
– 96% for doxorubicin and 3 – 5% for curcumin.
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Figure 2. Visualization and loading efficiency of doxorubicin and curcumin in lyophilisomes. (a and 
b) Lyophilisomes after incubation in doxorubicin containing HEPES buffer (a) or curcumin in ethanol 
(b) result in entrapment of the drug. In a4 and b4, lyophilisomes are depicted without drug to 
show their lumen. Note that since both anti-tumor drugs are also visible at wavelengths used to 
visualize lyophilisomes the lumen cannot be visualized in the presence of the drugs. The merge 
image (a3 and b3) is an overlay of image (a1 and b1) and (a2 and b2). Bar represents 1 µm. c 
and d) Entrapment efficiency in lyophilisomes of doxorubicin (c) and curcumin (d) after overnight 
incubation of lyophilisomes in 0.1 and 1.0 mg/ml drug; **p<0.001. (e) Centrifuged lyophilisome 
suspensions (1: without drug; 2: with doxorubicin; 3: with curcumin) show a clear supernatant and 
white, red, and yellow pellet, indicating entrapment of the drugs.
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Table 2 
Drug entrapment in lyophilisomes
Drug release studies
The drug release of doxorubicin and curcumin from lyophilisomes was studied both 
in PBS and medium supplemented with 10% FCS, for a time period up to 72 h at 4°C, 
room temperature and 37°C. The release of doxorubicin from loaded lyophilisomes was 
limited, both for PBS and medium (Figure 3A and B). The highest release was observed at 
37°C, i.e. 2.4±0.4% and 2.7±0.3% after 72 h in PBS and medium, respectively. In contrast, 
curcumin-loaded lyophilisomes showed a much higher release, i.e. in PBS 42±5% at 24 
h, 50±2% at 48 h, and 56±2% at 72 h (Figure 3C and D). Similar releases were obtained 
for medium (46±4% at 24 h, 52±6% at 48 h, and 55±8% at 72 h). Temperature did not 
influence the release profile of curcumin loaded lyophilisomes.
Cell viability in the presence of lyophilisomes
In order to investigate whether lyophilisomes are cytocompatible, empty lyophilisomes 
were administered to cells in ascending concentrations, ranging from 0 to 1000 µg/ml. 
Cell viability was not compromised as indicated by a WST-1 proliferation assay showing 
comparable values for SKOV-3 and HeLa cells with and without lyophilisomes (Figure 4). 
Despite coverage of cells by lyophilisomes, also no detectable morphological changes 
were visible at the light microscopical level (data not shown).
Intracellular uptake of lyophilisomes
The ability of lyophilisomes to be internalized by cells was studied by confocal microscopy. 
HeLa cells were incubated with lyophilisomes and after 24 h uptake of lyophilisomes was 
observed (Figure 5). When incubated with lyophilisomes, cells clearly contained green 
fluorescent hollow spheres at 24 h, representing the lyophilisomes (Figure 5B). The 
plasma membrane dye CellMask further indicated that the lyophilisomes were indeed 
internalized and not merely associated with the plasma membrane. In addition, the 
corresponding bright field image showed that lyophilisomes did not lead to detectable 
morphological changes of the cells (Figure 5C and D), further corroborating the absence 
of cytotoxic effects.
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Figure 3. Drug release from doxorubicin and curcumin loaded lyophilisomes in PBS and medium. 
(a and b) Lyophilisomes were incubated in 0.1 mg/ml doxorubicin in HEPES buffer, washed three 
times, and release was analyzed in PBS and medium. A similar release profile was obtained for 
PBS (a) and medium (b) with a maximum release of 2.4±0.4% and 2.7±0.3% after 72 h. (c and d) 
Curcumin release profiles of loaded lyophilisomes after incubation in 1.0 mg/ml curcumin in ethanol 
and washing three times. Curcumin release was 56±2% and 55±8% after 72 h in PBS and medium, 
respectively. Note variation in the range of y-axis.
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Cell eliminating potential of lyophilisomes loaded with doxorubicin or curcumin
To compare the cell eliminating potential of both anti-tumor drug loaded lyophilisomes, 
a WST-1 proliferation assay was used. A concentration of 20 µM of free doxorubicin or 
free curcumin was required to eliminate SKOV-3 and HeLa cells, respectively. To assess 
the effect of doxorubicin and curcumin loaded lyophilisomes on tumor cells, equivalent 
amounts of free and drug loaded lyophilisomes were used. As a control, a similar 
concentration of empty lyophilisomes was employed. Due to the high entrapment 
efficiency, doxorubicin loaded lyophilisomes with 0.1 mg/ml loading concentration were 
used. Since curcumin had a lower entrapment efficiency, lyophilisomes loaded with a 1.0 
mg/ml curcumin solution were applied. Lyophilisome contents correspond to 50 – 100 
µg/ml lyophilisomes, a concentration at which cell viability is ensured (Figure 4).
Figure 4. Cell viability of SKOV-3 and HeLa cells after incubation with lyophilisomes. Cells were 
exposed to various contents of empty lyophilisomes and cell viability assays (WST-1) were performed 
after 72 h. Cell viability was not affected by the presence of lyophilisomes.
Exposure to doxorubicin-loaded lyophilisomes (corresponding to 20 µM free doxorubicin) 
inhibited SKOV-3 ovarian cancer cell growth in a time-dependent manner (Figure 6A). 
Similar inhibition of cell proliferation was observed for free doxorubicin and entrapped 
doxorubicin, where entrapped doxorubicin only resulted in lower SKOV-3 cell viability at 
24 h (p<0.05). After 72 h of culture, cell viability had decreased to 6% in comparison to 
cells treated with non-loaded lyophilisomes.
86
Chapter 3
When HeLa cells were incubated with curcumin loaded lyophilisomes (corresponding to 
20 µM free curcumin) also a decrease in cell viability was observed. Curcumin loaded 
lyophilisomes exerted a more pronounced effect on the cancer cells as compared to free 
curcumin after 24 h (p<0.05), 48 h and 72 h (p<0.001; Figure 6B). After 72 h of culture, cell 
viability had decreased to 2% in comparison to cells treated with non-loaded lyophilisomes. 
The low cell viability results for both SKOV-3 and HeLa cells after incubation with loaded 
lyophilisomes were consistent with the small remaining number of cells observed by light 
microscopy (data not shown).
Figure 5. Cellular uptake of lyophilisomes studied by confocal laser scanning microscopy. HeLa cells 
were cultured in an 8-well microscopy chamber to 80% confluency and treated without (a and c) and 
with (b and d) lyophilisomes for 24 h. Note internalization of lyophilisomes (b). Inset: magnification 
of internalized lyophilisomes. Green fluorescence corresponds with FITC-lyophilisomes and 
fluorescence of CellMask orange is shown in red. Bright field images (c and d) show general 
morphology of the cells. The scale bar represents 20 µm in (a-d) and 2 µm in inset (b).
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Figure 6. Time dependent effect of doxorubicin and curcumin loaded lyophilisomes on cell viability 
of SKOV-3 (a) and HeLa cells (b). Similar dosages of free doxorubicin/curcumin and doxorubicin/
curcumin containing lyophilisomes were used, and cell viability was assayed using WST-1. (a) 
SKOV-3 cells generally responded to doxorubicin loaded lyophilisomes in a similar fashion as free 
doxorubicin. (b) HeLa cells showed a more pronounced response to curcumin loaded lyophilisomes 
compared to free curcumin at later time points. *p<0.05 **p<0.001.
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Discussion
In the past decade, the field of drug delivery for cancer has been revolutionized with 
the advent of nanotechnology, and biocompatible nanoparticles have been developed as 
systemic carriers for therapeutic compounds to target specific cells and tissues. Numerous 
investigations have been conducted to develop more efficient systems for drug delivery. 
The most important challenge in the formulation of drug delivery systems involves the 
preparation of carrier systems that are capable of encapsulating the desired drug and 
deliver it to the tumor tissue in its active form. Liposomes constitute an effective drug 
delivery system, as exemplified by Doxil [28]. However, their chemical and physical 
instability during manufacturing and storage still poses a challenge [29]. In a quest for stable 
and efficient carrier systems for anti-tumor agents, we have developed a drug delivery 
system named ‘lyophilisomes’ [5]. The process to produce lyophilisomes is physical rather 
than chemical in nature, and allows for the use of biological macromolecules, including 
proteins, as the wall material. Nanoparticles made from albumin are well tolerated by 
the body, as indicated by clinical studies with FDA approved albumin nano/micro particle 
formulations such as Albunex [30,31] and Abraxane [32,33].
Albumin is the main protein in the plasma and is best known for its remarkable ligand 
binding capacity, providing an arsenal of compounds with favorable, noncovalent 
reversible binding characteristics for transport in the body and release at the cell 
surface [34,35]. Potential drug loading mechanisms include electrostatic attraction and 
hydrophobic interactions. Moreover, albumin drug delivery systems offer possibilities 
for surface modification due to the presence of functional groups (i.e. carboxylic and 
amino groups) enabling specific drug targeting to the site of action [35]. Albumin-based 
systems are considered safe since they are metabolizable in vivo by digestive enzymes into 
innocuous peptides whereas synthetic polymers may give harmful degradation products 
[6]. In addition, albumin is thought to facilitate endothelial transcytosis of unbound and 
albumin-bound plasma constituents into the extravascular space. This process is initiated 
by binding of albumin to a cell surface, 60-kDa glycoprotein (gp60) receptor [36].
In this study we prepared albumin-based lyophilisomes. Even large numbers of 
lyophilisomes did not affect SKOV-3 and HeLa cell viability. After 24 h lyophilisomes were 
internalized by HeLa cells, without changes in proliferation or morphology, indicating 
that they are non-cytotoxic. Quite interestingly, this uptake occurred in the absence of 
an internalization signal such as a receptor ligand or a cell-penetrating peptide. It remains 
to be shown in which way such modifications would modulate uptake kinetics and/or 
efficiency.
To investigate whether lyophilisomes could be used for drug delivery, we used doxorubicin 
and curcumin as model drugs and analyzed their incorporation into lyophilisomes. This 
procedure was based on diffusion of the drug into the capsule. Interestingly, doxorubicin 
loaded lyophilisomes resulted in a high entrapment efficiency (95%) together with a very 
low release (2 – 3% after 72 h). This effect cannot be explained by the process of simple 
diffusion. Albumin is known as an important transport protein and has several binding sites 
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for hydrophobic compounds, which may explain the affinity of albumin for doxorubicin, 
maintaining the drug within lyophilisomes [37,38]. Albumin-based lyophilisomes may 
be a suitable delivery system for this drug and doxorubicin loaded lyophilisomes may be 
prepared upfront and stored at 4°C or in a lyophilized state. Next to doxorubicin, we also 
analyzed the drug curcumin. The entrapment efficiency of curcumin was quite low (4%) 
and release was rather fast (±55% after 72 h). Similar release profiles have been observed 
for curcumin in other nanoparticle systems, e.g. alginate-chitosan-pluronic composite, 
PLGA, and polymeric nanoparticles [23,39,40]. To retain the drug within the lyophilisomes 
for a longer time, lyophilisomes may be further crosslinked after loading which will make 
the capsule’s wall less porous and may result in a better retention of curcumin. 
In order to investigate the cell eliminating potential of our formulations, SKOV-3 and HeLa 
cells were treated with lyophilisomes loaded with doxorubicin or curcumin, respectively. 
Doxorubicin-loaded lyophilisomes showed a profound cytotoxic effect similar to free 
doxorubicin (20 µM in culture medium). This activity was contrasted with the low release 
of the drug from doxorubicin-loaded lyophilisomes in PBS or medium (3% of 20 µM is 0.6 
µM). This concentration is likely not sufficient to induce cell death. An explanation for 
the efficacy of loaded lyophilisomes may be their internalization into the cell, followed 
by drug release inside the cell, which may be assisted by the action of endogenous 
proteinases. Alternatively, the albumin wall of lyophilisomes attached to the outside 
of the cell may be damaged (e.g. by excreted enzymes) to locally release high doses of 
doxorubicin resulting in elimination of cells. For curcumin-loaded lyophilisomes, which 
are more effective than free curcumin, a similar effect may be put forward: local release 
of curcumin and internalization of drug-loaded lyophilisomes. It should be noted that the 
wall of the lyophilisomes can be made from any protein, and can be adapted to the type 
of drug and the proteases / microenvironment of specific tumor cells. 
Before drug delivery systems reach the target site, they need to travel through the 
vascular bed. Particle size has a fundamental effect on biodistribution [41]. For cancer, 
an effective strategy is based on the enhanced permeability effect (EPR) associated with 
hyperpermeability of tumor vasculature and lack of lymphatic drainage [42]. Nanoparticles 
usually do not extravasate through normal endothelium since tight endothelial junctions 
(5 – 10 nm) between endothelial cells prevent extravasations of small particles [43]. 
However, due to the EPR effect, nanoparticles (<500 nm) can extravasate from the blood 
vessels to the tumor and accumulate, creating high local drug concentrations [44]. The 
cut-off size for permeability in individual tumor varies between 200 and 800 nm [45]. 
Lyophilisomes have a rather large size distribution, ranging from 100 to 3000 nm. A next 
step is therefore to size them to appropriate diameters to make them more suitable to 
employ the enhanced permeability effect in tumors and functionalize the capsules with 
targeting molecules to increase specificity.
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Conclusions
This study demonstrates the potential of albumin-based lyophilisomes as a drug delivery 
system. Both doxorubicin and curcumin-loaded lyophilisomes were capable of efficiently 
eliminating tumor cells in vitro. 
Table S1
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Abstract
Epithelial ovarian cancer is characterized by a high mortality rate and is in need for 
novel therapeutic avenues to improve patient outcome. The tumor’s extracellular matrix 
(“stroma”) offers new possibilities for targeted drug-delivery. Recently we identified highly 
sulfated chondroitin sulfate (CS-E) as a component abundantly present in the ovarian 
cancer extracellular matrix, and as a novel target for anti-cancer therapy. Here, we report 
on the functionalization of drug-loaded lyophilisomes (albumin-based biocapsules) to 
specifically target the stroma of ovarian carcinomas with the potential to eliminate cancer 
cells. To achieve specific targeting, we conjugated single chain antibodies reactive with 
CS-E to lyophilisomes using a two-step approach comprising sortase-mediated ligation 
and bioorthogonal click chemistry. Antibody-functionalized lyophilisomes specifically 
targeted the ovarian cancer stroma through CS-E. In a CS-E rich micro-environment in vitro 
lyophilisomes induced cell death by extracellular release of doxorubicin which localized to 
the nucleus. Immunohistochemistry identified CS-E rich stroma in a variety of solid tumors 
other than ovarian cancer, including breast, lung and colon cancer indicating the potential 
versatility of matrix therapy and the use of highly sulfated chondroitin sulfates in cancer 
stroma as a micro-environmental hook for targeted drug delivery.
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Introduction
Epithelial ovarian cancer is the fifth leading cause of cancer-related death in women 
worldwide [1]. Most patients are diagnosed with an advanced stage of disease 
(Fédération Internationale de Gynécologie et d’Obstétrique (FIGO) stage III-IV) and 
suffer from extensive abdominal metastases [2, 3]. Aggressive surgical cytoreduction 
and chemotherapy are used as primary treatment, but nevertheless up to 70% of these 
patients will develop recurrent disease and eventually succumb. Long term survival is 
poor with a 5-year survival of less than 35% [2, 3]. Overall survival statistics have not 
significantly improved over the last decades and new avenues for better treatment are 
clearly warranted [4].
Conventional chemotherapeutics affect proliferating cancer cells as well as normal cells, 
resulting in systemic adverse events that greatly affect quality of life. As a consequence, 
the dose administered has to be limited resulting in a suboptimal treatment that negatively 
affects prognosis of cancer patients. The use of drug delivery systems may be helpful 
to overcome these problems by improving biodistribution, resulting in high local drug 
concentrations at the tumor site while minimizing exposure to healthy cells [5]. Beneficial 
effects of drug delivery systems such as liposomal doxorubicin (Caelyx/Doxil) and albumin 
bound paclitaxel (nab-paclitaxel), have been reported in several (pre)-clinical studies 
[6-9]. Previously we described a novel class of drug delivery vehicles, lyophilisomes, 
which are spherical nano- to microsized biocapsules that can be prepared from various 
proteins (e.g. albumin, collagen, and elastin) [10, 11]. Albumin-based lyophilisomes can 
be efficiently loaded with doxorubicin and are able to eliminate ovarian cancer cells in 
vitro [10]. In addition, the albumin wall of lyophilisomes offers opportunities for functional 
modification, e.g. by the incorporation or conjugation of components in and/or on the 
wall. Antibody-conjugated lyophilisomes have been shown to specifically bind to cancer 
cells expressing the corresponding antigen, thus enabling active cancer-targeting [12]. 
Although it is hypothesized that active targeting of cancer cells by drug delivery systems 
using specific antibodies or ligands has the potential to broaden the therapeutic index of 
anti-cancer drugs, the favorable effect of tumor-cell targeting over non-targeting systems 
was reported to be disappointing [5, 6, 13]. As most of these studies have focused on 
targeting cancer cells, other approaches such as targeting the cancer extracellular matrix 
(ECM) may offer valuable alternatives [14]. 
The ECM represents a network of proteins and proteoglycans that is abundantly remodeled 
during cancer development and actively contributes to cancer progression [15, 16]. A large 
amount of intratumoral matrix correlates with poor prognosis in cancer, including ovarian 
cancer [17]. Major components of the ECM are collagen, laminin and proteoglycans. 
Proteoglycans function to a large extent through their glycosaminoglycan side chains; 
linear negatively charged polysaccharides built from repeating disaccharides [18]. Highly 
4,6-sulfated chondroitin sulfate (CS-E), a specific class of glycosaminoglycans, is found 
to be abundantly expressed in the ovarian cancer stroma while being absent or present 
in only very small amounts in healthy stroma, thus representing an attractive target for 
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anti-cancer therapy [19, 20]. Interestingly, the amount of these targets expressed in the 
stroma is relatively high when compared to targets expressed at the cancer cell surface.
In this study, we present an innovative concept of an anti-cancer strategy aiming at 
forming a depot of chemotherapeutic-loaded lyophilisomes in the ovarian cancer ECM. 
Targeting the cancer ECM rather than cancer cells might be helpful to overcome hurdles 
observed in cell-targeting therapies as the cancer ECM is a relatively stable structure, 
unlike cancer cells that are characteristically genetically instable [21]. Due to intratumoral 
heterogeneity, cell-targeting therapies may only affect subpopulations of cancer cells, and 
leave other cancer cells and cancer-promoting cells (e.g. cancer-associated fibroblasts, 
endothelial cells, and macrophages) unaffected [22]. Release of chemotherapeutics from 
a depot of drug-loaded lyophilisomes in the cancer ECM may affect all cells in its vicinity 
including cancer cells, cancer stem cells and cancer-associated stromal cells. Collagens 
have been used as micro-environmental anchors for targeted anti-cancer therapy [23, 24], 
but collagen is also abundantly present in normal tissues. Therefore, in this study we focus 
on CS-E as a much more cancer-specific molecular target. We describe the construction 
and evaluation of a lyophilisome-based drug delivery system specifically targeting highly 
sulfated CS-E in the ovarian cancer stroma. 
Materials and methods
Patient material
Study approval was given by the Regional Committee for Medical Research Ethics and 
performed according to the Code for Proper Secondary Use of Human Tissue (Dutch 
Federation of Biomedical Scientific Societies, www.federa.org). Cryosections (5 µm) 
of advanced stage high grade serous ovarian cancer were used for immunofluorescent 
analysis of antibody-functionalized lyophilisome specificity. Paraffin embedded sections 
(4 µm) of lung, cervical, breast, renal cell, endometrial, and colon cancer were used for 
immunohistochemical analysis of CS-E expression.
Production of antibody-functionalized lyophilisomes
Modification of GD3G7 antibodies for sortase-mediated conjugation
The single chain antibody GD3G7 was previously selected against embryonic 
glycosaminoglycans and showed specificity for CS-E [19]. For site-selective conjugation 
of GD3G7 at the carboxy terminus, leaving the antigen-binding parts of this antibody 
intact, the LPETG sortase A-recognition motif was introduced. To this end the GD3G7 
reading frame was cloned in plasmid pHENIX-LPETG-His-VSV to yield pHENIX-GD3G7-
LPETG-His-VSV. Expression of the fusion protein in E.coli strain ER2566 was induced with 
isopropyl β-D-thiogalactoside (IPTG) as described previously [25]. GD3G7-LPETG-His-VSV 
was released from the periplasmic space via osmotic lysis using 200 mM Tris-HCl, pH 8.0, 
0.5 mM ethylenediaminetetraacetic acid (EDTA), 20% (w/v) sucrose containing protease 
inhibitors. Purification by nickel-NTA affinity chromatography was performed as described 
(NTA-Ni sepharose®, IBA Life sciences) [26]. 
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Introduction of DBCO functionality to GD3G7 by sortagging
pGBMCS-SortA, a gift from Dr. Fuyuhiko Inagaki [27] was transfected into E. coli ER2566 
for standard protein expression. Bacterial expression was performed as described and 
IPTG-induced cells were lysed by sonication at 4oC using a Bandalin Sonopuls HD2070 
sonicator. His-tagged sortase was purified with NTA-Ni Sepharose as described above. 
To equip the GD3G7 antibody with a bio-orthogonal chemical click handle (Figure 1), 16 
µM GD3G7-LPETG-His-VSV was incubated overnight at room temperature with 4 mM 
amino-PEG4-DBCO (Click Chemistry Tools, Scottsdale, USA) in the presence of 40 µM 
sortase A in 50 mM Tris, 150 mM NaCl, 10 mM CaCl2, pH 7.5. Reaction product was cleared 
from unreacted GD3G7-LPETG-His-VSV, cleaved G-His-VSV tags and sortase A by depletion 
on nickel-NTA beads. Free amino-PEG4-DBCO was removed by filtration in PBS over a 10 
kDa centrifugal filter device (Amicon® Ultra-4, Merck Millipore) using standard protocols. 
Routinely, filters were washed five times to obtain highly purified product. 
The sortase mediated reaction was evaluated by applying bioorthogonal click chemistry 
between DBCO and azide. The sortagged product was incubated with azido-cyanine-7.5 
(Lumiprobe GmbH, Hannover, Germany) for 1 h at 4° C, followed by sodium dodecyl 
sulfate polyacrylamide gel electrophoresis (SDS-PAGE) using 10% gels and gel imaging at 
800 nm (Odyssey® CLx imaging system). Thereafter, gels were stained for presence of 
proteins with 0.1% (w/v) Coomassie Brilliant Blue R-250 solution (MP Biomedicals, Santa 
Anna, CA) in 50% (v/v) methanol and 10% (v/v) acetic acid in water. 
Preparation of lyophilisomes and introduction of azide functionality
Lyophilisomes were prepared from bovine serum albumin (BSA; PAA Laboratories, Linz, 
Austria) as described previously [10]. Briefly, droplets of 20 µl 2.5 mg/ml BSA (containing 
10% FITC-labeled BSA (Sigma-Aldrich, St. Louis, MO, USA)) in 0.01 M acetic acid were 
snap frozen in liquid nitrogen. Capsules were formed using an annealing and lyophilization 
regimen [11]. Large structures were removed by centrifugation (60 x g).
Lyophilisomes were prepared for click chemistry by introducing azide groups to the surface 
of lyophilisomes. Lyophilisomes were suspended in PBS containing 0.1% tween20 (v/v) 
(PBST; pH 8.0), sonicated (Cycle 0.5; Amplitude 20; 10 cycles) with a Sartorius labsonic P 
sonicator (Göttingen, Germany), mixed with 100 times molar excess NHS-PEG4-azide (Jena 
Bioscience, Jena, Germany) and incubated under rotation at room temperature overnight. 
Next, lyophilisomes were washed three times with PBST and centrifuged at 17,000 x g for 
5 min to remove free NHS-PEG4-azide, and stored in PBST at 4°C.
Modification of lyophilisomes with PEG4-azide was analyzed using flow cytometry. 
Lyophilisomes (2.5 µg) with or without PEG4-azide were incubated with 1 µg/ml DBCO-IR 
dye 680RD (LI-COR Biotechnology, Bad Homburg, Germany), which binds only azido 
modified lyophilisomes, in PBST under rotation at room temperature for 1 h. Control 
samples were incubated in PBST only. Lyophilisomes were three times washed with PBST 
and centrifuged at 17,000 x g for 5 min, re-suspended in PBST and analyzed for their 680RD 
signal with a BD FACSCalibur flow cytometer (BD Biosciences, Breda, the Netherlands). 
Data were analyzed using FlowJo software (Version 10, Treestar, Ashland, OR).
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Loading of lyophilisomes with doxorubicin
Loading of lyophilisomes with doxorubicin was performed as described previously 
[10]. In short, 200 µg of lyophilisomes with or without GD3G7 antibody were washed 
twice with 10 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) buffer 
(pH 7.4; Promega, Madison, WI, USA) and centrifugated at 17000 x g for 5 min at 4°C. 
Next, lyophilisomes were incubated overnight with 500 µl 0.5 mg/ml doxorubicin 
(Accord Healthcare, the Netherlands) in 10 mM HEPES buffer v/v at room temperature. 
Non-entrapped doxorubicin was removed by centrifuging at 17 000 x g, 5 min, 4°C and 
collecting the supernatant. Subsequently, the lyophilisomes were washed three times 
with 10 mM HEPES buffer (17 000 x g, 5 min, 4°C) and the supernatants were collected. 
The doxorubicin concentration in 10 mM HEPES buffer of the three collected supernatants 
was quantified spectrophotometrically at 490 nm (Synergy BioTek 2 Plate reader, BioTek, 
Winooski, VT, USA). The entrapment efficiency was calculated using the following formula:
Antibody functionalization of lyophilisomes 
In order to achieve specific targeting of lyophilisomes to CS-E, GD3G7 antibodies were 
conjugated to lyophilisomes through bioorthogonal click chemistry. A 1.25x molar excess 
GD3G7-LPET-PEG-DBCO was reacted to azido-conjugated lyophilisomes in PBST via the 
scheme depicted in Figure 1C. Reaction was allowed to proceed overnight at room 
temperature. In a control reaction, azide-conjugated lyophilisomes were incubated with 
unmodified GD3G7 antibodies. Free antibodies were removed through three washing 
steps with PBST by centrifugation at 17,000 x g for 5 min.
Conjugation was evaluated using horseradish peroxidase-conjugated Protein A that 
binds to the VH3 domain of the antibody [19]. Antibody-functionalized lyophilisomes 
and non-functionalized lyophilisomes (2.5 µg) were incubated with 0.1 µg/ml 
peroxidase-Protein A (Merck Millipore, Darmstadt, Germany) in PBST for 1 h under 
rotation at room temperature. Afterwards, lyophilisomes were washed three times 
with PBST, centrifuged at 17,000 x g for 5 min and peroxidase activity in the pellets was 
measured by reaction in 0.0243 M citric acid, 0.0514 M K2HPO3, 0.012% H2O2 (v/v) and 
0.04% ortho-phenylenediamine (w/v). After 30 min at room temperature, 12.5% H2SO4 
(v/v) was added to stop the reaction. Subsequently, lyophilisomes were centrifuged and 
the absorbance of the supernatant was measured at 492 nm using a Synergy BioTek 2 
Plate reader (BioTek, Winooski, VT, USA).
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Evaluation of the targeting potential of antibody functionalized lyophilisomes
Binding to ovarian cancer stroma 
Human ovarian cancer cryosections (5 µm) were pre-treated with 2 mM MgAc2 in 25 
mM TrisHCl buffer (pH 8.0) with and without the chondroitin sulfate digesting enzyme 
chondroitinase-AC (30 mU/ml, 1 h, 37° C). After blocking with 2% BSA in PBS (w/v), sections 
were incubated with either antibody-functionalized lyophilisomes or non-functionalized 
lyophilisomes (0.1 mg/ml in 2% BSA in PBS) for 1 h. Nuclei were visualized by incubation 
with 10 µg/ml 4’,6-diamidino-2-phenylindole (DAPI; Merck, Darmstadt, Germany) and 
CS-E was visualized by immunofluorescence, sections were mounted with cover glasses 
in mowiol-488. 
Binding to peri-cellular chondroitin sulfate E in vitro
Although CS-E in ovarian carcinomas is predominantly localized in the cancer stroma and 
not (peri)cellularly, we used cell lines which do or do not produce CS-E in vitro as a model 
for analyzing the binding properties of the delivery system. Cell lines SKOV3 (ATCC, #HTB 
77) and SKOV3-F7 (overexpressing CS-E [28]) showed strong (peri)cellular CS-E expression 
while cell line HFF1 (ATCC, #SCRC-1041) showed no CS-E expression (Supplementary data, 
Figure S1). Cells were cultured in Dulbecco’s Modified Eagle Medium (DMEM)-glutamax 
(Gibco, ThermoFisher scientific, Waltham, MA, USA) containing 10% fetal bovine serum 
(PAN Biotech, Aidenback, Germany) (v/v) and 100 I.U./ml penicillin and 100 µg/ml 
streptomycin (Amresco, Solon, OH, USA), at 37°C in a humidified incubator in a 5% CO2 
atmosphere. When 80% confluency was reached, cells were dissociated using 0.05% trypsin 
(w/v) in 0.53 mM EDTA in Hank’s balanced salt solution (Corning Mediatech, Tweksbury, 
MA, USA) and maintained as proliferating cultures. Cells were tested for mycoplasma 
contamination every four months using a MycoAlert™ mycoplasma detection kit (Lonza, 
Basel, Switzerland). After thawing, cells remained in culture for a maximum of six months.
Cells were cultured in 10-well glass slides in 75 µl medium to ≥90% confluency. Next, 
cells were fixed with 4% paraformaldehyde (Sigma-Aldrich) in PBS (v/v) for 20 min, 
blocked with 2% BSA in PBS (w/v) and subsequently incubated for 1 h with 0.1 mg/ml 
antibody-functionalized lyophilisomes or non- functionalized lyophilisomes. Cells were 
incubated with 10 µg/ml DAPI for nuclear staining and mounted in Mowiol-488. 
Binding to immobilized chondroitin sulfate E
To evaluate the specificity of the antibody-functionalized lyophilisomes for CS-E, the 
following glycosaminoglycans were coated onto a 10-well glass slide (Thermo Fisher 
Scientific, Waltham, USA) all at 0.1 mg/ml: CS-A (from bovine trachea, Sigma-Aldrich), 
CS-B (dermatan sulfate, from porcine intestinal mucosa, Celsus Laboratories Inc.), CS-C 
(from shark cartilage, Sigma-Aldrich), CS-D (from shark cartilage, Seikagaku), CS-E (from 
squid cartilage, Seikagaku), heparin (from porcine intestinal mucosa, Sigma-Aldrich), 
and heparan sulfate (from bovine kidney, Sigma-Aldrich). After blocking with 2% BSA 
in PBS (w/v), glass slides were incubated for 1 h at room temperature with either 
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antibody-functionalized lyophilisomes or non-functionalized lyophilisomes (0.1 mg/ml), 
or GD3G7 antibodies as control. Thereafter, glass slides were rinsed in PBS and mounted 
in Mowiol-488 (Calbiochem, La Jolla, CA, USA). Lyophilisomes were visualized using their 
FITC label. 
Analyses were performed using a Leica DM6000B fluorescent microscope. Image 
processing was performed using ImageJ 1.48v (National Institutes of Health, USA). For 
visualization purposes, brightness and contrast were adjusted similarly for all images 
including the controls.
Visualization of chondroitin sulfate E 
The expression of CS-E was visualized by immunofluorescence or by applying the 
avidin-biotin complex method [29]. In brief, slides were incubated with the GD3G7 
antibody (1:5) after blocking, followed by a mouse anti-VSV antibody (clone P5D4, 1:10) 
and either a goat anti-mouse IgG Alexa Fluor 488 (Life Technologies, 1:500) or biotinylated 
horse-anti-mouse IgG antibody (Vector Laboratories Inc., CA, USA, 1:200) and ABC reagent 
(Vectastain ABC anti-mouse-IgG kit, Vector Laboratories Inc.).
Evaluation of cytotoxic potential of antibody-functionalized lyophilisomes
Cytotoxicity analysis in vitro
The cell eliminating potential of doxorubicin loaded, antibody-functionalized lyophilisomes 
was investigated using a cell viability assay. To mimic a CS-E rich extracellular matrix, 
96-wells cell culture plates (Corning Costar, NY, USA) were coated overnight with CS-E 
(0.1 mg/ml). The next day, non-immobilized CS-E was removed by washing with PBS and 
wells were incubated with either: 1) culture medium, 2) Caelyx (PEGylated liposomal 
doxorubicin, Janssen-Cilag B.V., Tilburg, the Netherlands), 3) free doxorubicin (Accord 
Healthcare, Utrecht, the Netherlands), 4) empty non-functionalized lyophilisomes, 5) 
empty antibody-functionalized lyophilisomes, 6) doxorubicin loaded non-functionalized 
lyophilisomes and 7) doxorubicin loaded, antibody-functionalized lyophilisomes, all 
preparations were diluted in culture medium. Doxorubicin concentration was 20 µM and 
the amount of lyophilisomes with or without doxorubicin were equal. After incubation 
for 1 h at 37 °C, wells were washed with culture medium. Subsequently, 5000 SKOV3-F7 
cells were seeded in 100 µl medium and cell viability was measured after 5 days. Wells 
were washed with medium and 100 µl medium containing 10% (v/v) Alamar blue reagents 
(ThermoFisher Scientific) was added with an incubation time of 4 h at 37 °C. Cell viability 
was measured by fluorescence (excitation at 570 nm, emission at 585 nm) using a Synergy 
BioTek 2 Plate reader (BioTek, Winooski, VT, USA).
In vitro doxorubicin release 
To determine whether lyophilisomes can eliminate cells by releasing doxorubicin, 
but without entering cells, an in vitro experiment using 2 kDa cut-off membranes 
(Slide-A-Lyzer®MINI dialysis units 2,000 MWCO, Thermo Scientific) was conducted. Free 
doxorubicin will pass the membrane, but doxorubicin in lyophilisomes or liposomes will 
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not. 5000 SKOV3-F7 cells were seeded in the upper compartment of the membrane, while 
in the lower compartment the following conditions were added: 1) culture medium, 2) 5 or 
20 µM Caelyx (liposomal doxorubicin), 3) 5 or 20 µM free doxorubicin, 4) lyophilisomes, 5) 
5 or 20 µM doxorubicin in lyophilisomes, 6) PBS and 7) 5 µM doxorubicin in lyophilisomes 
in PBS. The amount of doxorubicin loaded and empty lyophilisomes was equal. After 48 h, 
30 µl medium containing 30% (v/v) Alamar blue was added to the cells, with an incubation 
time of 4 h at 37 °C. Cell viability was measured as described. 
Visualization of cellular doxorubicin uptake
To visualize uptake of doxorubicin from lyophilisomes into cells (nuclei), 5000 SKOV3F7 
cells were cultured on a glass slide overnight and subsequently incubated with either 
free doxorubicin, Caelyx (liposomal doxorubicin) or lyophilisomes with or without 5 
µM doxorubicin for 24 h. Finally, cells were washed once with PBS and fixed with 4% 
paraformaldehyde (Sigma-Aldrich) in PBS (v/v) for 10 min. Nuclei were stained with 10 µg/
ml DAPI in PBS (w/v) for 10 min and cells were mounted in Mowiol-488. Analyses were 
performed using a Leica DM6000B fluorescent microscope.
Statistical analysis
Statistical analyses were tested by one-way analysis of variance (ANOVA) with posthoc 
Bonferroni’s Multiple Comparison Test using Graphpad Prism version 5.03 (Graphpad 
software, La Jolla, CA, USA). All tests were two-sided and p-values < 0.05 were considered 
significant. All experiments were performed at least three times independently.
Results
Generation and evaluation of antibody-functionalized lyophilisomes
Because random conjugation of single chain antibodies to albumin lyophilisomes using 
classical 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide/N-Hydroxysuccinimide (EDC/
NHS) chemistry carries a risk of modifying amino acids that are crucially involved in 
antigen binding, we chose to develop a method of controlled and site-specific conjugation 
using sortagging (Figure 1). GD3G7 antibodies harboring the LPETG sortase consensus 
motif (molecular weight of ~28.5 kDa) could be readily produced and purified and 
were labeled with PEG-DBCO (Figure 2A). The product was analyzed by a click reaction 
between DBCO and azido-cyanine 7.5, and in line with expectation, was only seen for 
GD3G7-PEG-DBCO as was demonstrated by SDS-PAGE analysis (lane 3 in Figure 2A; note 
that the molecular weight of the GD3G7-DBCO-N3-cyanine 7.5 is slightly lower than the 
unreacted GD3G7-LPETG-His-VSV in lane 2, due to loss of the G-His-VSV tag during the 
sortase reaction). 
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Figure 1. Construction of cancer targeting lyophilisomes. Schematic overview of the conjugation 
between albumin-based lyophilisomes and GD3G7 antibodies reactive with CS-E, by applying a 
two-step approach comprising sortase mediated ligation and click chemistry. A. LPETG-His-VSV 
tagged single chain GD3G7 antibodies were modified for click chemistry by introducing 
amino-PEG4-DBCO through a reaction mediated by Sortase A. B. Lyophilisomes were functionalized 
for click chemistry by conjugating PEG4-azide to the primary amine groups of lyophilisomes 
mediated by N-hydroxysuccinimide (NHS). C. Antibody-functionalized lyophilisomes were generated 
by a click reaction between azido-conjugated lyophilisomes and GD3G7-PEG4-DBCO antibodies. 
Abbreviations: CS-E, chondroitin sulfate E; DBCO, dibenzylcyclooctyne; VL, light chain variable 
domain; VH, heavy chain variable domain; SrtA, Sortase A.
The conjugation of amino-PEG4-azide to the surface of lyophilisomes was evaluated using 
flow cytometry. After incubation with DBCO-IR dye 680RD, which only binds azide modified 
lyophilisomes, the median fluorescent intensity of azide-conjugated lyophilisomes 
was 631 (95% confidence interval [CI]: 578-684) compared to 26 (95% CI: 21-30) for 
non-conjugated lyophilisomes (p < 0.001) (Figure 2B). Conjugation was further evaluated 
by using peroxidase-conjugated Protein A, which binds to single chain antibodies of the 
VH3 class, as is antibody GD3G7. High levels of Protein A bound to antibody-functionalized 
lyophilisomes compared to non-functionalized lyophilisomes [0.71 (95% CI: 0.53-0.89) vs 
0.19 (95% CI: 0.11-0.27), p<0.001] (Figure 2C).
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Loading of lyophilisomes with doxorubicin resulted in a mean entrapment efficiency of 28% 
(95% CI: 18-38%), which corresponds with a mean drug loading of 0.35 mg doxorubicin / 
mg lyophilisomes (95% CI: 0.23-0.48).
Figure 2. Evaluation of antibody-functionalized lyophilisomes. A. SDS-PAGE evaluation of sortase 
mediated ligation of amino-PEG4-DBCO to the GD3G7 antibody harboring a LPETG motif, using 
azido-cyanine 7.5 labeling. Coomassie brilliant blue staining and visualization in the 800 nm 
channel of GD3G7-PEG4-DBCO and unmodified GD3G7 antibodies after azido-cyanine 7.5 labeling; 
B. Median fluorescent intensity (MFI) of azide-conjugated lyophilisomes and non-conjugated 
lyophilisomes after DBCO-IR dye 680RD labeling assessed by flow cytometry; C. Absorbance of 
DBCO-modified GD3G7 antibodies conjugated to azide-conjugated lyophilisomes detected by the 
binding of peroxidase-conjugated protein A. Unmodified GD3G7 antibodies and non-conjugated 
lyophilisomes were included as controls; Bars represent mean ± standard deviation (n=3). *** 
indicates a statistical significant difference with p < 0.001.
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Specificity of antibody-functionalized lyophilisomes
Targeting properties of antibody-functionalized lyophilisomes were analyzed in 
patient derived ovarian cancer tissues (Figure 3A-B). Cryosections of high grade serous 
ovarian carcinomas were incubated with antibody-functionalized lyophilisomes and 
non-functionalized lyophilisomes. An abundancy of antibody-functionalized lyophilisomes 
associated with the cancer stroma (containing CS-E), whereas almost no binding to 
ovarian cancer epithelial cells was observed. Non-functionalized lyophilisomes showed 
background reactivity with both the ovarian cancer stroma and epithelial cells (Figure 3A). 
Specificity of binding was assayed by pretreatment of ovarian cancer sections with the 
chondroitin sulfate degrading enzyme chondroitinase-AC. Enzymatic treatment abolished 
the reactivity of antibody-functionalized lyophilisomes with the ovarian cancer stroma 
(Figure 3A). 
The specificity of antibody-functionalized lyophilisomes was further analyzed in vitro 
using two human ovarian cancer cell lines producing CS-E (SKOV3 and SKOV3F7) and 
a cell line not producing CS-E (HFF1 cells, human foreskin fibroblasts) (Figure 3B). The 
antibody-functionalized lyophilisomes showed strong reactivity with the CS-E producing 
cell lines (SKOV3 and SKOV3F7) compared to the CS-E-negative cell line HFF1. The 
non-functionalized lyophilisomes showed limited reactivity with any type of cell line. 
Finally, the specificity of the antibody-functionalized lyophilisomes for various 
glycosaminoglycans was determined. Antibody-functionalized lyophilisomes showed 
strong reactivity with the highly sulfated CS-E subtype (Figure 3C), while only background 
signal was observed with other immobilized glycosaminoglycans including CS-A, 
CS-B (also known as dermatan sulfate), CS-C, CS-D, heparan sulfate and heparin. The 
non-functionalized lyophilisomes showed no significant reactivity with any type of 
glycosaminoglycan (Supplementary data, Figure S2). 
Figure 3. Specificity of antibody-functionalized lyophilisomes for highly sulfated chondroitin 
sulfate E (CS-E). A. Effect of chondroitin sulfate degrading enzymes on targeting properties of 
antibody-functionalized lyophilisomes and non-functionalized lyophilisomes. Ovarian cancer 
cryosections were pre-incubated with either chondroitinase-AC that digests CS (ChAC+), or 
buffer without enzyme (ChAC-). Sections were stained with GD3G7 antibodies (visualized in red 
by Alexa-594) to indicate presence of CS-E chains in the cancer stroma. The general histology 
of the ovarian carcinoma cryosection is visualized by hematoxylin and eosin (H&E) staining and 
show epithelial cancer cells (marked with asterisk) surrounded by cancer-associated stroma. B. 
Reactivity of antibody-functionalized lyophilisomes and non-functionalized lyophilisomes with CS-E 
producing cell lines (SKOV3-F7, SKOV3) and a non CS-E producing cell line (HFF1); C. Reactivity of 
antibody-functionalized lyophilisomes and non-functionalized lyophilisomes with immobilized 
glycosaminoglycans CS-E and heparin, the reactivity with GD3G7 antibodies was used as control; 
Abbreviations: Ab, antibody. Scale bar represents 100 µm.
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Figure 4. Cell viability and doxorubicin release in vitro A. A chondroitin sulfate E (CS-E) rich 
environment was pretreated with either doxorubicin loaded lyophilisomes with/without antibody 
functionalization, free doxorubicin or Caelyx (liposomal doxorubicin), all preparations containing 
20 µM doxorubicin. After washings, ovarian tumor cells (SKOV3F7) were cultured and viability was 
assayed. Antibody-functionalized lyophilisomes with doxorubicin were most effective in eliminating 
ovarian cancer cells. B. Viability of SKOV3F7 cells cultured on a 2kDa dialysis membrane separating 
them from a lower compartment containing various conditions. Doxorubicin loaded lyophilisomes 
and free doxorubicin were equally effective, whereas Caelyx (liposomal doxorubicin) did not affect 
the cell viability. C. Nuclear localization of lyophilisomal derived doxorubicin in vitro. SKOV3F7 
cells were incubated for 24 h either with free doxorubicin, Caelyx (liposomal doxorubicin), empty 
lyophilisomes (depicted in green) or doxorubicin loaded lyophilisomes (depicted in red). Nuclei were 
stained blue with DAPI. Free doxorubicin and released doxorubicin from lyophilisomes localized to 
the nuclei (colored red). *** indicates a statistical significant difference with non-asterisks marked 
conditions with p < 0.001. Bars represent mean ± standard deviation (n=3). Scale bar represents 
100 µm.
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Cytotoxic potential of drug loaded, antibody-functionalized, lyophilisomes in vitro 
A CS-E rich environment was created to assess the effect of doxorubicin loaded 
antibody-functionalized lyophilisomes on ovarian cancer cells. As shown in Figure 4A, 
viability of cells cultured in CS-E coated wells that were pre-incubated with doxorubicin 
loaded antibody-functionalized lyophilisomes was decreased to 30% (95% CI: 22-39%), 
and was significantly lower compared to the cell viability after pre-incubation with 
doxorubicin loaded non-functionalized lyophilisomes, free doxorubicin, and Caelyx 
(liposomal doxorubicin) of 77% (95% CI: 65 – 89%), 70% (95% CI: 65 – 75%), and 103% 
(95% CI:97 – 109%), respectively (p < 0.001). Empty lyophilisomal control conditions 
(functionalized or non-functionalized) did not affect cell viability. 
Mode of doxorubicin release and nuclear localization 
To study whether cell death occurs by extracellular release of doxorubicin from 
lyophilisomes or by cellular uptake of doxorubicin loaded lyophilisomes, an in vitro study 
using 2 kDa cut-off membranes was performed. 2 kDa membranes allow free doxorubicin 
(544 Da) to pass, but not larger components such as lyophilisomes-associated doxorubicin, 
Caelyx (liposomal doxorubicin), cells, and enzymes. Free doxorubicin and doxorubicin 
loaded lyophilisomes in culture medium containing 10% FBS decreased cell viability in the 
upper compartment to 46.7% (95% CI: 39.4 – 54.0%, p<0.001) and 39.5% (95% CI: 25.9 
– 53.1%, p<0.001), respectively (Figure 4B). In contrast, equal doses of Caelyx and empty 
lyophilisomes did not significantly affect cell viability, 97.9% (95% CI: 83.3 – 112.4%) and 
93.9% (95% CI: 74.6 – 113.2%), respectively. Moreover, a lower dose of 5 µM of free 
doxorubicin and doxorubicin in lyophilisomes significantly affected cell viability, whereas 
the same concentration of Caelyx did not; interestingly, doxorubicin loaded lyophilisomes 
in PBS did not significantly affect cell viability (Supplementary data, Figure S3).
After incubation of cells with lyophilisomes loaded with doxorubicin, the drug localized to 
the nuclei, the site of action (Figure 4C). This was also observed with free doxorubicin, but 
not with Caelyx under the same conditions (24 h of incubation).
Generality of CS-E expression in the stroma of solid cancers
In order to explore the stromal CS-E expression associated with various solid cancers other 
than ovarian, we immunohistochemically analyzed five samples of lung, cervical, breast, 
renal cell, endometrial, and colon cancer for the expression of CS-E. In the vast majority of 
each cancer type, stromal overexpression of CS-E was observed (Figure 5).
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Figure 5. Stromal chondroitin sulfate E (CS-E) expression (in red) in various solid cancers including 
lung cancer, cervical cancer, breast cancer, renal cell cancer, endometrial cancer, and colon cancer. 
Scale bar represents 100 µm.
Discussion
In the current study, we have evaluated the feasibility of a novel concept of therapeutic 
tumor targeting based on an ECM-targeting drug delivery system. Largely neglected, 
the cancer ECM provides potential targets for therapy and may have advantages over 
targeting cancer cells. Due to intra-tumoral heterogeneity, targeted therapies against 
cancer cell specific targets may act only on a subpopulation of cancer cells whilst other 
subpopulations not expressing the target, and cancer-associated stromal cells (i.e. 
fibroblasts and endothelial cells), are left unaffected [21]. Cancer-associated stromal 
cells have been identified as significant contributors to cancer growth and dissemination, 
and the additional elimination of these cells may benefit clinical outcome [30, 31]. 
Furthermore, expression of cancer cell specific targets may change over time resulting in 
resistance to the applied targeted therapy [13]. Targeting anti-cancer drugs to the more 
stable ECM may be helpful to overcome these hurdles. 
The potency of ECM-targeting therapies is supported by recent studies which 
have demonstrated that delivering anti-cancer drugs to the tumor stroma can 
successfullyeliminate tumor cells and their micro-environment in vivo [23, 24]. However, 
the approaches that were used in these studies were of limited translational value because 
these were not specific for the cancer stroma. Because the antibody-functionalized 
lyophilisomes in our study target a unique cancer-specific stromal antigen, this may result 
in a more specific tumor targeting with concomitant less exposure to healthy surrounding 
tissues [23, 24]. 
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Here we report that antibody-functionalized lyophilisomes, generated by a stable and 
specific bioorthogonal click reaction between GD3G7-PEG4-DBCO and azido-functionalized 
lyophilisomes, have specific binding properties for the ovarian cancer stroma rich in 
CS-E motifs. In addition and focusing on targeting characteristics, ovarian cancer cells 
in a CS-E rich micro-environment were efficiently eliminated by antibody-functionalized 
lyophilisomes loaded with doxorubicin, in contrast to non-functionalized lyophilisomes 
and Caelyx (liposomal doxorubicin), the latter being a commonly used second line 
chemotherapeutic for the treatment of ovarian cancer. These results indicate the potential 
of the ECM-targeting drug delivery system as a novel class of targeted therapy for the 
treatment of ovarian cancer. 
To achieve specific stroma-targeting of the drug delivery system, we applied a two-step 
approach comprising sortase mediated ligation and bioorthogonal click chemistry. First, we 
equipped single chain GD3G7 antibodies with a click chemistry handle using the recently 
published sortagging approach [32]. Sortase A, a transpeptidase from Staphylococcus 
aureus, recognizes a LPXTG motif and catalyses cleavage between threonine and glycine 
residues forming an intermediate complex [33]. The complex is then resolved by a 
nucleophilic attack of the N-terminal protein thus forming a covalent bond [34]. Recently, 
it has been demonstrated that amine groups of other compounds (e.g. amino-PEG) 
can be substrate for the LPETG-sortase intermediate thus offering a versatile toolbox 
for sortase A catalyzed ligations in protein engineering [35]. By positioning the LPETG 
sequence upstream of purification tags, these tags can be replaced with handles for click 
chemistry, while allowing convenient and rapid purification of the reaction product from 
unreacted proteins and by-products of the reaction. Using this system, we generated 
GD3G7-PEG4-DBCO with high purity. Of note, because the click handle is positioned at the 
extreme carboxyterminal end, there is a minimal risk of affecting antibody affinity, unlike 
the widely used approach of EDC/NHS-mediated conjugation.
Lyophilisomes were used here as biocapsules for doxorubicin, and represent an attractive 
class of drug delivery systems for ECM-targeting since they can be prepared in a wide range 
of size (100 nm - 10 µm), thereby being eligible for systemic as well as intraperitoneal 
administration [11]. Ovarian cancer has a unique tumor biology and metastatic spread 
pattern since it is usually confined to the peritoneal cavity. Standard treatment regimes 
include debulking surgery and systemic chemotherapy. As these patients especially 
suffer from extensive abdominal metastases, delivering adjuvant chemotherapeutics into 
the peritoneal cavity in addition to systemically administered chemotherapy, has been 
shown to significantly improve survival rates of ovarian cancer patients and is currently 
the standard of care for a selected group of patients [36-39]. Lyophilisomes can be 
prepared with a diameter as small as 100-200 nm allowing them to extravasate from leaky 
intratumoral vessels and accumulate in the cancer interstitium (enhanced permeability 
and retention effect) [40, 41]. By subsequently binding to CS-E chains located in the stroma 
adjacent to intratumoral vessels, longer retention of nanoparticles in the cancer tissue and 
increased treatment efficacy may be achieved. On the other hand, it has been proposed 
that micro-metastases (≤1 mm) at the peritoneum have no vasculature and consequently 
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will not be reached by systemic therapy [42]. For an (adjuvant) intraperitoneal application, 
the use of micro-sized particles over nano-sized particles may be of benefit since uptake 
of microsized particles from the abdominal cavity into the circulation is restricted, thus 
elongating intraperitoneal half-life and treatment efficacy [43]. The use of a targeted 
drug delivery system for the intraperitoneal treatment of ovarian cancer may be of major 
interest since the beneficial effect of intraperitoneally administered chemotherapeutics is 
limited by substantial (local) toxicity [38].
Intense stromal CS-E expression has been associated with various ovarian cancer subtypes 
including low grade and high grade serous, clear cell, and low grade and endometrioid 
cancer [20]. In this study we showed that CS-E was highly upregulated in the stroma of a 
variety of solid tumors including breast cancer, endometrioid cancer, cervical cancer, lung 
cancer, colon cancer, and renal cell cancer. Accordingly, delivery systems targeting CS-E 
may be applicable to a large and diverse group of cancers. 
Release of drugs from stroma-targeting lyophilisomes is essential to eliminate cells. We 
demonstrated that doxorubicin loaded lyophilisomes in fetal bovine serum enriched 
culture medium release a substantial part of their drug resulting in nuclear localization of 
the drug (the site of action) and ovarian cancer cell death, in contrast to (Caelyx) liposomal 
doxorubicin that did not affect cell viability. This release cannot be explained by simple 
diffusion as the release in a neutral buffer (PBS) was minimal and did not result in cell death. 
Albumin represents an important transport protein and is known for its non-covalent 
reversible ligand-binding capacity. Moreover, it has several binding sites for hydrophobic 
components which may explain the affinity of albumin for doxorubicin, maintaining the 
drug within lyophilisomes [10] and which may contribute to the high drug loading capacity 
compared to Caelyx (0.35 mg doxorubicin / mg lyophilisomes vs 0.125 mg doxorubicin / 
mg liposomes) [44]. We hypothesize that hydrophobic components (e.g. fatty acids) or 
free albumin in serum-enriched medium may compete with the albumin-doxorubicin 
binding and lead to drug release. In addition, proteolytic enzymes in the cancer stroma 
may contribute to the degradation of the albumin lyophilisomes thus enabling release of 
its payload [45]. In order to enhance drug release, antibody-functionalized lyophilisomes 
hold potential for additional functionalization, e.g. by the incorporation of substrates for 
proteolytic enzymes upregulated in the ovarian cancer ECM, into the albumin wall.
Conclusion
In this study, we constructed and evaluated a drug delivery system targeting the 
cancer-associated stroma, based on albumin lyophilisomes loaded with doxorubicin and 
functionalized with antibodies to highly sulfated chondroitin sulfates. The delivery system 
may contribute to a novel class of therapy, based on addressing specific components in 
the extracellular matrix of tumors.
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Supplementary data
Figure S1. In vitro expression of CS-E, defined by the GD3G7 antibody. Cell lines SKOV3F7 and 
SKOV3 showed strong (peri)cellular expression of the epitope while the cell line HFF1 showed no 
expression. Scale bar represents 100 µm.
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Figure S2. Reactivity of antibody-functionalized lyophilisomes and non-functionalized lyophilisomes 
with various immobilized glycosaminoglycans. Antibody-functionalized lyophilisomes showed strong 
reactivity with CS-E while no reactivity was observed with other glycosaminoglycans including CS-A, 
CS-B (also known as dermatan sulfate), CS-C, CS-D, heparan sulfate (HS), and heparin. No reactivity 
with glycosaminoglycans was observed for the non-functionalized lyophilisomes. GD3G7 antibody 
staining was performed as control and showed strong reactivity with CS-E while no reactivity with 
other glycosaminoglycans was observed. abbreviations: Ab, antibody. Scale bar represents 100 µm
.
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Figure S3. In vitro doxorubicin release and cytotoxicity analysis. Cell viability of SKOV3F7 cells cultured 
on a 2kDa dialysis membrane containing different conditions (equivalent to 5 µM doxorubicin) in the 
lower compartment. Cells cultured with free doxorubicin that was able to diffuse through showed 
the lowest cell viability (21.9% [%CI: 9.2 – 34.6%]). Moreover, doxorubicin loaded lyophilisomes 
in medium significantly affected cell viability (51.7% [95%CI: 51.7 – 79.4%]), while non-loaded 
lyophilisomes in medium or doxorubicin loaded lyophilisomes in PBS did not affect the cell viability. 
** p<0.01. *** p < 0.001. Bars represent mean ± standard deviation (n=3).
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Abstract
Lyophilisomes are a novel class of proteinaceous biodegradable nano/microparticle 
capsules developed for tumor drug delivery. The in vivo characteristics of lyophilisomes 
are unknown and, therefore, the time course of biodistribution of sized albumin-based 
lyophilisomes in CD1 mice after intravenous administration was studied. Lyophilisomes, 
prepared from Dylight680-labeled albumin, were sized using a sucrose gradient 
centrifugation methodology and four fractions with a mean size of approximately 200 
nm, 400 nm, 550 nm, and 650 nm were pooled for in/ex vivo localization, (immuno)
histochemistry and biochemical analysis. Lyophilisomes were rapidly taken out of 
the circulation by the liver and spleen, which was supported by histological analysis. 
Immunohistochemistry revealed that lyophilisomes were taken up in the liver by 
F4/80 positive macrophages, and in the spleen by Sign-R1 positive macrophages 
specifically located in the marginal zones. Lyophilisomes were most likely degraded by 
the liver and spleen and subsequently excreted via the urine, as high levels of degraded 
Dylight680-labeled albumin were detected in the urine. This was corroborated by electron 
microscopy of the spleen, which showed intact lyophilisomes in the marginal zone 5 and 
30 min after injection, but not after 120 min. In conclusion, i.v. injected lyophilisomes 
are rapidly entrapped by liver and splenic macrophages, biodegraded, and excreted in 
the urine, indicating that albumin lyophilisomes have to be modified for intravenous 
application to increase circulation times.
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Introduction
Nanoparticles and their potential application as drug delivery systems for pharmaceuticals 
have been extensively studied [1,2]. Research has focused on drug delivery systems 
assembled from a range of materials including natural or synthetic lipid liposomes, 
metal particles, polymeric particles, amino acid-, sugar- and nucleotide-based micelles, 
and protein-based particles [3]. Sizes range from a few nanometers for dendrimers and 
micelles [4], up to hundreds of nanometers to micrometers for liposomes, polymersomes, 
and (protein-based) nanospheres [5–7]. Despite the abundant research on these drug 
delivery systems, only a few are currently clinically applied.
For cancer therapy, an effective strategy to deliver anti-tumor drugs may be intravenous 
injection of drug loaded nanoparticles. This methodology exploits the enhanced 
permeability and retention (EPR) effect that is associated with hyperpermeability of 
tumor vasculature and lack of lymphatic drainage [8–10]. Through normal endothelium, 
nanoparticles cannot extravasate as it is prevented by tight endothelial junctions (5 to 10 
nm) between endothelial cells [11]. However, the cut-off size for permeability in individual 
tumors is increased to 200 to 800 nm [12]. Due to this EPR effect, drug delivery particles 
(<800 nm) can extravasate from blood vessels to tumor tissue and accumulate, creating 
high local drug concentrations [13], with the potential to eliminate tumor cells more 
efficiently while reducing drug exposure to healthy cells. 
In a quest for stable and efficient carrier systems, we have developed a drug delivery 
system named ‘lyophilisomes’ [14]. Lyophilisomes are prepared by a freezing, annealing, 
and lyophilization process that results in stable nano to micrometer sized capsules. As 
base material, a wide range of water-soluble macromolecules can be used (e.g. albumin, 
elastin, and heparin), making it an adaptable carrier system towards multiple drug delivery 
applications. The system is flexible, allowing the incorporation of virtually any biomolecule 
in the wall and/or lumen. For instance, enzymes incorporated either in the capsule wall or 
the lumen remain biological active, partly due to mild preparation conditions [14]. 
Recently, we investigated lyophilisomes prepared from bovine serum albumin. Albumin 
as a core material for lyophilisomes harbors a number of beneficial characteristics for 
drug delivery systems, as it is biocompatible, biodegradable to yield only innocuous 
degradation products, non-toxic and non-immunogenic. Furthermore, albumin is easy to 
purify and widely available, making it a suitable candidate for nanoparticle preparation 
[15–19]. We have shown that albumin-based lyophilisomes can be efficiently loaded with 
doxorubicin or curcumin and are able to efficiently eliminate tumor cells in vitro [20]. In 
order to obtain a selective drug delivery system, albumin-based lyophilisomes have also 
been modified with antibodies resulting in specific targeting of the cell of interest and 
facilitating the uptake of lyophilisomes in vitro [21]. Moreover, lyophilisomes conjugated 
with cell penetrating peptides increased cellular association and internalization in tumor 
cells [22]. These data indicate that albumin-based lyophilisomes may be used as a targeting 
system for the delivery of therapeutic agents. Although many parameters of lyophilisomes 
have been investigated in vitro, little is known about their characteristics in vivo. 
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In this study, the biodistribution of lyophilisomes was investigated. Property sized 
lyophilisomes were administrated intravenously and the organ distribution and degradation 
characteristics were studied using bioluminescence, light/electron microscopy and 
biochemical assays.
Materials and methods
Materials
Bovine serum albumin (BSA) was purchased from PAA Laboratories (Linz, Austria). 
Dylight680 (amine reactive) was purchased from Pierce (Rockford, IL, USE). Glutaraldehyde, 
formaldehyde and 4’,6-diamidino-2-phenylindole (DAPI) were obtained from Merck 
(Darmstadt, Germany). Rat anti-mouse F4/80 monoclonal antibody (MCA497RT, clone 
Cl:A3-1, lot 0212) and rat-anti mouse Sign-R1 (MCA2394Tl, clone Cl:ER-TR9, lot 0413) 
were obtained from AbD Serotec (Bio-Rad Laboratories, Hercules, CA, USA). Goat anti-rat 
IgG (H+L) Alexa fluor 488 conjugated antibody (A-11006, lot 52955A) and goat anti-rat 
IgM (µ chain) Alexa fluor 488 conjugated antibody (A-21212, lot 1252825) were purchased 
from Molecular Probes (Life Technologies, Grand Island, NY, USA).
Methods
Preparation of lyophilisomes
To image the lyophilisomes in vivo, Dylight680 (amine reactive) was conjugated to the 
free amine groups in albumin, applying the manufacturer’s protocol, and after dialysis in 
0.01 M acetic acid, labeled and non-labeled albumin were mixed in a 1:4 ratio. Albumin 
lyophilisomes were prepared as described [20]. Briefly, droplets of a solution of 0.25% 
(w/v) (labeled) BSA in 0.01 M acetic acid were frozen in liquid nitrogen (-196 °C) and 
then incubated at -10 to -20 °C for 3 h (annealing step), followed by lyophilization. 
This procedure results in hollow nano/micro spheres (‘‘lyophilisomes’’). Generally, we 
used 40 mL of a 0.25% BSA solution, which corresponds to 100 mg albumin (2.5 mg/
mL). One batch of 40 mL was sufficient to perform the animal experiment. To stabilize 
lyophilisomes, they were vapor crosslinked with glutaraldehyde and formaldehyde. The 
final lyophilisome preparation was centrifuged three or four times at 60 g for 3 min to 
remove large lyophilisomes and sheet-like structures, until no pellet was observed. After 
this procedure, about 30% of the original weight of lyophilisomes remained. Lyophilisomes 
(1 mg/mL) were stored in 0.1% (v/v) Tween-20 (Sigma Aldrich, Steinheim, Germany) in 
phosphate buffered saline (PBS-T, pH 7.4). 
Selecting appropriate sized lyophilisomes by density gradient centrifugation
In order to sort nanoparticles out of the lyophilisome population prepared as described 
above, centrifugation was used with a linear sucrose density gradient [23]. The linear 
sucrose density gradients were prepared in 14 mm diameter and 13.2 mL capacity 
ultracentrifuge tubes (ultra clear tubes, Beckman, Indianapolis, IN USA) by a gradient 
device that is composed of two chambers connected via a channel with a stopcock. To 
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create a border for aggregated particles, 0.5 ml 60% (w/w) sucrose solution was placed 
on the bottom of the tube. Subsequently, the gradient was prepared by mixing 5.6 mL 
10% (w/w) and 5.6 mL 40% (w/w) sucrose solution in a mixing chamber of which the 10% 
sucrose solution is loaded first. The final gradient volume was 11.7 mL. The prepared 
gradient was stored for one h at ambient temperature and loaded with the lyophilisome 
suspension (0.5 mL, 1.0 mg/ml). The tubes were placed in a swinging bucket rotor (SW 41 
Ti rotor, Beckman) and centrifuged at 1,543 g in a Beckman Optima L-XP ultracentrifuge 
(Beckman) for 10 min. After centrifugation, fractions were collected using a peristaltic 
pump and a narrow tube, inserted from top to bottom in the centrifuge tube. For each 
fraction, 0.5 to 1.0 mL of the solution was collected. Dynamic light scattering (DLS), 
qNano and analytical ultracentrifugation (AUC) were used to analyze the mean size of the 
fractioned lyophilisomes. The lyophilisome concentration of each fraction was determined 
by optical density (λ = 280 nm) to investigate recovery. 
Particle characterization
Dynamic light scattering (DLS)
DLS was performed on a DynaPro Plate Reader Plus (Wyatt Technology Corporation, 
Santa Barbara, CA) equipped with a 60 mV linearly polarized gallium arsenide (GaAs) laser 
(λ = 832.5 nm), operating at an angle of 156°. DLS data were collected from lyophilisomes 
dispersed in PBS containing 0.1% (v/v) Tween-20 (Sigma Aldrich, Steinheim, Germany) (pH 
7.4). Data were analyzed using Dynamics software ver.6.10 by the method of cumulants 
[24]. 
qNano
The qNano (Izon, Science Ltd., Burnside, New Zealand) was used to measure particle size 
of lyophilisomes [20,25]. To ensure a continuous flow of particles, two different pore sizes 
were used. For unsorted lyophilisomes, a pore size of approximately 600 to 2000 nm was 
used, while for sorted lyophilisomes a pore size of approximately 100 to 800 nm was used. 
Data were analyzed with Izon Control Suite 2.1 software. 
Analytical ultracentrifugation
Sedimentation velocity experiments were performed with a ProteomeLab XLI analytical 
ultracentrifuge (Beckman Coulter, Brea, CA), using conventional double-sector Epon 
centerpieces of 12 mm optical path length and a four-hole rotor (AN-60Ti). Rotor speed 
was set at 3,000 – 6,000 rpm, depending on the sample. The rotor was equilibrated in 
advance for approximately 1 h at 20 °C in the centrifuge. Cells were filled with 420 μL 
sample solution and 440 μL solvent (0.5% BSA / 0.02% sodium azide in PBS). Sedimentation 
(s) profiles were obtained by interference optics at similar temperature. For analysis 
of the sedimentation velocity data, the distributions ls-g*(s) and c(s) with a Tikhonov–
Phillips regularization procedure implemented into the Sedfit program were applied. 
Ls-g*(s) represents a least-square boundary analysis which describes sedimentation of 
non-diffusing species. c(s) analysis is based on the numerical resolution of the Lamm 
equation assuming an equal frictional ratio value for each s value [26].
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In vivo biodistribution
The Ethical Committee on Animal Research of the Radboud University Nijmegen Medical 
Centre approved this study under protocol number RUDEC 2012-202. Twenty-one female 
CD-1 mice (Harlan Laboratories, Horst, the Netherlands, 8 to 12 weeks old) weighing 32 
to 40 g were caged in a controlled environment (23°C; 51% humidity, 12h light cycles). 
Food and water were available ad libitum. Mice were divided into seven groups of 3 mice. 
With the exception of the control group, all groups received an intravenous injection of 
DyLight680-labeled albumin-based lyophilisomes at a concentration of 5.0 mg/kg body 
weight dissolved in PBS (1.0 mg/ml). After 0, 5, 30, 120 and 300 min, 24 h and 96 h, 
mice were anesthetized with isoflurane/oxygen, placed on their back into a light tight 
chamber and imaged for 10 min with a CCD camera in an in vivo imaging system (Xenogen 
IVIS Lumina II). DyLight680-labeled lyophilisomes were excited at 640 nm and emission 
in the range of 695 to 770 nm. To correct for autofluorescence, DyLight680-labeled 
lyophilisomes were excited at 605 nm and emission was recorded in the range of 695 
to 770 nm. IVIS-images were quantified using the Living Image 3.0 software (Caliper Life 
Sciences, Hopkinton, MA, USA).
After imaging, mice were euthanized and urine was collected. In order to visualize 
lyophilisomes in individual organs, liver, spleen, lung, kidney, stomach, small intestine, 
colon, pancreas and skin tissue were dissected. These individual organs were imaged 
using similar settings as for the mice. For further examination, parts of liver, spleen, lung, 
and kidney tissue were collected and: 1) snap frozen in optimal cutting temperature 
compound (Tissue Tek, Sakura, Torrance, CA) for immunohistochemistry, 2) fixed in 
paraformaldehyde and paraffin embedded for semi-quantification and 3) fixed in 2% (v/v) 
glutaraldehyde in 0.1 M phosphate buffer (pH 7.4) for transmission electron microscopy.
Semi quantitative assessment using paraffin sections
Paraffin embedded tissue sections were cut at 5 µm, deparaffinized and rehydrated 
using standard procedures. Nuclei were stained with 1% (w/v) DAPI in 2% (w/v) BSA in 
PBS containing 0.05% (v/v) Tween-20 (BSA/PBS-T) for 15 min. For each mouse, a total 
of six fluorescent images were quantified per organ/time point out of two sections (40x 
magnification; 0.405 mm2 surface area). Sections were analyzed using a Zeiss LSM 510 laser 
scanning confocal microscope (Carl Zeiss, Sliedrecht, the Netherlands). Dylight680-labeled 
lyophilisomes were excited at 633 nm and emission was collected between 650 and 710 
nm. DAPI and Alexa fluor 488 were excited at 405 nm and 488 nm with emission collected 
between 420 to 480 nm and 500 to 550 nm, respectively. Dylight680-labeled lyophilisomes 
were quantified in tissue sections with ImageJ 1.48o (National Institutes of Health, USA) 
with an automated script (see Supplemental information) using a conservative threshold 
value of 100. 
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Immunohistochemistry
Frozen liver tissues were sectioned (5 µm) and air dried. Sections were fixed in ice cold 
methanol for 10 min. Blocking was performed with BSA/PBS-T for 10 min. Samples 
were subsequently incubated with primary antibody F4/80 (1:500 in BSA/PBS-T), which 
recognizes a Kupffer cell marker, for 1 h, washed three times with PBS-T and incubated 
with secondary antibody goat anti-rat IgG Alexa fluor 488 conjugated (1:200 in BSA/PBS-T) 
for 45 min. 
Frozen spleen sections (5 µm) were air dried and blocked with 10% normal goat serum 
in BSA/PBS-T for 45 min and stained with primary antibody rat-anti mouse Sign-R1 
(1:100), which recognizes a marker for marginal zone macrophages, in BSA/PBS-T for 1 h. 
Subsequently, sections were washed three times with PBS-T and blocked with 10% normal 
mouse serum BSA/PBS-T for 30 min. Secondary antibody Alexa fluor 488 conjugated goat 
anti-rat IgM (1:1000 in BSA/PBS-T) was applied for 45 min.
All tissue sections were then washed three times with BSA/PBS-T and stained with 1% (w/v) 
DAPI in BSA/PBS-T for 15 min, washed three times with PBS-T and mounted with cover 
glasses in mowiol (Calbiochem, La Jolla, CA, USA). DAPI, Alexa fluor 488 and Dylight680 
were visualized using settings as described in section ‘Semi quantitative assessment using 
paraffin sections’ using a Zeiss LSM 510 laser scanning confocal microscope. Contrast in 
all fluorescent channels was increased for visibility using Fiji imaging software (saturation 
set to 0.35).
Analysis of urine
After bioluminescence imaging, mice were euthanized and urine was collected. To 
investigate the presence of Dylight680-label in urine, Dylight680 fluorescent signal 
contained in 20 µl urine was determined in a 96-wells plate and analyzed by the IVIS 
apparatus. In addition, to investigate whether Dylight680-labeled lyophilisomes were 
degraded, sodium dodecyl sulphate polyacrylamide gel electrophoresis was performed. 
Urine samples (5 µl) were diluted (2x) in sample buffer and analyzed using a 4 to 20% 
precise protein gel (Thermo scientific, Rockford, IL, USA). As a reference, Dylight680-labeled 
lyophilisomes were digested with 2.5 U papain (Sigma Aldrich) in digestion buffer (50 
mM NaPO4, 2 mM cysteine, 2 mM EDTA, set at pH 6.5 with HCl) for 30 min at 65 °C. 
Fluorescent Dylight680 signal was detected with an Odyssey fluorescent gel scanner and 
analyzed using Odyssey software version 2.1 (Li-Cor Biosciences, Lincoln, Nebraska, USA). 
Subsequently gels were stained with 0.1% (w/v) Coomassie Brilliant Blue R-250 solution 
(MP Biomedicals, Santa Anna, CA) in 50% (v/v) methanol and 10% (v/v) acetic acid in 
water. 
Transmission electron microscopy
Glutaraldehyde-fixed samples were post-fixed with 1% (w/v) osmium tetroxide, dehydrated 
in an ascending series of ethanol, and embedded in Epon 812. Ultrathin sections (60 nm) 
were cut and picked up on Formvar-coated grids, post-stained with lead citrate and uranyl 
acetate, and examined in a JEOL 1010 transmission electron microscope (Tokyo, Japan).
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Statistical Analysis
Data are presented as mean with standard deviation. Experimental data were analyzed 
using a one-way ANOVA Bonferroni multiple comparison post-hoc tests. All statistical 
analyses were performed in Graphpad Prism 5.03 (Graphpad, San Diego, CA, USA).
Results
Characterization of lyophilisomes by dynamic light scattering, qNano and analytical 
ultracentrifugation
Analysis by qNano gave a mean size of 1216 ± 95 nm for unsorted lyophilisomes (please 
note that standard deviation represents deviation between means of three individual 
measurements). To probe the possibility of using lyophilisomes for tumor targeting, 
lyophilisomes were sorted by ultracentrifugation using a sucrose gradient. Particle size 
measurements were performed on four fractions (< 1000 nm) using DLS, qNano, and AUC 
(Table 1). Fraction 1, 2, 3, and 4 showed a mean size of approximately 200 nm, 400 nm, 
550 nm, and 650 nm, respectively (Figure 1). The protein concentration of the fractions 
was determined by optical density (λ = 280 nm) to analyze recovery. The combination of 
the four fractions represented 16% of the total lyophilisome protein content. The number 
of lyophilisomes is likely higher than 16% of the initial number as small lyophilisomes 
contain less protein and thinner walls [14]. 
Figure 1. Size distributions of the four smallest lyophilisome fractions after a sucrose-gradient 
ultracentrifugation procedure as analyzed by (A) analytical ultracentrifugation (AUC) and (B) dynamic 
light scattering (DLS). Lyophilisomes were prepared from 2.5 mg bovine serum albumin in 0.01 M 
acetic acid using a freezing, annealing, and lyophilization regime. The average size distribution of the 
initial unfractioned lyophilisome preparation was 1216 ± 95 nm (qNano measurement).
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Table 1 
Lyophilisome recovery and mean size measurements of sorted lyophilisome fractions analyzed by 
dynamic light scattering (DLS), qNano and analytical ultracentrifugation (AUC). 
Biodistribution
To investigate the biodistribution of sorted lyophilisomes, Dylight680-labeled 
lyophilisomes were injected intravenously in mice. After multiple time intervals, the 
distribution of lyophilisomes was visualized and quantified using the Xenogen IVIS Lumina 
II imaging system. Bioluminescence imaging showed a rapid uptake of lyophilisomes in 
the upper abdominal area of the mice (Figure 2). After 120 min, an additional fluorescent 
signal was visible in the lower abdominal area. Both fluorescent signals were considerably 
diminished 24 h post injection (Figure 2). Bioluminescence images of the individual organs 
are presented in Figure 3a. Quantitative analysis of excised individual organs indicated 
that the majority of the lyophilisomes accumulated in the liver (Figure 3B). However, 
when taking the weight of the organs into account, the spleen showed similar uptake of 
lyophilisomes per gram tissue compared to the liver (Figure 3C).
The number of lyophilisomes was also analyzed in paraffin sections of liver, spleen, 
kidney and lung. Figure 4 indicates that the liver and spleen entrapped the majority 
of the lyophilisomes per surface area. An interesting observation is that this analysis 
showed a higher uptake in the spleen than in the liver. Although both in vivo imaging 
and quantification in paraffin sections gave similar results in general, there are minor 
differences between liver and spleen entrapment. This is due to the specific entrapment in 
the marginal zone that was present in all images used for semi-quantification, which could 
induce an over-estimation. Compared to the liver and spleen, the number of lyophilisomes 
present in the lung was very small as only a few lyophilisomes were detected. In the 
kidney, only very few lyophilisomes were detected. Except for the kidney, in all tissue 
sections a rapid uptake of lyophilisomes was found with their number decreasing over 
time being almost gone 24 h post injection (Figure 4). However, some fluorescent signal 
was detected in the excised kidney (Figure 3C). As a result of the presence of fluorescent 
signal in the organ and absence of lyophilisomes in the kidney sections, it is expected that 
the fluorescent signal originates from degraded lyophilisomes. This hints to degradation 
of lyophilisomes and excretion by the kidneys (see section ‘Urine Analysis’).
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Figure 2. Biodistribution of Dylight680-labeled albumin-based lyophilisomes after intravenous 
injection in mice. At multiple time points, the distribution of lyophilisomes was visualized using an in 
vivo imaging system. Lyophilisomes appeared predominantly in the upper abdominal area at 5 – 30 
min. In between (120 – 300 min after injection), lyophilisomes appeared also in the lower abdominal 
area. The signal decreased over time and is more or less absent at 24 h. Note that occasionally a 
fluorescent signal in the stomach was observed, due to autofluorescence of dietary chlorophyll.
Immunohistochemistry
Immunohistochemistry was performed to further evaluate the distribution of the 
lyophilisomes and identify the cells involved in internalization. Since most lyophilisomes 
were found in the liver and spleen, it was hypothesized that lyophilisomes were internalized 
by cells of the mononuclear phagocyte system. Therefore, frozen sections of the liver and 
spleen were stained with mouse macrophage marker F4/80. F4/80 staining showed that 
the majority of lyophilisomes in the liver was internalized by F4/80 positive cells (Figure 
5). Although lyophilisomes present in the red pulp of the spleen were found in F4/80 
positive cells (results not shown), most lyophilisomes were internalized by cells present 
in the marginal zone. Macrophages of the spleen located in the rodent marginal zone are 
known to lack F4/80 expression [27]. Therefore, marginal zone macrophages were stained 
for Sign-R1 expression, a cell surface marker specific for marginal zone macrophages. 
Figure 6 shows that the majority of lyophilisomes was internalized by SignR1 positive cells 
in the marginal zone.
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Figure 3. Bioluminescence images of excised organs (liver, spleen, lung, kidney, stomach, small 
intestine, colon, pancreas and skin) (a) and quantitative analysis of fluorescent signal of lyophilisomes 
in liver, spleen, lung and kidney for total fluorescent signal of the organs (b) and fluorescent signal 
per mg wet weight tissue (c) after intravenous injection of Dylight680-labeled albumin-based 
lyophilisomes in mice. Absolutely, the highest uptake was observed in the liver, but per mg tissue a 
vast majority of lyophilisomes accumulated both in liver and spleen. In general, most fluorescence 
was measured after 5 – 30 min, after which the signal decreased over time. Fluorescence in stomach 
may be due to autofluorescence of dietary chlorophyll. Bars represent mean ± SD.
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Figure 4. Quantification of lyophilisomes present in liver, spleen, lung, and kidney at distinct time 
points after IV injection of lyophilisomes in mice by detection of Dylight680 label in paraffin sections. 
Left column: the number of lyophilisomes counted in tissue sections at several time points after 
injection. Lyophilisomes were predominantly found in liver and spleen and to minor extent in lung. 
From 120 min on, there was a slow decrease over time until hardly any lyophilisomes remained after 
24 h. Bars represent mean ± SD. * p<0.05, ** p<0.01 and *** p<0.001. Right columns: Representative 
images used for quantification of lyophilisomes 5 min after injection. Dylight680-albumin 
lyophilisomes are depicted in green and nuclei were stained with DAPI (blue). Magnifications of 
the white squared boxes are depicted on the far right. Arrows indicate lyophilisomes. Scale bars 
represent 20 µm.
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Figure 5. Uptake of Dylight680-lableded lyophilisomes by liver cells at distinct time points after 
intravenous injection of Dylight680-labeled albumin-based lyophilisomes in mice by detection of 
Dylight680 label in frozen sections. Lyophilisomes (green) were specifically internalized by F4/80 
positive macrophages (red) in the liver. Nuclei were stained blue using DAPI. Magnifications of the 
white squared boxes are depicted in the figures below. Arrows indicate lyophilisomes. Scale bars 
represent 20 µm.
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Figure 6. Uptake of Dylight680-lableded lyophilisomes by splenic cells at distinct time points after 
intravenous injection of Dylight680-labeled albumin-based lyophilisomes in mice by detection of 
Dylight680 label in frozen sections. Lyophilisomes (green) were especially taken up by Sign-R1 splenic 
marginal zone macrophages (red) in the spleen. Nuclei were stained blue using DAPI. Magnifications 
of the white squared boxes are depicted in the figures below. Arrows indicate lyophilisomes. Scale 
bars represent 20 µm.
Urine analysis
To investigate the fluorescent signal in the lower abdominal area, urine was collected 
after euthanizing the mice, and analyzed for the presence of Dylight680-label. Using the 
Xenogen IVIS Lumina II, a high fluorescent value was detected in urine 120 and 300 min 
post injection (Figure 7A and B). To evaluate whether lyophilisomes were degraded and 
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excreted in the urine, urine samples were analyzed on a protein gel in combination with 
fluorescence imaging (Figure 7C and D). All urine samples, including controls, showed 
large bands around 19 kDa corresponding to major urinary proteins [28,29]. Lyophilisomes 
(unlabeled) display a major band at about 70 kDa, representing albumin. After proteolytic 
digestion of lyophilisomes (Dylight680-labeled) using papain, no clear protein band was 
visible indicating major degradation (Figure 7C). In this case, the fluorescent label was 
found in the dye front of the gel (Figure 7D). A similar pattern was found in urine from 
mice 120 and 300 min after injection: no clear protein band visible at about 70 kDa but a 
clear fluorescent label in the gel’s dye front. This indicates that lyophilisomes are degraded 
and excreted in urine within 300 min after injection.
Figure 7. Excretion of degraded lyophilisomes via urine after intravenous injection of 
Dylight680-labeled albumin-based lyophilisomes in mice as analyzed by in vivo imaging (a and b) 
and SDS-PAGE (c and d) Dylight-680 signal in the urine was visualized (a) and quantified (b) using 
an in vivo imaging system. c-d) Gel electrophoresis analysis of urine with Coomassie brilliant blue 
staining (c) and Dylight680 detection (d). Normal non-digested lyophilisomes show a band around 
70 kDa indicating albumin. Papain digested Dylight680 lyophilisomes do not show this band but do 
show fluorescence in the dye front of the gel, indicating degradation. In urine, major urinary proteins 
(±19 kDa) but no albumin/lyophilisomes (±70 kDa) were present. Presence of Dylight680 signal in 
dye front in urine samples taken 120-300 min after injection suggests lyophilisome degradation and 
excretion through urine. Bars represent mean ± SD. **120 and 300 min are significantly different 
from other time points (p<0.01).
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Transmission electron microscopy
In order to visualize lyophilisomes within cells, transmission electron microscopy (TEM) 
was performed, focusing on the marginal zone areas in the spleen. Lyophilisomes that 
were largely intact could be identified primarily at time points 5 and 30 min after injection 
(Figure 8). At 120 min, no lyophilisomes or lyophilisome-like structures could be detected, 
which suggests degradation (results not shown). Control samples also did not show any 
lyophilisomes-like structures (results not shown). 
Figure 8. Transmission electron microscopical images of lyophilisomal structures in the spleen 5 
min (left) and 30 min (right) after intravenous injection of Dylight680-labeled albumin-based 
lyophilisomes in mice. Lyophilisomal structures were found in the marginal zone area in the spleen. 
Scale bar represents 2 µm.
Discussion 
Drug delivery systems require several properties to successfully deliver their cargo at the 
target site. Ideally, they are biocompatible, biodegradable, non-immunogenic and able 
to specifically deliver their cargo to target cells. Lyophilisomes are considered as new 
candidates for drug delivery. Recently, it has been shown that lyophilisomes can be loaded 
with anti-tumor drugs [20] and can specifically target MUC1 expressing tumor cells [21]. 
To ensure an effective treatment in vivo, long circulation times are preferred, whereas 
accumulation in non-targeted organs and premature degradation should be avoided. 
Particle size is considered as an important factor for circulation time since removal from 
circulation increases if the diameter of particles increases [30–32]. Previously, we sorted 
lyophilisomes using fluorescent activated cell sorting [21]. In this study, a straightforward 
sucrose-gradient centrifugation methodology was used to size lyophilisomes into 
fractions with mean diameters of about 200 nm, 400 nm, 550 nm and 650 nm. These 
four fractions were pooled to have sufficient lyophilisomes for the in vivo study. Since 
human albumin has a circulation time up to 19 days under physiological conditions 
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[16,17], and is used to coat nanoparticles to improve circulation time [33], it was expected 
that our bovine albumin-based lyophilisomes would also exhibit a long circulation time. 
Surprisingly, bioluminescence imaging revealed that the majority of intravenously injected 
albumin-based lyophilisomes were rapidly removed from circulation by the liver and 
spleen from 5 min after injection. Semi-quantitative histology of paraffin tissue sections 
confirmed these findings. 
Rapid removal from the circulation is a common problem for drug delivery systems. 
The specific removal from circulation into liver and spleen can most likely be assigned 
to members of the mononuclear phagocyte system (MPS), also known as the 
reticuloendothelial system [16,34]. As the MPS is responsible for clearance of particles 
from the circulation, it was hypothesized that organs of this system clear lyophilisomes 
as well. Indeed, results indicate rapid removal from circulation by MPS members. Staining 
for F4/80 expression, a cell surface marker for macrophages cells [35], and Sign-R1, a cell 
surface marker specific for marginal zone macrophages, confirmed MPS based removal 
[35,36]. 
Our results are consistent with the kinetics and biodistribution of other non-modified 
drug delivery systems. Rapid removal of unmodified (nano)particles from circulation 
into liver and spleen has been observed for drug delivery systems prepared from various 
materials such as poly(lactic-co-glycolic) acid [37], poly D,L-lactide (PLA) [33], and egg 
phosphatidylcholine combined with cholesterol [38]. Albumin-based particles that were 
prepared by other methods than used in lyophilisome preparation were also scavenged 
by the liver and spleen. For instance, almost 60% of drug loaded BSA particles (mean 
diameter 600 nm) injected in rats were entrapped in the liver after 1 h [39]. In another 
drug loaded BSA particle system (mean size 826 nm), approximately 70% of the injected 
drug from particles ended up in the liver of mice after 24 h, indicating phagocytic uptake 
[40]. However, results from these studies and this biodistribution study are in contrast 
with the kinetics of Abraxane, a clinically approved albumin nanoparticular drug delivery 
system, which shows prolonged circulation times (t1/2: 19 h) [41,42]. A possible explanation 
could be that Abraxane has an average diameter of approximately 130 nm, while the 
BSA particles and lyophilisomes have average diameters of about 600, 826 and 150 to 
800 nm, respectively. This could explain the swift removal from circulation, as larger 
particles are removed more rapidly [30–32]. To verify this, lyophilisomes should be sized 
to approximately 130 nm to investigate whether size does indeed matter for this specific 
drug delivery system.
Depending on the biodegradability of the applied material, nanoparticles will either 
be degraded in MPS organs or accumulate and potentially induce toxic effects 
[43]. Lyophilisomes show superior degradation characteristics compared to less or 
non-degradable particles such as gold [44,45], titaniumoxide [46], silver [47] and 
silica nanoparticles [48], which accumulate in tissue organs for longer periods of time, 
specifically in liver in which they induced inflammation [44], apoptosis [44] and hepatic 
necrosis [48]. Several lines of evidence indicate that lyophilisomes are degraded and do 
not accumulate in the body. We observed a significant decrease of lyophilisome signal 
after 300 min compared to 5 min after injection in combination with almost no signal 
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after 24 h observed by full body in vivo imaging, substantiated by histological quantitative 
analysis and urine analysis. In addition, TEM results indicate that lyophilisomes could be 
identified in the spleen up to 30 min, while lyophilisomes or lyophilisome-like fragments 
could not be found at the next time point (120 min), again suggesting rapid degradation 
and excretion.
When lyophilisomes are to be used as a drug delivery system, longer circulation times 
are required. Various methods have been developed to enable prolonged circulation 
times, such as PEGylation [37,43], mimicking “self” by conjugating small peptide markers 
of self CD47 to the particle wall [49] or the use of smaller capsules [30]. Albumin 
Dylight680-lyophilisomes as prepared in this study are rapidly removed from circulation 
and efficiently degraded. To increase circulation times, lyophilisomes could also be 
modified by either PEGylating or a more biological method by using self-peptides. To 
investigate the importance of lyophilisomal size and its effect on biodistribution, a study 
investigating the biodistribution of only the smallest sized fraction (with a mean size of 
about 200 nm in diameter) should be performed.
Lyophilisomes may also be used in other settings that do not rely on long circulation 
times, but do take into account the biodegradability of albumin lyophilisomes. One 
example is the application of lyophilisomes in intraperitoneal chemotherapy [50,51] 
of malignant ascites, caused by ovarian, colorectal, pancreatic, or uterine cancers [52]. 
There is evidence that after intraperitoneal administration small particles (50 to 720 
nm) are removed more rapidly than large particles (>4 µm) due to lymphatic drainage 
[53]. Originally developed lyophilisomes with sizes ranging from 200 nm to 10 µm [14] 
would very well fit this application. In addition, a previous study indicated that non-sized 
antibody-modified lyophilisomes were able to specifically target ovarian cancer cells 
under dynamic conditions making them suitable for this application [21]. This suggests 
that for future clinical IP administration, sizing of lyophilisomes and/or modification to 
prevent rapid removal from circulation may not even be necessary. 
Conclusion
Findings from this study indicate that lyophilisomes can be sorted by sucrose-gradient 
centrifugation. A biodistribution study in mice revealed that lyophilisomes (approximately 
150 - 800 nm) were rapidly removed by members of the mononuclear phagocyte system 
by liver and spleen, degraded and excreted in the urine. 
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Supplemental information
Automated script to count Dylight680 albumin labeled lyophilisomes in tissue sections using ImageJ 1.48o 
(National Institutes of Health, USA) with a conservative threshold value of 100.
// Get data set root folder from user
 sourcePath = getDirectory(“Choose a Directory”);
//create a goal path
goalPath = createGoalPath(sourcePath);
File.makeDirectory(goalPath);
//list the files
fileList = getFileList(sourcePath);
for (i=0; i<fileList.length; i++) {
if (endsWith(fileList[i], “/”)) {
imageList = getFileList(sourcePath + fileList[i]);
for (j = 0; j < imageList.length; j++) {
if (endsWith(imageList[j], “.lsm”)) {
imagePath = sourcePath + fileList[i] + imageList[j];
fileName = fileList[i] + imageList[j];
id = openImage(imagePath);
cOneFileName = fileName + “ - C=1”;
cTwoFileName = fileName + “ - C=3”;
cThreeFileName = fileName + “ - C=0”;
selectWindow(fileName + “ - C=1”);
setAutoThreshold(“Default dark”);
//run(“Threshold...”);
setThreshold(100, 255);
run(“Convert to Mask”);
run(“Make Binary”);
run(“Watershed”);
run(“Analyze Particles...”, “size=1-Infinity pixel circularity=0.00-1.00 show=Outlines clear summarize”);
// close the image
closeImage(id);
closeImage(id);
closeImage(id);
closeImage(id);
     } // end if
    } // end for
   } // end if
  } // end for
//create goal path
function createGoalPath(sourcePath) {
firstCharacter = 0;
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finalCharacter = lengthOf(sourcePath) - 1;
cleanSourcePath = substring(sourcePath, firstCharacter, finalCharacter);
goalPath = cleanSourcePath + “_enhanced”;
File.makeDirectory(goalPath)
return “” + goalPath + “/”; 
}
// Open an image
 function openImage(path) {
  run(“Bio-Formats Importer”, “open=[path] autoscale color_mode=Default split_channels 
view=Hyperstack stack_order=XYCZT”);
    return getImageID();
 }
 // Close an image
 function closeImage(id) {
  close();
 }
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Abstract
Epithelial ovarian cancer has the fifth worst prognosis among all cancers in women. 
Recently, we developed a strategy for targeted chemotherapeutic delivery using antibody 
modified lyophilisomes directed towards highly sulfated chondroitin sulfate E (CS-E), 
which is abundantly expressed in the extracellular matrix of ovarian tumors. In the present 
study, we explored the in vivo characteristics of these lyophilisomes in an orthotopic 
SKOV3-GFPluc ovarian cancer mouse model. Histology indicated that doxorubicin was 
released from the lyophilisomes and localized to the nuclei of tumor cells. Penetration 
of lyophilisomes was limited to the surface of tumors. Tumor and organ distribution of IP 
injected lyophilisomes (FITC and DyLight680 labeled) with and without anti-CSE antibodies 
was imaged in vivo and ex vivo by fluorescent imaging. Both targeted and non-targeted 
lyophilisomes were found throughout the peritoneal cavity, whereas the bioluminescent 
tumor signal was located more specifically in the upper left abdominal area. Ex vivo imaging 
and semi-quantitative analysis indicated limited tumor accumulation, and minor spleen 
and liver accumulation. Immunohistochemistry revealed both targeted and non-targeted 
lyophilisomes at the borders of tumors. Absence of clear CS-E targeting and limited tumor 
penetration is most likely due to the large size of lyophilisomes (approximately 1 – 2 µm). 
However, since lyophilisomes were able to localize to the tumor surface and release 
doxorubicin, they hold potential as a local chemotherapeutic depot.
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Introduction
Epithelial ovarian cancer is considered the most lethal gynecologic malignancy. Over the 
past decades, the 5-year survival-rate has considerably improved from about 36% in the 
1970s to 46% nowadays (data based on US cohorts, all disease stages) [1]. Despite the 
increase in survival, the prognosis is still the fifth leading cause of cancer related deaths 
among women [2]. Current treatment strategies involve debulking surgery with either 
presurgical and/or post-surgical chemotherapy. While chemotherapy improves patient 
survival, it has serious limitations including its toxicity to healthy cells and unfavorable 
biodistribution indicating the urge to improve chemotherapeutic delivery strategies.
The use of drug delivery systems is a major area of interest in the development of 
novel strategies for ovarian cancer treatment. By encapsulating chemotherapeutics in 
a drug delivery system, exposure to healthy cells may be prohibited, which can result 
in a reduction of the side effects. Specific delivery to tumor cells only can increase the 
treatment efficacy of chemotherapeutics [3]. This may be achieved by active targeting, 
targeting to tumor cells using antibodies or tumor-specific ligands conjugated to drug 
delivery systems [4].
Targeting to the tumoral extracellular matrix (ECM) may have several advantages over 
conventional active tumor targeting strategies of which the majority is aimed at tumor 
cells. In the first place, targeting a drug delivery system to a unique tumor ECM target with 
subsequent extracellular release of chemotherapeutics, may result in not only removal 
of tumor cells, but also in removal of tumor supportive cells such as cancer-associated 
fibroblasts, endothelial cells and macrophages [5]. Moreover, tumor cells are considered 
highly genetically instable resulting in intratumoral heterogeneity [6]. This implicates 
that only a subset of tumor cells expressing the specific target will be affected by tumor 
cell specific targeting, leaving non-expressing cells unaffected. In contrast, extracellular 
release of chemotherapeutics targeted to the tumoral ECM could affect all heterogenic 
tumor cells within a tumor. Hence, targeting the more stable tumoral ECM may therefore 
be a promising drug delivery strategy. 
Our group developed a targeting strategy to the tumoral ECM rather than tumor 
cells [7]. The ECM of tumors is vastly different from healthy ECM in, for instance, the 
increased amount of matrix remodeling enzymes, growth factors, fibrous proteins, and 
glycosaminoglycans (GAGs) [8, 9], and therefore offers tumor specific anchors for drug 
delivery. The chondroitin sulfate type E (CS-E) glycosaminoglycan, was identified as a 
target abundantly present in the ECM of ovarian tumors and practically absent in the ECM 
of healthy tissue [10], making it a suitable candidate for ECM targeting. Indeed, using CS-E 
targeting lyophilisomes, a versatile protein-based drug delivery system [11, 12], ovarian 
cancer cells cultured in a CS-E rich micro-environment could be efficiently eradicated by 
extracellular release of a chemotherapeutic in vitro [7].
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To elaborate on our research showing the possibilities of the ECM targeting lyophilisomes 
in vitro, the current study was designed to explore its in vivo characteristics in a tumor 
model. We first evaluated the release and uptake of doxorubicin from CS-E targeting 
lyophilisomes to the tumor cells. Subsequently we investigated the tumor penetration of 
lyophilisomes without antibody modification by comparing the in vivo tumor targeting and 
organ distribution of CS-E targeting and non-targeting fluorescent labeled lyophilisomes.
Materials and Methods
Preparation of CS-E targeting single chain variable fragment antibodies GD3G7
Highly sulfated chondroitin sulfate type-E (CS-E) single chain variable fragment antibodies 
GD3G7 were prepared and modified for bioorthogonal click chemistry as described [7, 10]. 
In short, expression of GD3G7 with a His-tag, VSV-tag, and LPETG sortase A recognition 
motif was induced in E. coli strain ER2566 using isopropyl β-D-thiogalactoside (IPTG). 
Thereafter, GD3G7-LPETG-His-VSV was released through osmotic lysis (200 mM Tris-HCl, 
pH 8.0, 0.5 mM ethylenediaminetetraacetic acid [EDTA]), purified using nickel-NTA affinity 
chromatography (NTA-Ni Sepharose, IBSA Life Sciences) and dialyzed against 50 mM Tris 
pH 7.5, containing 150 mM NaCl.
To enable straightforward conjugation possibilities, dibenzocyclooctyne (DBCO), a 
bioorthogonal click-chemistry partner, was conjugated to the antibody by sortagging 
[7]. Briefly, sortase A cleaved G-His-VSV from GD3G7-LPETG-His-VSV, enabling binding 
of amino-PEG4-DBCO (Click Chemistry Tools, Scottsdale, USA) to GD3G7 in an overnight 
incubation in 50 mM Tris, 150 mM NaCl, 10 mM CaCl2, pH 7.5. The final product, 
GD3G7-H2N-PEG4-DBCO was subsequently purified using nickel-NTA beads and a 10 kDa 
centrifugal filter (Amicon Ultra-4, Merck Millipore).
To confirm DBCO addition to GD3G7, GD3G7-H2N-PEG4-DBCO was labeled with the 
fluorophore Cyanine5.5 (Cy5.5). GD3G7-H2N-PEG4-DBCO was incubated with a 50 times 
molar excess azido-Cy5.5 (Lumiprobe GmbH, Hannover, Germany) at 4°C under rotation 
overnight. The next day, excess azido-Cy5.5 was removed using 10 kDa centrifugal filters 
(Amicon Ultra-4) according to the manufacturer’s instructions. Labeling of GD3G7 with 
Cy5.5 was evaluated with sodium dodecyl sulfate polyacrylamide gel electrophoresis 
(SDS-PAGE) [7]. GD3G7 antibodies with or without Cy5.5 were analyzed on 10% gels and 
subsequently imaged at 700 nm using an Odyssey CLx imaging system (LI-COR, NE, USA). 
Subsequently, gels were stained for protein with 0.1% (w/v) Coomassie Brilliant Blue 
R-250 solution (MP Biomedicals, Santa Anna, CA) in 50% (v/v) methanol and 10% (v/v) 
acetic acid in water.
Preparation of antibody-functionalized lyophilisomes
Lyophilisomes were prepared as described [11]. Briefly, lyophilisomes were prepared 
from 2.5 mg/ml bovine serum albumin (BSA; PAA Laboratories, Linz, Austria) in 0.01 M 
acetic acid. For detection purposes, 10 mg BSA was labeled with a six-fold molar excess 
NHS activated DyLight680 (ThermoFisher Scientific, Waltham, MA) according to the 
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manufacturer’s protocol. Unbound DyLight680 was removed from BSA by dialysis (10 kDa 
MWCO) to 0.01 M acetic acid overnight. The final BSA mixture containing 10% FITC-BSA 
(Sigma-Aldrich, Saint Louis, MO), 20% DyLight680-BSA and 70% non-labeled BSA was 
snap frozen in 20 µl droplets in liquid N2 and lyophilized [12]. Formed lyophilisomes were 
stabilized by vapor crosslinking in formaldehyde and glutaraldehyde and free aldehydes 
were quenched by incubation in 1% glycine (w/v) in phosphate buffered saline (PBS, pH 
7.4). Finally, lyophilisomes were separated from large structures by gentle centrifugation 
(60g).
To enable modification with GD3G7-H2N-PEG4-DBCO, lyophilisomes were functionalized 
with NHS-PEG4-azide, DBCO’s opposite click chemistry partner [7]. Shortly, lyophilisomes 
were incubated with a 100 times molar excess NHS-PEG4-azide (Jena Bioscience, Jena, 
Germany) under rotation overnight in 0.1% Tween20 (v/v) in PBS, pH 8.0 (PBST). Unbound 
NHS-PEG4-azide was removed by centrifugation (5 min 17,000g) and resuspension of 
lyophilisomes in PBST (pH 7.4). To functionalize lyophilisomes with GD3G7, azide-modified 
lyophilisomes were incubated with a 1.25x molar excess GD3G7-H2N-PEG4-DBCO overnight 
at room temperature, followed by centrifugation (5 min 17,000g) and three washings with 
PBST to remove unbound GD3G7.
The presence of PEG4-azide on lyophilisomes was assessed by incubating 
PEG4-azide-lyophilisomes with DBCO-PEG3-biotin (Sigma-Aldrich) and horseradish 
peroxidase-conjugated-streptavidin (Pierce, ThermoFisher Scientific). After washing, 
lyophilisomes were incubated with 24.3 mM citric acid, 51.4 mM K2HPO3, 0.012% H2O2 
(v/v) and 0.04% ortho-phenylenediamine (w/v) for 30 min after which 12.5% H2SO4 (v/v) 
was added to stop the reaction. The peroxidase activity was measured at 492 nm with a 
Synergy BioTek 2 Plate reader (BioTek, Winooski, VT, USA). Control conditions included 
lyophilisomes not modified with PEG4-azide or not incubated with DBCO-PEG4-biotin. 
GD3G7 conjugation to lyophilisomes was tested in a similar way but with peroxidase-Protein 
A (Merck Millipore, Darmstadt, Germany) that binds to the VH3 domain of the antibody 
[10].
Doxorubicin loading
Loading of lyophilisomes with doxorubicin was performed as described [7, 11]. In short, 
lyophilisomes functionalized with GD3G7 antibody were incubated with 0.5 mg/ml 
doxorubicin (Accord Healthcare, the Netherlands) in 10 mM HEPES buffer (w/v; pH 7.4) 
at room temperature overnight. Not entrapped doxorubicin (supernatant) was collected 
three times by centrifuging 5 min at 17 000g at 4°C and washing with 10 mM HEPES buffer. 
The doxorubicin concentration in 10 mM HEPES buffer of the three collected supernatants 
was quantified spectrophotometrically at 490 nm with a Synergy BioTek 2 Plate reader. 
The entrapment efficiency was calculated using the following formula:
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Evaluation of fluorescent quenching properties of doxorubicin
To evaluate whether doxorubicin is responsible for quenching of the fluorescence 
of DyLight680-FITC lyophilisomes, a fluorescent intensity assay was performed. The 
fluorescence of non-doxorubicin loaded DyLight680-FITC lyophilisomes (25 µg/ml) 
and doxorubicin loaded DyLight680-FITC lyophilisomes (25 µg/ml) was determined 
at an excitation of 688 nm (±9 nm) and emission of 720 nm (± 20 nm) for DyLight680 
fluorescence and an excitation of 488 nm (±9 nm) and emission of 530 nm (± 20 nm) 
for FITC fluorescence using a Tecan infinite 200Pro fluorescent plate reader (Tecan, 
Switzerland).
Characterization of particle size
To characterize particle size, dynamic light scattering (DLS) was performed using a 
DLS-Zetasizer (Malvern Instruments, Worcestershire, UK). Hydrodynamic diameters 
of lyophilisomes (0.2 mg/ml) in PBST were measured using a backscatter detector at an 
operating angle of 173° at 25°C after an equilibration time of 120 s. Intensity-based data 
of three batches lyophilisomes with or without GD3G7 modification were analyzed (in 
triplicate) using Zetasizer version 7.11 (Malvern).
Cell culture
Luciferase (luc)-green fluorescent protein (GFP) transfected human ovarian cancer cells 
(SKOV3) [13] were cultured in Dulbecco’s Modified Eagle Medium (DMEM)-GlutaMAX 
(Gibco, ThermoFisher scientific, Waltham, MA, USA) supplemented with 10% fetal bovine 
serum (PAN Biotech, Aidenback, Germany) (v/v), 100 IU/ml penicillin and 100 µg/ml 
streptomycin (Amresco, Solon, OH, USA) at 37°C in a humidified incubator at 5% CO2. 
When 80% confluency was reached, cells were dissociated using 0.05% trypsin (w/v) in 
0.53 mM EDTA in Hank’s balanced salt solution (Corning Mediatech, Tweksbury, MA, USA) 
and maintained as proliferating cultures.
Animals
The Dutch national central committee on animal research and the local ethical committee 
on animal research of the Radboud University approved this study under protocol 
2015-0070. All animal experiments were performed according to the institutional 
guidelines. Upon arrival, mice were randomly tattooed for identification and were 
acclimatized for ≥7 days before any experimental procedure. Mice had unlimited access to 
food (chlorophyll-free diet after tumor inoculation) and water and were maintained with 
3-5 mice per cage in a controlled environment (22±1°C, 55±10% humidity, 12 h dark/light 
cycle). Cages were weekly replaced by clean cages. Mice were assessed daily for welfare 
and weighted every two days after tumor inoculation. Mice were randomly allocated to 
the experimental groups according to a random sequence generator and experiments 
regarding tumor targeting of non-targeting and CS-E targeting lyophilisomes were blinded.
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In vivo ovarian cancer tumor model and tumoral extracellular matrix CS-E evaluation
Twenty-seven BALB/cAnNRj-Foxn1nu/Foxn1nu mice (Janvier Labs, France, 4-6 weeks old, 
17-22 g, female) were injected intraperitoneally (IP) with 5·106 human ovarian cancer 
SKOV3-GFP-luc cells in 500 µl PBS. After 7, 14, and 21, tumor growth was evaluated 
using an In Vivo Imaging System (IVIS Lumina, PerkinElmer, Waltham, MA). Mice were 
imaged under general anesthesia (2-3% isoflurane) for bioluminescence 10 min after they 
had received an IP injection of 150 mg D-luciferin in PBS (15 mg/ml, Cayman chemicals, 
Ann Arbor, MI) per kg bodyweight. The mouse with the smallest detectable tumor was 
euthanized and the tumor was dissected and processed for immunohistochemical analysis 
to detect stromal CS-E (see section “Immunohistochemistry”).
Evaluation of in vivo tumoral doxorubicin localization of doxorubicin loaded CS-E targeting 
lyophilisomes
To investigate whether doxorubicin of doxorubicin loaded CS-E targeting lyophilisomes 
would localize to the nuclei of tumor cells, 3 BALB/cAnNRj-Foxn1nu/Foxn1nu 
SKOV3-GFP-luciferase tumor bearing mice were IP injected with 5 mg/kg bodyweight 
doxorubicin loaded CS-E targeting lyophilisomes. Twenty-four hours after injection, mice 
received an IP luciferin injection and after a 10 min incubation they were imaged for 
luminescence and subsequently for DyLight680 fluorescence. DyLight680 fluorescence 
was excited at 640 nm and emission recorded between 695 – 770 nm. Autofluorescence 
correction images were obtained by excitation at 605 nm and collected between 695 
to 770 nm. Thereafter, mice were euthanized by CO2 inhalation. Subsequently, blood 
(collected in EDTA), feces and urine were collected and tumor and organs (heart, lung, 
liver, spleen, kidney, ovary, stomach, intestine, colon and an ear) were dissected and 
imaged for bioluminescence and DyLight680 signal using the IVIS. Subsequently, tumors 
were snap frozen in optimal cutting compound (Tissue Tek, Sakura, Torrance, CA) for 
immunohistochemistry.
Evaluation of organ distribution and tumor targeting of CS-E targeting lyophilisomes
To further study the additive value of CS-E targeting in delivering doxorubicin to the 
tumor cells through extracellular doxorubicin release, the organ distribution and tumor 
targeting potential of CS-E targeting lyophilisomes were evaluated in a similar experiment 
as described above. Twenty-eight days after tumor inoculation 24 SKOV3-GFP-luciferase 
tumor bearing mice were IP injected with 5 mg/kg bodyweight CS-E targeting lyophilisomes, 
non-targeting lyophilisomes or with 10 µl/g bodyweight PBS (3 mice per group). In Table 1, 
the conditions are summarized. After 0 min (PBS control group only), 15 min, 3 h, and 24 
h, mice were imaged, euthanized and organs were collected as described above.
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Table 1 
Overview of conditions evaluated in the orthotopic ovarian cancer mouse model.
Semi-quantification of in vivo fluorescence
To semi-quantify the fluorescent signal in vivo of injected lyophilisomes, fluorescent images 
of dissected organs obtained by the IVIS were analyzed with Living Image 4.2 software 
(PerkinElmer, Waltham, MA). DyLight680 fluorescence was semi-quantified using ROIs set 
around the tumors and organs and calculated per mg wet organ weight. Collected blood 
was centrifuged (10 min, 3000g) and the supernatant (plasma) was collected. Plasma, urine 
and feces were transferred into a 96 wells plate and imaged for DyLight680 fluorescence 
using the IVIS. ROIs were set around the wells and the fluorescence was measured. 
Autofluorescence was subtracted in all images before analysis. In case autofluorescence 
was higher than the DyLight680 fluorescence, DyLight680 was considered absent and the 
data point was set to zero. These results give an indication of the fluorescence intensity 
and should be interpreted with caution. Consequently, no statistical analyses were 
performed on these results.
Immunohistochemistry
To visualize CS-E within dissected tumors or the distribution of lyophilisomes within 
tumors, immunohistochemistry was performed. 5 µm frozen tumor sections were air 
dried. Sections were fixed in 4% paraformaldehyde in PBS (w/v) for 10 min and blocked 
with 2% BSA in PBST (w/v) for 30 min. Thereafter nuclei were visualized by incubation with 
10 μg/ml 4′,6-diamidino-2-phenylindole (DAPI; Merck, Darmstadt, Germany) in 2% BSA/
PBS and mounted with cover glasses in mowiol-488. Moreover, to visualize CS-E within 
the tumor, tumor sections were incubated with GD3G7-His-VSV, mouse monoclonal 
anti-VSV antibody (clone P5D4) and goat anti-mouse AlexaFluor-594. Subsequently, nuclei 
were stained with DAPI and sections were mounted with cover glasses in mowiol-488. 
Stained sections were visualized using Leica DM6000B fluorescent microscope (Wetzlar, 
Germany). Overlays were created using ImageJ 1.48v (National Institutes of Health, USA). 
Brightness and contrast were adjusted to improve visualization similarly for all images.
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Results
Preparation and analysis of CS-E targeting antibody GD3G7
GD3G7 antibodies with a LPETG-His-VSV tag were produced and modified with a DBCO 
bioorthogonal (click chemistry) group as described [7]. Using Sortase A, G-His-VSV was 
removed from the antibody after which the antibody was modified with NH2-PEG4-DBCO 
for conjugation purposes, using azide-cyanine 5.5 (Cy5.5) to confirm the DBCO modification 
(Figure 1A-B). SDS-PAGE showed a clear band for azido-Cy5.5 modified GD3G7, which 
was absent for DBCO functionalized antibodies not treated with azido-Cy5.5, similar to 
published results [7].
Preparation, modification and characterization of lyophilisomes with CS-E targeting 
antibody GD3G7
Lyophilisomes were prepared from albumin (70% non-labeled, 20% DyLight680 labeled 
and 10% FITC labeled) and functionalized with PEG4-azide for DBCO-GD3G7 modification. 
The conjugation of PEG4-azide to lyophilisomes was evaluated using DBCO-PEG4-biotin 
and horseradish peroxidase-conjugated-streptavidin. This assay showed an abundant 
signal for lyophilisomes functionalized with azide, while non-functionalized lyophilisomes 
and control conditions without DBCO-PEG4-biotin only showed a minor signal (Figure 1C).
Modification of lyophilisomes with GD3G7 was evaluated in a similar manner but using 
peroxidase-conjugated protein A that binds to GD3G7. The peroxidase signal was more 
than three times higher for lyophilisomes with GD3G7 than for lyophilisomes not modified 
with GD3G7, while the signal was almost absent when peroxidase-conjugated protein A 
was omitted (Figure 1D). Results were similar to published data [7].
Dynamic light scattering analysis of lyophilisomes without and with CS-E targeting 
antibody GD3G7 indicated a mean hydrodynamic particle diameter of 1183 ± 184 nm and 
1776 ± 493 nm with a polydispersity index of 0.26 ± 0.16 and 0.39 ± 0.09 (all mean ± SD), 
respectively.
Doxorubicin loading resulted in an entrapment efficiency of 31%, corresponding with a 
drug loading of 0.23 mg doxorubicin/mg lyophilisomes.
To evaluate whether doxorubicin is responsible for quenching of the fluorescence of 
DyLight680-FITC lyophilisomes, the fluorescence of DyLight680 and FITC in lyophilisomes 
was investigated after doxorubicin loading. Fluorescent measurements showed that 
the DyLight680 and FITC fluorescent signal of doxorubicin loaded lyophilisomes was 
decreased to 4% (± 0.29%) and 22.4% (± 1.24%), respectively, of the fluorescent intensity 
of non-loaded lyophilisomes with 100% being the signal for non-loaded lyophilisomes.
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Figure 1. Biochemical evaluation of CS-E targeting lyophilisomes. (A) SDS-PAGE of GD3G7 antibodies 
(± 28.5 kDa) with amino-PEG4-DBCO used for azido-cyanine5.5 (CY5.5) labeling. (B) Visualization of 
the same gel as in (A) in the 700 nm channel of GD3G7-PEG4-DBCO and unmodified GD3G7 antibodies 
after azido-CY5.5 labeling. Arrows identify functionalized antibody. The lowest fluorescent line in 
lane 2 and 5 indicates free CY5.5. The second lowest line in lane two could indicate the result of 
the reaction of azido-CY5.5 with free NH2-PEG4-DBCO left in the antibody mixture after sortagging 
and purification. (C) Azide-conjugated lyophilisomes detected after binding of DBCO-Biotin 
and horseradish peroxidase conjugated avidin by absorbance at 492 nm after reaction with 
peroxidase substrate. Lyophilisomes with and without azide were evaluated. (D) DBCO-modified 
GD3G7 antibodies conjugated to azide-conjugated lyophilisomes and detected by the binding of 
peroxidase-conjugated protein A by absorbance at 492 nm after reaction with peroxidase substrate. 
Lyophilisomes with and without GD3G7 were evaluated. Bars represent mean ± standard deviation 
of triplicate measurements (n = 1).
Presence of CS-E in orthotopic ovarian cancer model
Tumors of the orthotopic ovarian cancer mouse model were evaluated for extracellular 
CS-E production. At three time points after tumor inoculation (7, 14 and 21 days), tumors 
were detected in vivo using bioluminescence imaging. At each time point, the mouse with 
the smallest detectable tumor was euthanized and the tumor was dissected and processed 
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for immunohistochemistry to determine the presence of CS-E. In general, a major tumor 
was found in the omentum located between the stomach and the spleen. Smaller tumor 
spots were found all around the peritoneal cavity, especially at the intestine attached 
mesentery. As shown in Figure 2, minor CS-E staining was observed in the stromal areas 
of tumors 7 days after tumor inoculation, while more prominent staining was detected 
at 14 and 21 days. Tumor targeting studies therefore commenced 28 days after tumor 
inoculation, a comparable time span to others that used a similar model [14-17].
Figure 2. Stromal chondroitin sulfate E (CS-E) expression in red (detection by antibody GD3G7) in 
tumors dissected from mice 7, 14 and 21 days after tumor inoculation. Nuclei were stained blue 
with DAPI. Scale bar represents 50 µm.
Evaluation of in vivo tumoral doxorubicin localization of doxorubicin loaded CS-E targeting 
lyophilisomes
Mice intraperitoneally injected with doxorubicin loaded, CS-E targeting lyophilisomes 
were evaluated 24 h after injection. Lyophilisomes could be detected by their FITC 
signal in tumor sections (Figure 3A). No GFP signal in tumor cells could be detected. Red 
colored nuclei were visible in the red fluorescence channel, most likely originating from 
doxorubicin present in the nuclei after release from lyophilisomes. In all images, cells with 
red nuclei were surrounded by lyophilisomes.
Whole mice imaging did not show any DyLight680 signal, representative for lyophilisomes 
(Figure 3B), most likely caused by a decrease of DyLight680 fluorescent intensity after 
doxorubicin loading. Luminescence, representative for tumor cells, was present in the 
lower and upper left abdominal area. Dissected tumors did not show a fluorescent 
signal, while DyLight680 fluorescence could be detected in other organs (Figure 3C). 
Semi-quantification per mg organ weight indicated a minor increase of fluorescence in 
the spleen (Figure 3D).
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Figure 3. Overview of the localization of doxorubicin in the tumor, and tumor targeting and organ 
biodistribution of doxorubicin loaded CS-E targeting lyophilisomes. Twenty-eight days after IP tumor 
inoculation, mice were injected IP with 5 mg/kg doxorubicin loaded, CS-E targeting lyophilisomes 
and evaluated after 24 h. Nuclei of frozen tumor sections were stained with DAPI and merged with 
FITC and doxorubicin images (A). FITC lyophilisomes (green) and red colored nuclei were both 
visible, which is most likely doxorubicin leaked from lyophilisomes. Whole body fluorescence and 
luminescence (after luciferin injection) was imaged using an IVIS Lumina (B). After imaging, mice 
were euthanized and tumors and organs were dissected and imaged (C) and semi-quantified (by 
applying ROIs) for DyLight680 fluorescence (D). No DyLight680 was detected after whole mouse 
imaging, probably caused by quenching of DyLight680 fluorescence by doxorubicin. Imaging of 
dissected tumors showed no presence of DyLight680, while other organs did show a DyLight680 
signal of which most was present in the spleen according to semi-quantification. Bars represent 
mean ± SD. Scale bars represent 50 µm.
Tumor penetration, targeting and biodistribution after IP injection of lyophilisomes 
with or without CS-E targeting antibody GD3G7
In vivo and ex vivo imaging of CS-E targeting lyophilisomes
To investigate the targeting potential of CS-E targeting lyophilisomes, tumor targeting and 
organ distribution of lyophilisomes with and without antibody were investigated in SKOV3 
tumor bearing mice after intraperitoneal injection. Whole mice imaging was performed 
15 min, 3 h and 24 h after IP injection. As can be seen in Figure 4A, the DyLight680 signal, 
an indicator of lyophilisomes, was present in the abdominal area at all time points. CS-E 
targeting and non-targeting lyophilisomes localized at several areas in the lower abdomen 
15 min and 3 h after injection. At the final time point, 24 h after injection, spots of 
DyLight680 signal were present in the upper left abdominal area and in the lower middle 
to right abdomen. The control condition (PBS) that was imaged directly after injection 
showed no fluorescence. The luminescent signal, an indicator for the tumor cells, was 
present in the upper left abdominal area in most mice (Figure 4A). Semi-quantification of 
the signal in the peritoneal cavity (Figure 4B) confirmed its presence at all time points in 
mice that received an intraperitoneal injection of lyophilisomes.
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In dissected tumors, the fluorescent signals of CS-E targeting and non-targeting 
lyophilisomes were weakly present in the tumor 15 min, 3h and 24 h after injection (Figure 
4C). Tumors of the control condition (PBS injection, imaged directly after injection) did not 
show fluorescence. Among other imaged organs, most fluorescence was visible in the 
liver 3 h after injection of CS-E targeting lyophilisomes and in the spleen as specific spots 
for both CS-E targeting and non-targeting lyophilisomes at 15 min and 3 h after injection 
(Figure 4D). Moreover, minor fluorescent spots were present in livers from mice injected 
with non-targeting lyophilisomes. Livers and kidney from mice injected with CS-E targeting 
lyophilisomes showed a diffuse fluorescent signal with similar intensity which was visible 
only at 3 h post injection. Of all imaged lungs of mice injected with CS-E targeting or 
non-targeting lyophilisomes, only one fluorescent spot was visible which was in one lung 
of a mouse 3 h after injection of CS-E targeting lyophilisomes. Other dissected organs 
(heart, ovary, stomach, intestine, colon and ear) did not show fluorescence.
Semi-quantification was performed to gain insight in the amount of fluorescence present 
in tumors and organs using similar sized regions of interest set around the fluorescent 
images. The highest signal per mg wet weight was found in tumors 24 h after injection 
(Figure 4E). Next to tumors, fluorescence was observed in the spleen. While fluorescence 
was visible in the liver (Figure 4D), this signal only had a low intensity when semi-quantified 
and presented per mg organ weight. No major differences between CS-E targeting and 
non-targeting lyophilisomes were measured, despite a minor increased signal that was 
measured in spleens of CS-E targeting lyophilisomes treated mice 3 h after injection.
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Figure 4. Overview of tumor targeting and biodistribution of non-targeting and CS-E targeting 
lyophilisomes in an ovarian cancer mouse model. A) Imaging of fluorescent DyLight680-lyophilisomes 
and tumor luminescent signal in live mice. B) Quantified fluorescent DyLight680 in peritoneal area 
of whole mice images. C) Fluorescent DyLight680 and luminescent signal visualized in dissected 
tumors detected with identical settings. D) Fluorescent DyLight680 signal in dissected livers, spleens, 
kidneys and lungs. E) DyLight680 fluorescence quantified per mg tumor or organ. F) Quantified 
DyLight680 fluorescence in collected feces, urine and plasma. Imaging in whole mice showed 
presence of DyLight680 fluorescence throughout the peritoneal cavity. Luminescence was absent 
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in some mice because of low intensity (below the imaging threshold) or because of an erroneous 
luciferin injection. Dissected tumors displayed several fluorescent tumor spots and almost all 
showed a luminescent signal. DyLight680 fluorescence was most prominent in dissected livers and 
spleen. Quantification of DyLight680 fluorescence per mg tumor or organ weight showed most 
fluorescence in the tumors and spleen. Feces, urine and plasma analysis showed a peak fluorescent 
signal in feces from mice 15 min after injection with CS-E targeting lyophilisomes. Moreover, in urine 
an increasing signal was found over time. Bars represent mean ± SD.
To investigate whether injected lyophilisomes remained in the blood or were excreted, 
plasma, urine and feces were collected and the fluorescent signal was semi-quantified 
(Figure 4F). Compared to the control condition, almost no increase in fluorescence was 
measured in the feces, despite one outlier in the feces from mice 15 min after injection 
with CS-E targeting lyophilisomes. The fluorescence measured in urine was almost similar 
for CS-E targeting and non-targeting lyophilisomes. Over time, the fluorescence signal in 
the urine increased for both conditions. Almost no increased fluorescence was measured 
in the plasma of mice injected with either CS-E targeting or non-targeting lyophilisomes, 
except for a slight increase in plasma collected 24 h after injection with non-targeting 
lyophilisomes.
Immunohistochemistry
To further discriminate between CS-E targeting and non-targeting lyophilisomes within 
the tumor, immunohistochemistry was performed. Lyophilisomes were easily detectable 
in tumor sections by their FITC signal (Figure 5). Cryosections revealed that lyophilisomes 
were present in the tumor and especially accumulated in areas at the borders of the 
tumors. No differences between CS-E targeting and non-targeting lyophilisomes were 
observed. GFP fluorescence from tumor cells could be detected.
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Figure 5. Visualization of CS-E targeting and non-targeting lyophilisomes in tumor sections. Tumors 
were dissected from ovarian tumor bearing mice that were intraperitoneally injected with PBS 
(A) or 5 mg/ml CS-E targeting lyophilisomes (B) or non-targeting lyophilisomes (C). After various 
time points, mice were euthanized and tumors were dissected, snap frozen and sectioned (5 µm). 
Nuclei were stained blue with DAPI (left column). CS-E staining (red, middle and right column) was 
performed to show the location of lyophilisomes (green) within the tumors. CS-E targeting and 
non-targeting lyophilisomes mainly accumulated in the peripheral site of the tumors. GFP from 
tumors could not be detected in the FITC channel. Scale bars represent 50 µm. Right column 
represents enlargements from the middle column.
Discussion
In this study, we explored the in vivo characteristics of (doxorubicin loaded) lyophilisomes 
modified with single chain variable fragment antibodies (GD3G7) directed against 
chondroitin sulfate type-E (CS-E) [7], which is abundantly present in the extracellular 
matrix (ECM) of ovarian tumors. Targeting chemotherapeutic drug delivery systems to 
CS-E in the ECM of ovarian cancer is part of a novel targeting strategy aimed at extracellular 
delivery of chemotherapeutics to tumor ECM. By targeting the more stable tumor ECM 
instead of a specific tumor cell subset only, all heterogeneous tumor cell subsets as well 
as tumor supportive cells (e.g. tumor supportive fibroblasts and macrophages) may be 
removed. The abundant expression of CS-E in the ECM of ovarian cancer [18] and other 
types of cancer [7], while almost absent in healthy tissue, makes CS-E an ideal target. In 
order to be clinically effective, CS-E targeting lyophilisomes should target and bind CS-E 
specifically in the ECM of tumors, before being removed from the body. Moreover, to 
limit potential toxicity, binding to healthy tissues should be avoided. In a previous study 
we found, however, that intravenously injected non-modified lyophilisomes were rapidly 
removed from the circulation of healthy mice by hepatic and splenic macrophages [19]. To 
circumvent rapid removal from the circulation with accumulation in the spleen and liver, 
lyophilisomes were injected intraperitoneally (IP) in the present study. IP injection may 
have advantages over IV administration in the treatment of ovarian cancer as suggested 
by improved survival rates in patients that received IP administered chemotherapy [20]. 
Moreover, the relatively large size of lyophilisomes (± 1-2 µm) may retain them in the 
intraperitoneal environment, thereby increasing the possibility of target binding and 
preventing uptake in the circulation since it has been described that micro-sized particles 
show prolonged intraperitoneal retention and improved treatment efficacies over 
nano-sized particles [21].
Indeed, results of the present study indicate that lyophilisomes are retained in the 
intraperitoneal cavity and are able to deliver doxorubicin to tumor cells. Tumor sections 
of mice injected with doxorubicin loaded CS-E targeting lyophilisomes showed specific 
red colored nuclei surrounded by lyophilisomes, indicating that the doxorubicin was 
released from lyophilisomes localized at the tumor site. As lyophilisomes were able to 
deliver doxorubicin to only a limited number of tumor cells, it is not clear whether this 
will finally result in improved treatment efficacies over free administered doxorubicin. 
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To improve the efficacy and reduce the side-effects of chemotherapeutics, we applied a 
specific targeting strategy towards CS-E. However, modification of lyophilisomes with CS-E 
targeting antibodies did not result in specificity towards CS-E rich regions in the tumoral 
CS-E in vivo in the current experimental set-up. Despite the abundant presence of CS-E 
in the ECM of the tumors as shown by immunohistochemistry, similar numbers of CS-E 
targeting and non-targeting lyophilisomes were found in tumors by in vivo and ex vivo 
fluorescent imaging.
Several reasons may explain this lack of targeting towards CS-E in the tumoral ECM 
observed in this study. Most likely the size of lyophilisomes hindered efficient penetration 
into CS-E rich areas of the tumor, which made CS-E targeting almost unfeasible. Despite 
the possible advantage of the relative large lyophilisomes to remain in the intraperitoneal 
cavity, it may also be a disadvantage in penetrating to the tumor core, where the majority 
of the CS-E is located. It has been described that particles larger than 60 nm are not able to 
penetrate into the tumor through the dense tumoral ECM collagen network [22]. Indeed, 
histology showed that lyophilisomes were found only at the border of tumors indicating 
difficulties in penetration. Lyophilisomes without antibody modification showed similar 
results in tumor penetration, despite their smaller diameter. Tumor priming to reduce 
the dense ECM using for instance enzymatic degradation, a chemotherapeutic treatment 
or specific targeting of CAFs has shown to open the tumor for drug delivery particles 
and thus may open the way for efficient CS-E targeting by lyophilisomal treatment, with 
smaller sized lyophilisomes [19, 22-24].
Future studies should focus on the optimal dose and time frame. No dose optimization 
was determined for the antibody modified lyophilisomes used in the present study, 
and the dose used may be too low for sufficient tumor targeting resulting in a too low 
concentration of lyophilisomes at the tumor. Also, the time frame to detect tumoral CS-E 
targeting of lyophilisomes was not investigated, which could have resulted in missing of the 
optimum time-span needed for lyophilisomes to diffuse and target to CS-E in the tumor. 
The time to localize to the tumor may have been longer than the 24 h used in the present 
study. A next study with longer observation times (e.g. 72 and 144 h) and increasing doses 
may reveal the true CS-E targeting potential of CS-E targeting lyophilisomes, be it that the 
size of the lyophilisomes may present an obstacle.
Absence of the majority of lyophilisomes in tumors hints to accumulation in other organs 
or excretion from the body before the majority of the lyophilisomes could reach the 
tumor. However, except for minor spots in the spleen and liver that suggest local presence 
of lyophilisomes on the exterior of the organs, no specific organ in which a majority 
of lyophilisomes (CS-E targeting and non-targeting) specifically accumulated could be 
identified. On the other hand, whole mice imaging indicated fluorescence scattered over 
the abdominal area at all time points suggesting that lyophilisomes might have remained 
in the intraperitoneal fluid. This can be supported by the lack of detection of substantial 
amounts of lyophilisomes in specific organs and plasma. The most apparent explanation 
for the lack of tumoral CS-E targeting, but presence of lyophilisomes specifically at the 
tumor border, may be the intraperitoneal fluid flow within the peritoneal cavity. Others 
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found similar distribution patterns for intraperitoneally injected drug delivery particles 
or injected tumor cells. For instance, Steinkamp et al. found the largest tumors in the 
omentum located around the stomach [17], similar as the location of the tumors 
in the present study. Lu et al. also identified tumors in the omentum of mice injected 
intraperitoneally with SKOV3 cells [24]. More interestingly, they found that 4 µm 
non-targeting microparticles localized on the surface of tumors 72 hours after injection, 
suggesting that non-targeting microparticles indeed are able to move to intraperitoneal 
tumors. The physiological intraperitoneal fluid has an upwards direction with a favored 
flow along the right part resulting in a directional fluid flow throughout the peritoneal 
cavity [25]. This natural flow is considered as an explanation for the specific metastatic 
route throughout the peritoneal cavity often found in advanced staged ovarian cancer 
patients. The circulating peritoneal fluid is removed from the peritoneal cavity mainly 
through lymphatic drainage by diaphragmatic lymph vessels [26, 27]. The presence of 
a major bulk of tumor cells in similar regions upon IP injection of tumor cells in mice 
identified in the present study and by others suggest the existence of such peritoneal fluid 
flow in mice as well [17, 24]. The combination of directional fluid flow and drainage could 
have brought the intraperitoneally injected lyophilisomes to the tumor side where they 
were able to adhere to the tumor surface. This can be confirmed by the migration pattern 
of the tumor cells that were injected in the lower right peritoneal cavity to establish the 
tumor model which resulted in a bulk of tumor located in the upper left omentum location 
in all mice.
This study indicates that lyophilisomes localized to the tumor border upon IP injection, 
most likely through peritoneal fluid flow, and were able to deliver doxorubicin to nuclei of 
tumor cells. However, specificity towards CS-E was not observed. Specificity to CS-E rich 
regions may be improved by alternative dosages, increased follow-up times or by tumor 
priming before lyophilisomal treatment to ensure penetration into the tumoral ECM. On 
the other hand, lyophilisomes could be used without targeting modification and act as a 
chemotherapeutic depot at the tumor area, localizing to the tumor area by the interstitial 
tumor fluid flow. Using lyophilisomes as a local depot at the tumor surface, released 
chemotherapeutics could diffuse locally into tumors and eliminate tumor cells and the 
tumor supportive cells. Moreover, by local delivery, side-effects frequently experienced 
with intraperitoneal administration of free chemotherapeutics may be reduced. However, 
whether treatment with the CS-E specific lyophilisomes with alternative approaches will 
increase the efficacy and simultaneously reduce side-effects of chemotherapy remains to 
be elucidated in future in vivo studies.
Conclusion
In this exploratory study the targeting towards CS-E in the extracellular matrix of tumors 
was investigated in an orthotopic ovarian cancer mouse model. Lyophilisomes remained 
in the peritoneal cavity and doxorubicin could be delivered to the tumor surface. Despite 
the abundant presence of CS-E in the ECM of tumors, no specificity towards CS-E was 
observed, likely due to the large size of lyophilisomes (generally 1 – 2 µm).
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Summary
Despite abundant research to improve the outcome of epithelial ovarian cancer 
treatment, it is still the fifth leading cause of cancer related deaths among women. 
Next to debulking surgery, systemic chemotherapy is a major element of the treatment 
strategy. While chemotherapy often has a high initial treatment efficacy, in many cases 
patients cease chemotherapy due to the severe side effects caused by high toxicity and 
unfavorable distribution of chemotherapeutic agents. To increase the treatment efficacy 
and decrease the side effects, drug delivery systems can be used to specifically deliver 
chemotherapeutics to cancer cells. By encapsulating chemotherapeutic agents, healthy 
cells and tissues are protected from exposure to toxic chemotherapeutics which can result 
in reduced toxicity and side effects. To increase the efficacy of chemotherapy, targeting 
drug delivery systems have been developed addressing ovarian cancer cells by using 
antibodies or receptor specific ligands. 
This form of active targeting strategy does not take into account the tumor supportive 
cells and the complex tumoral extracellular matrix. Targeting a single subset of cancer 
cells defined by a specific marker, may result in removal of only that specific cancer 
cells subset, leaving the remaining heterogenic cancer cells not expressing that specific 
target unaffected. Moreover, important cancer supportive cells such as cancer associated 
fibroblasts and cancer associated macrophages, but also cancer stem cells, are left 
unaffected. Therefore, a strategy that delivers chemotherapeutics locally at the tumor 
site thus limiting the exposure to healthy cells, while also affecting the tumor supportive 
cells, heterogenic subsets of cancer cells and cancer stem cells may have advantages 
over conventional targeting strategies. The extracellular matrix of tumors is different 
from healthy ones and therefore offers targets for specific drug delivery. Upon binding, 
release and diffusion of chemotherapeutics into the tumor, it can result in an increased 
treatment efficacy compared to conventional drug delivery systems. An overview of drug 
delivery systems developed for cancer treatment using extracellular matrix targeting was 
presented in Chapter 1. 
The aim of this thesis was to develop a drug delivery system targeting the extracellular 
matrix of epithelial ovarian cancer. To gain insights in the current preclinical work performed 
in the field of drug delivery systems for ovarian cancer treatment, a systematic review was 
conducted in Chapter 2. Literature was systematically searched and screened for animal 
studies. Data were extracted from 44 in vivo studies and meta-analyses were performed 
to assess the efficacy of drug delivery systems over free administered chemotherapeutics. 
Results indicated that, overall, treatment with drug delivery systems had an improved 
efficacy over treatment with free chemotherapeutics. Subgroup analyses performed to 
identify specific characteristics of drug delivery systems, such as the type of drug delivery 
system, active targeting, route of administration and type of chemotherapeutic, did not 
indicate a specific characteristic that significantly improved outcome.
Using the information from Chapters 1 and 2, we further focused on the development of a 
drug delivery strategy for ovarian cancer treatment in Chapter 3, the main aim of this thesis. 
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Chapter 3 describes experiments performed to investigate the potential of lyophilisomes 
to be used as a drug delivery system for chemotherapeutics. Lyophilisomes are nano to 
micro-sized capsules that can be prepared from various materials. Lyophilisomes were 
prepared from albumin by a procedure that involved freezing, annealing, lyophilisation, 
chemical crosslinking and low-speed centrifugation. The resulting 100 – 3000 nm sized 
lyophilisomes could be loaded with the anti-tumor drugs doxorubicin and curcumin. In 
vitro, only 3% of the doxorubicin was released from the lyophilisomes after 72 hours 
at various temperatures. This suggested that doxorubicin is stably entrapped in the 
lyophilisomes. When these drug-loaded lyophilisomes were applied to ovarian and 
cervical tumor cells in vitro, a significant inhibition in tumor growth was observed after 72 
hours of incubation, whereas non-loaded lyophilisomes did not affect cell viability. Since 
albumin-lyophilisomes showed the potential to be used as a system for chemotherapeutic 
drug delivery, we next focused on a method to increase the specificity towards ovarian 
tumors.
In Chapter 4, albumin based lyophilisomes were modified to target specifically to the 
extracellular matrix (ECM) of ovarian cancer. The highly sulfated glycosaminoglycan 
chondroitin sulfate type-E (CS-E) was selected as a target in the extracellular matrix 
of ovarian cancer because of its abundant presence in the tumoral ECM, while being 
almost absent in the ECM of healthy tissue. Lyophilisomes were first functionalized 
with azide groups to enable modification with CS-E specific antibodies. Single chain 
variable fragments directed against CS-E were functionalized with a dibenzocyclooctyl 
(DBCO) group by sortagging. Azide and DBCO are bioorthogonal click chemistry partners 
and were therefore used to modify lyophilisomes with the antibodies. The resulting 
antibody-modified lyophilisomes specifically bound CS-E present in the ECM in tumor 
sections of human ovarian tumors and to ovarian tumor cells that produced CS-E. 
Doxorubicin loaded, antibody-modified, lyophilisomes could efficiently eradicate ovarian 
tumor cells that were cultured in a CS-E rich environment. Released doxorubicin from 
lyophilisomes localized to the nuclei of ovarian tumor cells. 
To evaluate the clinical potential of lyophilisomes, we studied their in vivo characteristics in 
Chapter 5. A sucrose-gradient centrifugation method to size lyophilisomes to specific sized 
small fractions, important to establish a long blood circulation and high tumor penetration, 
was successfully set up. Lyophilisomes injected intravenously in healthy mice were rapidly 
removed from the circulation by macrophages from mononuclear phagocyte system in 
the liver and the spleen, and were degraded and excreted in urine. These results indicated 
that the injected lyophilisomes were possibly too large for long circulation. Nevertheless, 
in advanced stage epithelial ovarian cancer the majority of the patients has tumor 
lesions spread throughout the peritoneal cavity. Consequently, we explored the targeting 
potential and organ distribution of CS-E targeting lyophilisomes after intraperitoneal 
injection in a mouse model with peritoneal ovarian tumors in Chapter 6. The larger size 
of lyophilisomes can have advantages in using intraperitoneal administration because of 
an extended retention time in the peritoneal cavity. Indeed, lyophilisomes remained in 
the peritoneal cavity over a period of 24 h. Tumors of mice injected intraperitoneally with 
168
Chapter 7
human ovarian cancer cells displayed specific CS-E expression in the extracellular matrix, 
similar to human ovarian tumor sections. Nuclei of tumor cells contained doxorubicin 
released from doxorubicin loaded CS-E targeting lyophilisomes bound to, but limited to, 
the tumor surface. This observation suggested that (non-targeted) lyophilisomes show 
potential to be used as an addition to or alternative for systemic or intraperitoneally 
administered chemotherapy.
Future outlook
To improve the current ovarian cancer treatment strategies, the use of drug delivery 
systems may offer promising advantages. In this thesis, we have evaluated the use of 
albumin based lyophilisomes as a drug delivery system. The unique tumoral extracellular 
matrix (Chapter 1) was used for delivery of doxorubicin to the ovarian tumor using 
lyophilisomes [1, 2]. Nevertheless, results presented in this thesis indicate that, in the 
current state, lyophilisomes should be further improved to have an impact on the clinical 
outcome of ovarian cancer treatments.
Next to lyophilisomes, a wide range of drug delivery systems, such as liposomes, micelles 
or ‘nanoparticles’, have been developed and evaluated to improve the current ovarian 
cancer treatment strategies [3]. Despite these abundant efforts, only a few made their 
way into the clinic. A well-known example is PEGylated liposomal doxorubicin (i.e. Caelyx® 
or Doxil®) which has been approved as a second-line treatment for advanced ovarian 
cancer [4]. PEGylated doxorubicin has a similar efficacy as free administered doxorubicin, 
but lower cardiotoxicity [5]. On the other hand, the use of PEGylated liposomes for 
doxorubicin delivery can result in desquamating dermatitis of especially skin of hand and 
foot [6]. A study by Seynhaeve et al. suggested limited efficacy and localization to the 
nucleus of doxorubicin from PEGylated liposomes, possible due to lysosomal sequestering 
[7]. Even with the clinical success of this drug delivery system, there is room for novel drug 
delivery systems that improve both the efficacy and side-effects. Whether lyophilisomes 
may eventually be used as a drug delivery system to overcome the limitations of free 
administered chemotherapeutics and the limitations of PEGylated liposomal doxorubicin 
depends on two major aspects. To increase the treatment efficacy, lyophilisomes should 
be able to deliver a high concentration of chemotherapeutics to the tumor. To decrease 
side-effects, the chemotherapeutics should be released in tumor areas only, to prevent 
exposure to healthy cells. While both aspects indicate the ideal situation, lyophilisomes 
may have the characteristics to achieve such aspects in the future. 
The current size range of lyophilisomes (100 nm – 10 µm) makes the system well suited 
for intraperitoneal administration. Larger particles are restricted to the intraperitoneal 
cavity upon IP injection due limited removal through lymphatic drainage [8], as we indeed 
have found for IP injected lyophilisomes as well (Chapter 6). Metastasis of ovarian cancer 
patients, that in most cases is spread through the peritoneal cavity, may efficiently be 
targeted after intraperitoneal administration of doxorubicin loaded lyophilisomes. Results 
described in this thesis indicate that this approach can result in delivery of doxorubicin 
to ovarian tumor cells in mice. A future efficacy study should be performed to indicate 
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the treatment efficacy. However, room for improvement was indicated as well since 
lyophilisomes were only identified at the surface of tumors. This lack of penetration 
may be a downside of the relatively large sized lyophilisomes. It has been described 
that particles with a mean size of ± 30 nm show the most promising tumor penetration 
[9, 10]. This may explain the difficulties of lyophilisomes to penetrate the dense tumor 
extracellular matrix. In Chapter 5 we were able to size lyophilisomes to smaller fractions 
with a smallest mean diameter of 200 nm [11]. This may still not be small enough to 
establish efficient tumor penetration. Sizing of the initial lyophilisomes population, which 
consist of lyophilisomes with a diameter ranging from about 100 nm to 10 µm to a size 
sufficient for tumor penetration (± 30 nm) may perhaps be too much of an effort. In this 
case, adjustments in the preparation process of lyophilisomes could result in improved 
size characteristics. The annealing step is important because of the formation of spheres 
due to temperature change [12]. Adding compounds that reduce the surface tension may 
result in smaller sized lyophilisomes. Decreased surface tension could result in smaller ice 
crystals, and thus finally in smaller lyophilisomes. Alternatively, snap freezing the albumin 
mixture in liquid helium (-269 °C) instead of using liquid nitrogen (-196 °C) may even 
further decrease the size of ice crystals. An extensive study that compares freezing liquids, 
surface tension and annealing times and temperatures could indicate a condition that 
results in a smaller population of lyophilisomes. If smaller lyophilisomes can be prepared, 
a combination treatment of large lyophilisomes with slow release characteristics that act 
as a local chemotherapeutic tumor depot at the tumor surface and small lyophilisomes 
that penetrate and target the tumor extracellular matrix to attack tumor spheres from its 
core may offer improved results.
Lyophilisomes can potentially achieve a high concentration of chemotherapeutics at the 
tumor site upon injection. The concentrations of doxorubicin that can be loaded into the 
lumen of lyophilisomes is sufficient and outperforms the drug to carrier ratio achieved 
with doxorubicin loaded PEGylated liposomes, 1.2 and 0.125, respectively (FDA.gov 
[13] and Chapter 3). Nevertheless, a high payload of doxorubicin is worthless when it 
cannot be released in the tumor extracellular matrix. The unique preparation method of 
lyophilisomes allows adjustments in the composition of lyophilisomes that may change 
the release characteristics of lyophilisomes. Enzyme triggered release of doxorubicin 
specifically in tumor areas could be achieved by adding materials such as collagen, gelatin 
or elastin that could serve as substrate for tumor specific enzymes. Incorporation of these 
materials in the wall of lyophilisomes may result in small holes in the wall of lyophilisomes 
because of proteolytic enzymes present in the matrix of ovarian tumors [14, 15]. Through 
these small holes, the entrapped doxorubicin could slowly be released. The speed of 
drug release can then be adjusted by tweaking the amount of collagen, gelatin or elastin 
in lyophilisomes. Daamen et al. have shown the feasibility of the incorporation of such 
materials in lyophilisomes [12], but the enzymatic release characteristics in vitro and in 
vivo remain to be elucidated.
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Once the above-mentioned aspects show promising characteristics that indicate 
encouraging clinical outcome by lyophilisome treatment, an extensive comparison study 
should be performed. All drug delivery systems that are being developed for ovarian 
cancer treatment struggle with similar problems. A preclinical comparison study may 
therefore offer valuable information on which type of drug delivery system has the most 
suitable characteristics for a favorable clinical outcome. Moreover, in a similar study, 
the effect of other parameters such as particle size, drug release characteristics and 
peritoneal retention may also be identified. Only after this comparison study and by also 
incorporating aspects such as ease of preparation, costs, and translation to other types 
of cancer, a drug delivery system can be selected that will have the most impact ovarian 
cancer treatment.
Whether lyophilisomes or another capsule-like drug delivery system will be used as a drug 
carrier for the promising extracellular matrix targeting strategy in the future remains to be 
elucidated. Alternatively, antibody drug conjugates (ADCs) may be used for this purpose 
and deserve some words of attention in this future outlook. While ADCs generally only 
carry a couple of drug molecules per carrier, they are significantly smaller and thus able to 
penetrate to the tumoral extracellular matrix. For this purpose, antibodies directed against 
tumor specific extracellular targets or non-internalizing tumor cell specific antibodies 
are potential candidates. Using novel drug to antibody linkers, triggered drug release of 
chemotherapeutics at the tumor site is feasible. Indeed, various ADCs with extracellular 
(triggered) drug release characteristics have successfully been developed [16-18]. In the 
end it will all come down to one to one comparison studies to show efficacy and the 
number and severity of side-effects of ADCs and nanoparticles to find whether ovarian 
cancer treatment can be significantly improved.
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Samenvatting
Ondanks uitgebreid wetenschappelijk onderzoek om de behandeling van ovariumkanker 
te verbeteren is het nog steeds de vijfde kankergerelateerde doodsoorzaak onder 
vrouwen. Naast chirurgie speelt systemische chemotherapie een belangrijke rol in de 
behandelingsstrategie van ovariumkanker. Hoewel chemotherapie in eerste instantie vaak 
een goede effectiviteit laat zien, stopt een deel van de patiënten met de therapie vanwege 
de ernstige bijwerkingen die veroorzaakt worden door de toxiciteit en de ongewenste 
biodistributie van de chemokuurmedicatie. Om de effectiviteit van de behandeling te 
verhogen en daarbij tegelijkertijd de bijwerkingen te verminderen, kunnen medicijnafgifte-
systemen, ook wel drug delivery systeem genoemd, gebruikt worden. Hiermee wordt 
geprobeerd de chemokuurmedicatie specifiek naar de tumorcellen te brengen. Door de 
chemotherapeutica in te pakken in capsules worden gezonde cellen en weefsels beschermd 
tegen de toxiciteit van de chemotherapeutica. Dit zou uiteindelijk kunnen leiden tot een 
vermindering van de bijwerkingen. Om de effectiviteit van de chemotherapie te verhogen 
zijn tumorspecifieke gerichte drug delivery systemen ontwikkeld die gebruik maken van 
antilichamen of liganden gericht tegen receptoren die specifiek op ovariumtumorcellen 
tot expressie komen.
Deze vorm van actieve binding houdt echter geen rekening met tumor-ondersteunende 
cellen en de complexe extracellulaire matrix van tumoren. Het binden van een subset 
tumorcellen gedefinieerd door een specifieke marker kan resulteren in het verwijderen van 
alleen die specifieke subset tumorcellen. De overlevende heterogene tumorcellen die de 
specifieke marker niet tot expressie brengen kunnen overleven en doorgroeien. Daarnaast 
worden belangrijke tumorondersteunende cellen zoals tumorgeassocieerde fibroblasten 
en macrofagen, maar ook tumorstamcellen niet aangepakt. Een behandelstrategie die 
chemotherapeutica lokaal afgeeft in de tumor en daarbij dus zorgt voor minder systemische 
bijwerkingen, maar ook tumorondersteunende cellen, heterogene tumorcel subsets en 
tumorstamcellen aanpakt, kan vele voordelen hebben ten opzichte van de conventionele 
tumorgerichte behandelstrategieën. De extracellulaire matrix van tumoren verschilt van 
die van gezonde weefsels en heeft daardoor mogelijkheden voor gerichte medicijnafgifte. 
Binding van een drug delivery systeem aan de extracellulaire matrix van tumoren met 
vervolgens afgifte van het chemotherapeuticum wat kan diffunderen naar de tumor- en 
tumorondersteunende cellen, zou kunnen resulteren in een verhoogde effectiviteit van de 
behandeling in vergelijking tot conventionele tumor gerichte drug delivery systemen. Een 
overzicht van drug delivery systemen ontwikkeld voor de behandeling van kanker door 
binding aan de tumor extracellulaire matrix is beschreven in Hoofdstuk 1. 
Het doel van het werk beschreven in dit proefschrift was de ontwikkeling van een drug 
delivery systeem specifiek gericht tegen de extracellulaire matrix van ovariumtumoren. 
Om inzichten te verkrijgen in de al reeds ontwikkelde drug delivery systemen voor 
de behandeling van ovariumkanker is in Hoofdstuk 2 een systematisch review met 
meta-analyse uitgevoerd. In de wetenschappelijke literatuur is systematisch gezocht 
en gescreend op preklinische studies. Uit de 44 gevonden studies zijn de data gehaald 
en gebruikt voor meta-analyses om de effectiviteit van chemotherapie toegediend 
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middels drug delivery systemen ten opzichte van vrij geïnjecteerde chemotherapie te 
onderzoeken. De resultaten laten zien dat in het algemeen chemotherapie via drug delivery 
systemen een betere effectiviteit laat zijn dan vrij geïnjecteerde chemotherapie. Echter, 
subgroep-analyses die zijn uitgevoerd om te onderzoeken of specifieke eigenschappen 
van drug delivery systemen, zoals het type drug delivery systeem, gebruik makend van 
tumorspecifieke binding, de toedieningsroute en het type chemotherapeuticum, lieten 
geen voordelen zien van een bepaalde eigenschap.
Op basis van de informatie verkregen in Hoofdstukken 1 en 2, hebben we ons in Hoofdstuk 
3 gericht op de ontwikkeling van een drug delivery systeem voor de behandeling van 
ovariumkanker; het hoofddoel van dit proefschrift. In Hoofdstuk 3 zijn experimenten 
beschreven om de potentie van lyophilisomen als een drug delivery systeem voor 
chemotherapie te onderzoeken. Lyophilisomen zijn nano-micrometergrote capsules die 
gemaakt kunnen worden van verschillende materialen. Middels een invries-, verwarm-, 
en vriesdroogprocedure gevolgd door chemische fixatie en centrifugatie op lage snelheid 
zijn lyophilisomen van albumine gemaakt. De 100 – 3000 nm grote lyophilisomen konden 
worden opgeladen met de cytostatica doxorubicine en curcumine. Over een periode 
van 72 uur lekte slechts 3% van de doxorubicine uit de lyophilisomen in in vitro studies. 
Toediening van deze opgeladen lyophilisomen aan ovarium- of cervicale tumorcellen 
zorgde voor een significante remming van de tumorgroei over een periode van 72 uur, 
terwijl de lyophilisomen zonder doxorubicine de celviabiliteit niet aantastte. Omdat de 
albumine-lyophilisomen een goede potentie als drug delivery systeem liet zien, hebben we 
het vervolgonderzoek gericht op een methode om de specificiteit naar ovariumtumoren 
te verhogen.
In Hoofdstuk 4 zijn albumine-lyophilisomen gemodificeerd om deze specifiek te kunnen 
binden aan de extracellulaire matrix (ECM) van ovariumtumoren. Het hooggesulfateerde 
glycosaminoglycaan chondroitine sulfaat type-E (CS-E) is geselecteerd als target in de 
ECM van ovariumtumoren vanwege de sterk verhoogde aanwezigheid van CS-E in de 
ECM van ovariumtumoren. Bovendien is CS-E bijna volledig afwezig in de ECM van gezond 
weefsel. Lyophilisomen zijn eerst gefunctionaliseerd met azidegroepen om vervolgens 
de modificatie met CS-E specifieke antilichaamfragmenten te kunnen bewerkstelligen. 
Deze antilichamenfragmenten gericht tegen CS-E zijn hiervoor gefunctionalizeerd met 
een dibenzocyclooctyl (DBCO) groep via sortagging. Azide en DBCO zijn bioorthogonale 
clickchemie-partners. De resulterende antilichaam-gemodificeerde lyophilisomen 
bonden specifiek aan het CS-E in de ECM van secties humaan ovariumtumorweefsel en 
met CS-E geproduceerd door ovariumtumorcellijnen. Bovendien bleken doxorubicine 
geladen, antilichaamgemodificeerde lyophilisomen in staat efficiënt ovariumtumorcellen 
uit te schakelen in een CS-E-rijke omgeving. Doxorubicine kwam vrij uit de lyophilisomen 
en werd uiteindelijk teruggevonden in de celkernen van ovariumtumorcellen.
Om de klinische mogelijkheden van de lyophilisomen te bepalen, hebben we in Hoofdstuk 
5 de in vivo karakteristieken van de lyophilisomen in kaart gebracht. Lyophilisomen 
werden gesorteerd op grootte in verschillende fracties door gebruik te maken van een 
sucrose-gradiënt centrifugatiemethode. Dit is van belang omdat grootte een belangrijke 
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factor is voor een lange circulatietijd en goede tumorpenetratie. Wanneer deze 
lyophilisomen intraveneus werden geïnjecteerd in gezonde muizen, werden ze snel uit de 
circulatie gehaald door macrofagen van het zogenoemde ‘mononucleaire fagocyterend’ 
systeem in de lever en de milt waar ze vervolgens werden afgebroken en uitgescheiden 
in de urine. Deze resultaten laten zien dat de geïnjecteerde lyophilisomen mogelijk 
toch te groot zijn voor een lange circulatie in de bloedbaan. Echter, in vergevorderde 
stadia van ovariumkanker heeft het grootste deel van de patiënten tumoren verspreid 
door de intraperitoneale ruimte. Vandaar dat we in Hoofdstuk 6 de biodistributie en 
de mogelijkheden om ovariumtumoren te binden middels binding aan CS-E hebben 
onderzocht na intraperitoneale toediening in muizen met peritoneale ovariumtumoren. 
De grootte van de lyophilisomen is hier juist een voordeel, omdat dit kan zorgen voor een 
langere retentietijd in de peritoneale ruimte. In het experiment verbleven de lyophilisomen 
inderdaad in de peritoneale ruimte over een tijdsbestek van 24 uur. De tumoren van 
muizen geïnjecteerd met humane ovariumtumorcellen lieten expressie van CS-E zien in de 
extracellulaire matrix, zoals ook wordt gezien in tumoren van patiënten. In de celkernen 
van de tumorcellen was doxorubicine aanwezig, vrijgekomen uit de CS-E gerichte 
doxorubicine opgeladen lyophilisomen. De lyophilisomen werden echter gevonden aan 
het oppervlakte van de tumoren. Deze observatie laat zien dat lyophilisomen, al dan niet 
specifiek gericht tegen CS-E, potentie hebben om gebruikt te worden als een alternatief 
voor systemische of intraperitoneale toegediende chemotherapie.
Toekomstvisie
Om de huidige behandelingsstrategieën voor ovariumkanker te verbeteren, heeft 
het gebruik van drug delivery systemen veelbelovende voordelen. In dit proefschrift 
hebben we het gebruik van albumine-lyophilisomen als drug delivery systeem getest. De 
unieke eigenschappen van de tumor extracellulaire matrix (Hoofdstuk 1) zijn gebruikt 
om doxorubicine af te geven aan ovariumtumoren met lyophilisomen [1, 2]. Echter, de 
resultaten beschreven in dit proefschrift laten zien dat, in de huidige staat, lyophilisomen 
verder verbeterd moeten worden om een impact te hebben op de uitkomst van de 
behandeling van ovariumkanker.
Naast lyophilisomen zijn verschillende drug delivery systemen, zoals liposomen, micellen 
of ‘nanoparticles’, ontwikkeld om de behandeling van ovariumkanker te verbeteren 
[3]. Ondanks de vele wetenschappelijke onderzoeken, worden slechts enkele van deze 
systemen gebruikt in de kliniek. Een bekend voorbeeld is het gePEGyleerde liposomale 
doxorubicine (Caelyx® of Doxil®), wat goedgekeurd is als een tweedelijns behandeling 
voor vergevorderde ovariumkanker [4]. GePEGyleerde liposomale doxorubicine heeft 
eenzelfde effectiviteit als vrije doxorubicine, maar zorgt voor minder cardiotoxiciteit 
[5]. Daarentegen kan het gebruik van gePEGyleerde liposomale doxorubicine tot andere 
bijwerkingen leiden zoals huidontstekingen aan de handen en voeten [6]. Een studie van 
Seynhaeve et al. suggereert dat de beperkte effectiviteit en lokalisatie van doxorubicine 
uit gePEGyleerde liposomen veroorzaakt kan worden door lysosomale opname [7]. 
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Ondanks het klinische succes van dit drug delivery systeem is er ruimte voor andere drug 
delivery systemen die zorgen voor een verbeterde effectiviteit en minder bijwerkingen. 
Of lyophilisomen uiteindelijk gebruikt zullen worden als het drug delivery systeem om de 
nadelen van vrij toegediende chemotherapie en gePEGyleerde liposomale doxorubicine 
te overbruggen, hangt af van twee belangrijke aspecten. Om de effectiviteit van de 
behandeling te verhogen, moeten lyophilisomen in staat zijn een hoge concentratie van 
chemotherapeutica af te geven aan de tumor. Om de bijwerkingen te verlagen, moeten 
deze chemotherapeutica specifiek afgegeven worden in de tumor om blootstelling van de 
chemotherapeutica aan gezonde cellen te voorkomen. Beide aspecten schetsen de ideale 
situatie, maar lyophilisomen hebben de eigenschappen om deze doelen in de toekomst 
te bereiken.
De huidige grootte van de lyophilisomen (100 nm – 10 µm) maakt het systeem geschikt 
voor intraperitoneale toediening. Grote partikels blijven langer aanwezig in de peritoneale 
ruimte na intraperitoneale (IP) injectie door de gelimiteerde afvoer via het lymfatisch 
systeem [8], zoals we ook hebben gevonden voor IP geïnjecteerde lyophilisomen (Hoofdstuk 
6). Metastasen bij ovariumkankerpatiënten, die zich in de meeste gevallen verspreiden 
door de peritoneale ruimte, zouden behandeld kunnen worden met doxorubicine geladen 
lyophilisomen intraperitoneale toediening. De resultaten beschreven in dit proefschrift 
maken duidelijk dat deze benadering daadwerkelijk kan resulteren in de afgifte van 
doxorubicine aan ovariumtumorcellen in muizen. Een toekomstige effectiviteitsstudie zal 
echter uitgevoerd moeten worden om de effectiviteit van deze behandeling aan te tonen. 
Desalniettemin is er ruimte voor verbetering omdat de lyophilisomen alleen zichtbaar 
waren aan het oppervlakte van de tumoren. De afwezigheid van tumorpenetratie kan 
een nadeel zijn van de relatief grote lyophilisomen. Het is beschreven dat partikels met 
een gemiddelde diameter van ± 30 nm de beste tumorpenetratie laten zien [9, 10]. Dit 
kan verklaren waarom de lyophilisomen nauwelijks door de dikke extracellulaire matrix 
van de tumoren penetreerden. In Hoofdstuk 5 is het gelukt lyophilisomen te scheiden 
in kleine fracties. De kleinste fractie had een gemiddelde diameter van 200 nm [11]. Dit 
is wellicht nog niet klein genoeg voor efficiënte tumorpenetratie. Het scheiden van de 
initiële populatie lyophilisomen, wat bestaat uit lyophilisomen met een diameter van 
100 nm tot 10 μm tot een populatie met een diameter geschikt voor tumorpenetratie 
(± 30 nm) zal waarschijnlijk te veel moeite zijn. In dit geval zouden aanpassingen in het 
proces waarin de lyophilisomen gemaakt worden kunnen zorgen voor een verbeterde 
diameter van de lyophilisomen. De verwarm-stap is belangrijk voor de vorming van de 
capsules vanwege de temperatuursverandering [12]. Het toevoegen van stoffen die de 
oppervlaktespanning verminderen zou kunnen resulteren in kleinere lyophilisomen. Een 
lagere oppervlaktespanning kan leiden tot kleinere ijskristallen en dus uiteindelijk in 
kleinere lyophilisomen. Een alternatief zou het invriezen van de albumine oplossing in 
vloeibare helium (-269 °C) in plaats van invriezen in vloeibare stikstof (-196 °C) kunnen 
zijn. Dit zou kunnen zorgen voor nog kleinere ijskristallen. Een uitgebreide studie 
waarin verschillende invries-vloeistoffen, oppervlaktespanningen en verwarmtijden 
en -temperaturen worden getest zou een indicatie kunnen geven welke conditie in een 
kleinere populatie lyophilisomen resulteert. Indien kleinere lyophilisomen gemaakt 
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kunnen worden, zou een behandeling met zowel grote lyophilisomen - met een langzame 
medicijnafgifte die als depot dienen aan de rand van tumoren - en kleinere lyophilisomen 
- die de tumor penetreren en binden aan de extracellulaire matrix om zo de tumor van 
binnen aan te vallen - kunnen zorgen voor verbeterde behandelresultaten.
Lyophilisomen kunnen in potentie na toediening een hoge concentratie 
chemotherapeuticum naar het tumorgebied brengen. De concentratie doxorubicine 
die kan worden opgeladen in het lumen van de lyophilisomen is voldoende en heeft 
een betere medicijn tot capsule verhouding dan doxorubicine geladen gePEGyleerde 
liposomen; respectievelijk 1,2 en 0,125 (FDA.gov [13] en Hoofdstuk 3). Echter, een hoge 
concentratie doxorubicine in de lyophilisomen is waardeloos als het niet vrijgelaten kan 
worden in de extracellulaire matrix van tumoren. Door de unieke methode waarmee 
lyophilisomen gemaakt worden is het mogelijk aanpassingen in de compositie van 
lyophilisomen te maken welke uiteindelijk tot andere medicijnafgifte karakteristieken 
kunnen leiden. Enzymatische afgifte van doxorubicine specifiek in het tumorgebied 
kan worden bewerkstelligd door materialen zoals collageen, gelatine of elastine toe te 
voegen die als substraat voor tumor-specifieke enzymen dienen. Het mengen van deze 
materialen in de wand van lyophilisomen kan resulteren in kleine holten in de wand, 
veroorzaakt door de proteolytische enzymen aanwezig in de extracellulaire matrix van 
ovariumtumoren [14, 15]. Door deze kleine holten kan het doxorubicine langzaam uit 
de lyophilisomen lekken. De snelheid van dit lekken kan worden aangepast door de 
hoeveelheid collageen, gelatine of elastine te veranderen. Daamen et al. heeft laten 
zien dat deze materialen daadwerkelijk geïncorporeerd kunnen worden in lyophilisomen 
[12], maar de enzymatische afgiftekarakteristieken dienen zowel in vitro als in vivo nog te 
worden onderzocht.
Als de hier bovengenoemde aspecten goede resultaten laten zien en er potentie is dat 
lyophilisomen mogelijk de uitkomst van ovariumkankerbehandeling kan verbeteren, zal 
er een uitgebreide vergelijkende studie moeten worden uitgevoerd. Alle drug delivery 
systemen die in ontwikkeling zijn voor de behandeling van ovariumkanker hebben 
dezelfde problemen. Een preklinische vergelijkende studie kan daarom belangrijke 
informatie verschaffen over het type drug delivery systeem dat de beste eigenschappen 
heeft voor een goede klinische behandeling. In eenzelfde studie kunnen daarnaast ook 
andere parameters zoals partikelgrootte, medicijnafgifte eigenschappen en verblijfsduur 
in de peritoneale ruimte naar voren komen. Met de resultaten van deze vergelijkende 
studie en daarmee in acht nemende het gemak van de synthese, kosten en translatie naar 
andere typen kanker, kan het meeste geschikte systeem met de meeste impact op de 
behandeling van ovariumkanker worden geselecteerd.
Het is nog onduidelijk of lyophilisomen of een ander drug delivery systeem gebruikt kan 
worden om medicijnen naar de extracellulaire matrix te brengen. Het gebruik van an-
tilichaam-medicijn-conjugaties (antibody-drug conjugates; ADC’s) is een goed alternatief 
en dient daarom ook besproken te worden in deze toekomstvisie. Terwijl ADC’s slechts 
enkele medicijnmoleculen per antilichaam dragen, zijn ze significant kleiner en dus 
geschikter om de extracellulaire matrix van tumoren te penetreren. Voor deze toepassing 
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zijn antilichamen gericht tegen tumorspecifieke extracellulaire matrix componenten of 
niet-internaliserende tumorcelspecifieke antilichamen potentiële kandidaten. Door gebruik 
te maken van nieuwe linkermoleculen om medicijnen aan antilichamen te koppelen, kan 
afgifte van medicijnen specifiek in het tumorgebied worden bewerkstelligd. Verschillende 
ADC’s die extracellulair (gemedieerde) medicijnen afgeven zijn succesvol ontwikkeld 
[16-18]. Uiteindelijk zal het allemaal tot vergelijkende studies komen om de effectiviteit 
en de bijwerkingen van ADC’s en nanopartikels te onderzoeken om te selecteren welke 
strategie de beste verbetering geeft voor de behandeling van ovariumkanker.
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Dankwoord
Dit is het dan, het laatste deel van het proefschrift. Een deel wat wellicht door velen als 
eerste, of misschien zelfs als enige deel van dit proefschrift gelezen zal worden. Ik wil dan 
toch even benadrukken dat alle overige hoofdstukken ook best de moeite waard zijn om 
te lezen. 
Middels deze weg wil ik een groot aantal mensen bedanken die direct of indirect hebben 
bijgedragen aan de totstandkoming van dit proefschrift. 
Allereerst wil ik mijn copromotoren dr. ir. W. Daamen en dr. T. van Kuppevelt bedanken. 
Beste Willeke, jouw manier van werken heeft me enorm veel geleerd. Je kritische blik 
op figuren, abstracts en manuscripten bracht de kwaliteit naar een veel hoger niveau. 
Daarnaast wist je me vaak te wijzen op controle-condities die de resultaten van de 
experimenten betrouwbaarder maakten. Als ‘mede-uitvinder’ van de lyophilisomen en 
met je kennis van biomaterialen heb je een grote bijdrage geleverd aan dit proefschrift. 
Bedankt voor de fijne samenwerking. Beste Toin, jouw onuitputtende biochemische kennis 
heeft me altijd verbaasd. Vaak wist je te vertellen hoe bepaalde medicijnen zijn ontdekt, 
wat het mechanisme is van de vele biochemische conjugaties die we hebben getest of hoe 
een specifieke labtechniek nu precies tot stand is gekomen. Naast de vele inhoudelijke 
discussies hebben we het ook vaak over de andere zaken van het wetenschappelijk 
onderzoek gehad; zoals het huidige systeem van publiceren, de beoordeling van 
onderzoeks-aanvragen en de carrièremogelijkheden na een promotieonderzoek. Deze 
gesprekken waardeer ik enorm en hebben er mede voor gezorgd dat ik in het academisch 
onderzoek ben blijven werken.
Grote dank ook voor mijn promotor prof. dr. Brock, Roland. Als hoofd van biochemie heeft 
u mij regelmatig betrokken bij de diverse onderzoekslijnen binnen de afdeling. Zodoende 
kwam ik er achter dat ook buiten de matrix-biochemie onderzoeksgroep veel kennis van 
drug-delivery systemen aanwezig was binnen de afdeling. Dit heeft mij zeker geholpen met 
het succesvol afronden van mijn proefschrift. Ik wil u ook bedanken voor de uitnodigingen 
voor de wekelijkse targeting-meeting en de jaarlijkse discussies over de inhoud van dit 
proefschrift. Het zorgde voor structuur en focus op het onderzoek. Mede door uw advies 
ben ik uiteindelijk bij mijn huidige afdeling terecht gekomen. Bedankt hiervoor!
Etienne, waarschijnlijk ben je je het er niet van bewust, maar door jou ben ik enthousiast 
geworden voor het werken op het lab. Als een ietwat ongemotiveerde bachelor student 
die toentertijd meer bezig was met zijn bestuursfunctie bij café de Aesculaaf begon ik 
mijn stage bij jou. Als snel leerde je me de ins en outs van het labwerk, raakte ik zeer 
gemotiveerd en erg betrokken bij je onderzoek. De stage bij jou heeft mij uiteindelijk doen 
besluiten een projectaanvraag voor promotieonderzoek te schrijven waar jouw werk als 
basis voor diende. Dit blijkt uit de verschillende hoofdstukken in dit proefschrift die we 
samen hebben gepubliceerd. Fijn dat je mijn paranimf wilt zijn.
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Ik wil ook prof. dr. Leon Massuger, dr. William Leenders en dr. Rob de Vries bedanken voor 
de prettige samenwerking. Zonder jullie bijdrage zouden een aantal hoofdstukken niet tot 
stand zijn gekomen.
De collega’s van matrix-biochemie wil ik ook bedanken voor de fijne samenwerking. Elly, je 
stond altijd voor alle vragen klaar en zorgde voor een goed georganiseerd lab. 
Marianne, ik waardeer je positiviteit en interesse in anderen. Zelfs in mindere tijden stond 
jij voor iedereen klaar en nam je zelfs de tijd om even te vragen hoe het met iedereen ging 
en of de proefschriften al bijna af waren. Jammer dat je uiteindelijk het lab hebt verlaten, 
je was altijd hulpzaam met het aanleren van de verschillende lab technieken. 
Arie, ik waardeer het dat je elk jaar zo’n 9 – 10 maanden van huis bent om in Nederland 
te werken. Volgens mij heb je het thuis in Bali allemaal maar goed voor elkaar. Bedankt 
voor je hulp op het lab.
Els, bedankt voor je hulp bij het maken van de single chains en het gieten van de gelen.
Theo, als jij langs kwam op het lab was het weer feest! Bedankt voor de hulp met de 
elektronenmicroscopie en voor alle gezelligheid.
“Promoveren is de leukste baan van je leven!” is een uitspraak die ik vaak heb gehoord en 
waar ik op momenten van mijn promotietijd toch zo nu en dan vraagtekens bij heb gezet. 
Hoewel ik vind dat je altijd pas een aantal jaar later kan terugkijken naar een periode en kan 
zeggen of dit een mooie tijd was durf ik nu toch al toe te geven dat mijn promotietijd een 
geweldige periode was. Veruit het grootste aandeel hiervan ligt bij de mede-promovendi: 
Henk, Luuk, Michiel, Sophieke, Corien en Danique. De weekendjes weg, avonden Aesculaaf, 
barbecues in de collagen mansion, fietstochten, bierbrouwavonden, whiskeyproeverijen, 
foute-uurtjes, celkweekdagen, en ga zo maar door waren erg mooi en zorgden daarnaast 
voor een relaxte sfeer op de werkvloer. Stuk voor stuk bedankt voor de geweldige tijd. 
Ook andere mede-promovendi Dirk, Marije, Peter, Paul en Myrtille bedankt voor de fijne 
tijd op en buiten het lab. Ik hoop dat we allemaal nog regelmatig wat blijven afspreken om 
bij te praten en na te praten over de “leukste baan van je leven”.
Tijdens het promotieproject heb ik het geluk gehad om met veel enthousiaste studenten 
samen te werken. Als enige promovendus op de lyophilisomen was het goed om jullie erbij 
te hebben. De vele kritische vragen hielden me scherp en daarnaast was het leuk om jullie 
wegwijs te maken in het wetenschappelijk onderzoek. Dimitris, Sophie, Laurens, Ellen, 
Suze, Evy, Martine en Sjoerd bedankt voor jullie inzet en bijdrage aan dit proefschrift. 
Huib en Marieke, bedankt voor de hulp met de microscopie. Jullie wisten met gemak de 
microscopen goed in te stellen wat vaak resulteerde in mooie plaatjes waarvan enkelen 
opgenomen zijn in dit proefschrift. Dorien en Kees van de afdeling Urologie wil ik bedanken 
voor de gezelligheid op het lab en de hulp met coupes snijden of immunokleuringen. 
Wilma, Bianca, Kitty, Karin, Iris en Maikel bedankt voor de hulp met de experimenten op 
PRIME. Jullie zijn erg goed in het werk en dat zie je terug in de resultaten. Er heerst altijd 
een goede sfeer op PRIME en het is mooi om nu nog steeds samen te werken.
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De nieuwe collega’s van Nucleaire geneeskunde wil ik ook graag bedanken voor het warme 
welkom. Vanaf het begin af aan voelde ik me meteen thuis. Ik ben terecht gekomen in een 
geoliede machine, een lab waar op hoog niveau en met veel plezier onderzoek wordt 
gedaan. Kamergenoten Marti, Annemarie, Suzanne en Nienke; ik hoop dat ik jullie niet 
teveel van het werk heb gehouden met mijn frustraties rond de laatste loodjes van het 
proefschrift. In het bijzonder wil ik Mark en Sandra bedanken voor de ruimte om het 
proefschrift af te ronden. Het feestje komt er nu eindelijk aan!
Naast de vele collega’s wil ik ook een flink aantal personen bedanken die gezorgd hebben 
voor (positieve) afleiding tijdens het promoveren.
Frank, Jeffrey, Bart, Michiel, Nick, Remko, Rik en Rob het voelt altijd als thuiskomen in het 
mooie Heitse. Bedankt voor de leuke feestjes en weekendjes weg. Dit zorgde altijd voor 
een goede afleiding. Hopelijk hebben jullie na het lezen van dit proefschrift een betere 
indruk gekregen van het werk wat ik allemaal in Nijmegen doe. Kevin, Michiel, Nick, 
Sander, Simon, Stef en Toon bedankt voor de afleiding middels de vele FIFA-toernooitjes, 
Aesculaafmiddagen of weekendjes Oostblok. Na jaren “nee” te hebben moeten 
antwoorden op de vraag of ik al gepromoveerd was kan ik die vraag na het verdedigen 
van dit proefschrift dan eindelijk positief beantwoorden. Kevin, we kennen elkaar, als 
mede-Limburger, al vanaf de eerste week van de studie. Mooi dat je naast me staat als 
paranimf bij de afsluiting van mijn academische opleiding. 
Dan wil ik uiteraard (schoon)familie Joosten bedanken. Elbert, Bertine, Eva, Sjors, 
Giovanna, en Twan bedankt voor de leuke weekenden, etentjes en uitstapjes. Elbert, 
bedankt voor je interesse in mijn onderzoek en de gesprekken over de wetenschap. Dit 
heeft bij mij soms tot een nieuwe kijk op het wetenschappelijk onderzoek geleid. 
Pap en mam, bedankt voor jullie steun. Zonder jullie had dit werk er zeker niet gelegen. 
Zonder jullie had ik niet gestaan waar ik nu sta. Jullie hebben me geleerd mijn interesses 
te volgen en er het beste uit te halen. Zie hier het resultaat. Evelien, ik vind het mooi om 
te zien dat je met Rémond samen de wereld over reist. Dit inspireert mij nog steeds om 
de wereld te blijven ontdekken. Een betere familie dan jullie kan ik mij niet voorstellen.
Roos, bedankt voor het aanhoren van de vele presentaties, frustraties, successen en lab 
verhalen. Jouw relativerende en positieve kijk op “werken” zorgt ervoor dat we genieten 
van het leven. Zonder jouw motivatie was ik nooit zo ver gekomen. Waar ik tijdens de 
laatste loodjes vaak de neiging had te veel tijd te besteden aan dit proefschrift zorgde jij 
juist voor de nodige remming. Bovendien heb je met je creativiteit een uitzinnig kunstwerk 
gemaakt voor de omslag van dit proefschrift. Bedankt voor al je steun en liefde!
René Raavé 
Nijmegen, 2018
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